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In recent years, LIM domains-containing protein 1 (LIMD1) has been identified as a 
critical component in microRNA (miRNA)-induced silencing complex (miRISC) to regulate 
miRNA-mediated gene silencing. Human Argonaute (AGO) 2 with its family members 
(AGO1-4) are critical for the biogenesis of miRNA and thus miRNA-mediated gene 
silencing. In this study, we have investigated the direct interaction interfaces between 
LIMD1 and AGO2. A distinct interface within LIMD1, amino acid (a.a) 140-166, is 
identified to be responsible for the binding to AGO2 and other members of AGO family. 
Furthermore, the Linker-2 (L2) domain within AGO2 is identified to be responsible for 
LIMD1 binding and its dependency on the phosphorylation at serine 387 (S387) residue 
within the L2 domain of AGO2. The phospho-mimic mutant (S387E) enhances the 
binding of AGO2 to LIMD1, whereas the phospho-deficient mutant (S387A) attenuates 
AGO2-LIMD1 interaction. In addition, the association of LIMD1 with other AGOs is also 
dependent on the phosphorylation at the equivalent conserved serine residue within 
the L2 domain on other AGOs.  
In addition to the above aspects, LIMD1 is a tumour suppressor gene frequently down-
regulated in more than 75% human lung tumours. Because of their loss of expressions 
or functions, it is of the inherent difficulty in targeting tumour suppressor genes to treat 
cancers. In this study, the concept of synthetic lethality was used to identify possible 
protein kinases, the ablation of which are synthetically lethal to LIMD1 negative cancer 
cell lines. As a result, drugs that target these kinases may represent novel targeted 
therapies for LIMD1 negative lung tumours. ACVR2B and STK39 are validated to be 
synthetically lethal with LIMD1 loss. Additionally, the complete loss of LIMD1 expression 
causes a dramatic increase of STK39 expression due to miRNA-mediated gene silencing 
pathway. The inverse relationship between LIMD1 and STK39 may represent a 
conserved and fundamental signalling response and may be a predictive marker for 
STK39-targeted therapy. 
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1.1 Thesis overview 
This thesis focuses on the biological functions of the tumour suppressor protein LIM 
domains-containing 1 (LIMD1) involved in miRNA-mediated gene silencing. LIMD1 
interacts with Argonaute (AGO) 2, the key component of miRNA-induced silencing 
complex (miRISC), to control the gene expression on the post-transcriptional level [1]. 
However, the precise interaction/association with AGO2 is unclear. In addition, little is 
known about how LIMD1 and its family members (AJUBA and WTIP) associated with 
human AGO proteins (AGOs) with regards to the high homology within the 
phosphorylation-dependent L2 domain of AGOs. The present studies will help to 
improve our knowledge of LIMD1 characteristics in miRISC assembly and put forward a 
more detailed mechanism of miRNA-mediated silencing. 
The loss of LIMD1 has been correlated with a variety of cancers, but it is difficult to treat 
these LIMD1 negative cancer by simply targeting LIMD1. To address these questions, 
each result chapter presents experimental findings that address the precise interfaces 
responsible for AGO2-LIMD1 interaction, potential LAW-AGOs interaction and the 
mechanisms, and how LIMD1 regulates a novel oncogene, STK39, which shows synthetic 
lethality with LIMD1 loss.  
The first two results chapters focus on AGO2-LIMD1 interaction/association with respect 
to miRISC assembly. The first results chapter investigated and characterised the precise 
interfaces both within AGO2 and LIMD1 for their physical interaction (Chapter 3). The 
second results chapter broadened the AGO2-LIMD1 interaction to their family members, 
four human AGOs (AGO1-4) and LAW family members (AJUBA and WTIP) with respect 
to the mechanism found between AGO2 and LIMD1 (Chapter 4). In the final results 
chapter, the concept of synthetic lethality was employed to identify the synthetic lethal 
genes with LIMD1. The mechanism for such gene(s) and the potential approach for 
cancer treatment were discussed (Chapter 7). Because this thesis contains two separate 
studies, the results will be presented separately following after each introduction 
chapter and discussed individually for each study (Chapter 5 and Chapter 8). 
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The degradation of messenger RNA (mRNA) is not only achieved by the decay pathway 
but also mediated by non-coding RNAs. Therefore, to be relevant to this project, mRNA 
degradation pathways will be reviewed. The discovery and the machinery of RNA 
interference (RNAi) will then be introduced. The main focus will be miRNA-mediated 
gene silencing including the biogenesis of miRNA and the assembly. The degradation of 
mRNA competes with translation initiation, depending on which group of proteins 
bound to the mRNA. In addition, the miRNA-mediated gene silencing involves 
translational repression. As a result, the eukaryotic translation will be outlined to 
provide the background of translation initiation and a better understanding of the 
miRNA-mediated translational repression. Past and current models of the mechanism 
of miRNA-mediated gene silencing, as well as the function of LIMD1 involved in miRNA-
mediated gene silencing, will be discussed, followed by the first two results chapters. 
The known properties of STK39 biology will then also be presented separately after the 
first study.  
1.2 Messenger RNA degradation pathways 
The degradation of mRNA is an essential step in gene expression to regulate the 
abundance of mRNAs. This includes the detection and rapid degradation of any RNA 
molecules with defects in synthesis, processing, or folding. In addition, mRNA 
degradation can also be dictated by non-coding RNAs with RNA-binding proteins at the 
post-transcriptional level. The degradation of mRNA is ubiquitous in all cells and the rate 
various to control the mRNA abundance to meet the various needs for the individual 
protein within cells. Therefore, the degradation of mRNA is accurately controlled at 
differential rates by various machinery [2].  
1.2.1 Deadenylation-dependent mRNA decay 
In eukaryotic cells, the 5’ cap structure and the 3’ polyadenylation (poly(A)) tail of mRNA 
are required for translational efficiency and protecting the mRNA from the non-specific 
degradation in the cytoplasm. The poly(A) tail is an important structure in regulating the 
mRNA decay; deadenylation of mRNAs is the initial step in mRNA decay, followed by the 
degradation of mRNAs in a 3’ – 5’ direction by the exosome complex (Figure 1.1). 
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Alternatively, following the deadenylation, decapping and degradation in a 5’ – 3’ 
direction dictated by decapping proteins (DCPs) and the exonuclease 1 (XRN1).  
 
 
Figure 1.1 The deadenylation-dependent degradation of mRNA 
The deadenylation-dependent mRNA degradation initiates when two main deadenylases complexes, 
PAN2-PAN3 and CCR4-NOT, remove the poly(A) tail. Following the deadenylation, mRNA is degraded by 
the exosome in a 3’ – 5’ direction. The residual cap structure is then hydrolysed by the scavenger 
decapping enzyme (DCPS). Alternatively, mRNA is decapped by DCP1-DCP2, followed by the degradation 
by XRN1 in a 5’ – 3’ direction.  
 
Mammalian deadenylation contains two consecutive steps which involve two major 
deadenylases complexes, poly(A)-nuclease 2 (PAN2)-PAN3 and carbon catabolite 
repression 4-negative on TATA-less (CCR4-NOT) (Figure 1.1) [3, 4]. PAN2 is responsible 
for digest the distal adenines (As) and CCR4 then digests the approximately As. 
Therefore, deletion of PAN2 results in a long poly(A) tail, whereas deletion of CCR4 
leaves the final approximately As. The promoted decay was observed when either PAN2 
or CCR4 was overexpressed [4, 5]. The PAN2-PAN3 complex, as the poly(A)-specific 
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nucleases, binds to the poly(A) tail by the interaction between (poly(A)-binding protein 
c-terminal domain) PABC and poly(A)-binding protein (PABP)-interacting motif 2 (PAM2) 
within the N-terminus of PAN3 [6]. The enzymatic activity of PAN2-PAN3 relies on the 
PAN2 and mainly depends on the interaction with PABC. It was also demonstrated that 
PAN3 could directly bind to poly(A) tail and supply PAN2 with poly(A) RNA as the 
substrate [7]. The PAN2-PAN3 complex initiates to trim the distal poly(A) until the final 
25 As due to the dissociation of PABC with poly(A) tail [4, 8]. Subsequently, the CCR4-
NOT multi-deadenylase complex, which is the major deadenylases complex in 
eukaryotes, removes the remaining As to complete the deadenylation step [5, 9, 10]. 
The PAN2-PAN3 and CCR4-NOT are recruited by eukaryotic release factor 1 (eRF1) and 
eRF3 [11]. CCR4-NOT can also be recruited by the interaction with RNA binding proteins 
(RBPs) such as PUF, POP2 and tristetraprolin [12, 13].   
After deadenylation, mRNA body is degraded in the 3’ – 5’ direction by the cytoplasmic 
exosome, which is a multi-protein complex. It consists of nine core subunits and one 
enzymatically active ribonuclease [14]. According to the crystal structure, human 
Ribosomal RNA-processing protein 41 (RRP41), RRP45, RRP46, RRP43, mRNA transport 
regulator 3 (MTR3) and RRP42 form the RNase PH domain ring, and C.elegans p53-like 
protein 1 (CEP1) synthetic lethal protein (CSL) 4, RRP4 and RRP40 form the cap [15]. 
Human cytoplasmic Dis3 (also known as RRP44 mainly expressed in the nucleus)-like 
exonuclease (Dis3L) associated with the exosome ring performs the enzymatic activity. 
The human superkiller family (Ski) complex (consisting of Ski2, Ski3 and Ski8) serves as 
the cofactor to be associated with and regulate the activity of the exosome [16]. After 
mRNA body is degraded by the exosome, the residual cap structure is hydrolysed by the 
scavenger decapping enzyme (DCPS) and Fragile Histidine Triad (FHIT) [17, 18].  
In addition to the 3’ – 5’ decay, mRNA degradation can also occur in a 5’ – 3’ direction 
after deadenylation. This step is initiated by the binding of the holoenzyme DCP1-DCP2 
to the 5’ m7G cap structure. DCP2 catalyses the cap structure and generates 5’ 
monophosphorylated mRNA body. The catalytic activity of DCP2 requires its binding to 
the 5’ end of mRNA, but the cap structure is normally protected by the eukaryotic 
initiation factor 4F (eIF4F) complex. Therefore, RCK/p54 represses the mRNA translation 
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to release the eIF4F complex from mRNA so that DCP2 is accessible to the 5’ cap 
structure [19]. Besides, LSM1-7 complex associated with Pat1 binds to the deadenylated 
mRNA which in turn inhibiting the translation and activates the decapping process [19, 
20]. The decapped mRNA is then destructed by 5’ – 3’ exonuclease XRN1 (Figure 1.1). 
1.2.2 Deadenylation-independent mRNA decay 
Nonstop mRNA decay (NSD) degrades mRNAs without the stop codon for translation to 
control the mRNA quality [21]. The degradation is not required deadenylation. Nonstop 
mRNAs result from the abortion of transcription, premature polyadenylation or point 
mutations which disrupt the in-frame stop codon. Therefore, during the first round of 
translation, the ribosome reaches the very 3’ end of mRNA (poly(A) tail) and remains 
stalled onto the mRNA [21] (Figure 1.2). The C-terminal domain of Ski7 recognises this 
stalled ribosome and in turn recruiting the Ski complex (consisting of Ski2, Ski3 and Ski8). 
The exosome complex is then recruited to the 3’ end and start degrading mRNA in a 3’ 
– 5’ direction. The C-terminal domain of Ski7 mimics the GTPase domain of eRF3 [22, 
23]. As a result, in addition to mediating NSD, Ski7 can dissociate the stalled ribosome 
from the 3’ end of mRNA and recycle it for translation of the normal mRNA. By contrast, 
Ski7 was found in the yeast, and it is not conserved in mammals. Therefore, mammalian 
cells utilise HBS1, which is homologous to Ski7, to interacting with Ski complex and 
conduct the NSD degraded by exosome [24]. 
 
  





Figure 1.2 Nonstop mRNA decay (NSD) pathway 
NSD pathway does not require deadenylation as an initial step for mRNA degradation. The defective 
mRNA is lacking the stop codon. As a result, the ribosome is unable to dissociate from mRNA and remains 
stalled at the very 3’ end. Ski7 (HBS1 in mammalian cells) recognises the stalled ribosome and release 
ribosomes from mRNA. Ski7/HBS1 recruits Ski2-Ski3-Ski8 complex and exosome, leading to the major 
mRNA degradation pathway in a 3’ – 5’ direction.  
 
In addition to the exonucleolytic decay, Global analysis of the mammalian RNA 
degradome revealed that endonucleolytic decay is also a deadenylation-independent 
pathway for mRNA degradation [25]. The two fragments of the endonucleolytic cleavage 
are digested by both decapping followed by the degradation in the 5’ – 3’ direction by 
XRN1, and the deadenylation pathway followed by the degradation in the 3’ – 5’ 
direction by exosome (Figure 1.3). The endonucleolytic cleavage can be triggered by 
numerous endonuclease [26]. For instance, The Zc3h12a protein has the 
endonucleolytic activity due to the PilT N-terminus (PIN)-like domain on its N-terminus 
[27, 28]. It modulates the immune response by targeting interleukin-6 (IL-6); Zc3h12a-
deficient cells exhibited the overexpressed IL-6. The Zc3h12a-deficient mice grew slowly 
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and suffered from immune disorders [27]. In addition, the RNAi process also depends 
on the endonucleolytic activities by RISC, which will be described in Chapter 1.3.5.   
 
 
Figure 1.3 Endonucleolytic cleavage conducts the deadenylation-independent degradation of mRNA 
For the deadenylation-independent mRNA degradation pathway, endonuclease (for example Zc3h12a or 
AGO2) cleaves the mRNA into two fragments, followed by the degradation in a 3’ – 5’ decay and a 5’ – 3’ 
decay. 
 
Endonucleolytic activities are also involved in mRNA surveillance pathways to control 
the quality of mRNA in the cytoplasm. In addition to NSD, two more surveillance 
pathways have the role to eliminate mRNA with specific errors to prevent producing 
potentially defective proteins: 1) nonsense-mediated decay (NMD) eliminates mRNAs 
containing a premature termination codon (PTC) to minimize the truncated protein 
products [29], and 2) no-go mRNA decay (NGD) removes mRNAs containing the stalled 
ribosomes due to the secondary structure of mRNA or the collision of ribosomes during 
translation [30, 31]. PTC (nonsense codon) is a result of mutations in genes, errors in 
transcription and splicing which retains introns. The exon-exon junction complex (EJC) 
assembles approximately 20-24 nucleotides (nts) upstream of an exon-exon junction 
during mRNA splicing and remains deposited onto the mRNA. The function of EJC is to 
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provide a position-specific memory of the splicing event to determine whether the 
mRNA is defective or not. For the normal mRNA, the EJC displaces when the ribosome 
encounters the EJC site during the pioneer round of translation (Figure 1.4). However, if 
the ribosome reaches a PTC which locates approximately >50-55 nts upstream of EJC, 
the ribosome then recruits Up-Frameshift Suppressor (UPF) 1 and SMG1 by the 
interaction with eRF1-eRF3. SMG1 phosphorylates UPF1 after binding to UPF2-UPF3 
within the downstream EJC on the mRNA [32]. The phosphorylated UPF1 subsequently 
phosphorylates and activates SMG6 for the endonucleolytic cleavage (Figure 1.4) [33, 
34]. SMG6 is vital for the NMD pathway, the deletion of which was revealed to be unable 
to degrade the faulty mRNAs [34, 35]. Following the endonucleolytic cleavage, the 
mRNA undergo the 5’ – 3’ and 3’ – 5’ decay (Figure 1.4). 
 
  





Figure 1.4 Nonsense mRNA decay (NMD) pathway 
The NMD pathway eliminates the mRNA containing PTCs. When the ribosome encounters the EJC site 
during the pioneer round of translation; if PTC locates approximately >50-55 nts upstream of EJC, the 
ribosome then recruits UPF1 and SMG1 by the interaction with eRF1-eRF3. SMG1 phosphorylates UPF1 
after binding to UPF2-UPF3 within the downstream EJC on the mRNA. The phosphorylated UPF1 then 
phosphorylates SMG6 to activate the endonucleolytic cleavage. After the cleavage, two fragments 
undergo the degradation in a 3’ – 5’ decay and a 5’ – 3’ decay.  
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NGD is initiated as the result of the stalled elongation during mRNA translation when 
the ribosome reaches the stem-loop structure in the mRNA or rare codons [36, 37]. The 
recent study showed that the ribosome collision is a crucial trigger for NGD and the 
cleavage of mRNA is required for multiple stalled ribosomes [30]. However, if the 
defective mRNA with the stalled ribosome near the initiation codon, it is not subject to 
NGD as the result that multiple ribosomes do not accommodate [30]. The ribosomes 
accommodate at the stall site causing the collision which subsequently recruits HBS1. 
HBS1, exhibiting the structural similarities to eRF3, dissociates the stalled ribosome from 
mRNA. With the assistance of its binding partner Dom34, HBS1-Dom34 complex induces 
the endonucleolytic cleavage at the stall site. 3’ – 5’ decay by exosome and 5’ – 3’ decay 
by XRN1 consequently start to degrade the two fragments (Figure 1.5) [2].  
The deadenylation-independent mRNA degradation also takes place in the regulation of 
the histone mRNA. The degradation of histone mRNA helps to keep the balance between 
the histone protein and DNA replication to avoid the toxic to cell proliferation [38]. 
Histone mRNA contains a stem-loop structure instead of a poly(A) tail close to the stop 
codon. Its rapid degradation occurs at the end of S phase or when DNA replication is 
inhibited and is initiated by the addition of short oligouridines (oligo(U)) to the 3’ end of 
the histone mRNA [39]. The oligo(U) serves as the substrate for the LSM1-7 complex, 
which subsequently recruits the decapping complex and the decay machinery factors to 
degrade the histone mRNA in a 5’ – 3’ direction [40]. Simultaneously, the exosome 
complex is recruited by the LSM1-7 complex and degrade the histone mRNA in a 3’ – 5’ 
direction [39] (Figure 1.6).  
 
  





Figure 1.5 No-go mRNA decay (NGD) pathway 
The NGD pathway eliminates the mRNA containing the stem-loop structure or the rare codon, which 
result in the collision of multiple ribosomes during the translation. The collision of ribosomes recruits the 
HBS1-Dom34 complex. The HBS1-Dom34 complex dissociates the stalled ribosomes from mRNA and 
induces the endonucleolytic cleavage at the stall site. After the cleavage, two fragments undergo the 
degradation in a 3’ – 5’ decay and a 5’ – 3’ decay. 
 
  





Figure 1.6 Degradation of the histone mRNA 
The degradation of histone mRNA occurs at the end of S phase or when DNA replication is inhibited. Given 
that the histone mRNA lacks the poly(A) tail, the degradation is not deadenylation-dependent. It is 
initiated by the oligouridylation of the stem-loop sequence at the 3’ end. The poly(U) tail permits the 
binding of the LSM1-7 complex, which subsequently recruit the decapping and decay machinery factors 
(DCPs, XRN1 and Exosome) to degrade the histone mRNA in both 5’ – 3’ and 3’ – 5’ direction. 
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1.2.3 Anti-viral response of the mRNA degradation  
Viruses induce double-stranded RNAs (dsRNAs) during their replication. Depletion of 
NMD factors resulted in the increased replication of the alphaviruses Semliki Forest virus 
[41]. Therefore, in addition to the elimination of defective mRNAs, the mRNA 
degradation pathway is also playing a crucial role in anti-viral response as an innate 
immunity to destruct the viral RNAs (Figure 1.7). Interferon (IFN)-based anti-viral innate 
immunity is one of two anti-viral defence mechanism and is well characterised [42-44]. 
IFN-activated mRNA degradation pathway is one part of IFN-based innate immunity. 2’-
5’-oligoadenylate synthetases (2’-5’OAS) are activated by the binding of long viral 
dsRNAs. This results in the binding of the cellular endonuclease RNase L and facilitates 
the dimerisation of RNase L. Consequently, the dimerised RNase L non-specifically 
degrades RNAs including both viral and host RNAs [45]. Moreover, viral RNA contains a 
zinc-finger anti-viral protein (ZAP) response element (ZRE). Once recognising and 
binding to ZRE, ZAP recruits the cellular RNA decay machinery, including DCP1-DCP2, 
poly(A)-specific ribonuclease (PARN) and exosome [46]. In addition to the above-
mentioned viral RNA degradation pathways, IFN-based innate immunity also contains 
other pathways. For instance, the pattern recognition receptors, including Toll-like 
receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), melanoma 
differentiation associated factor 5 (MDA5) and cGMP-AMP synthase (cGAS), detect the 
viral DNA/RNA and mediate downstream transcription factors which consequently 
eliminate the infected cells by programmed cell death [42-44].  
  





Figure 1.7 Anti-viral response of RNA degradation 
A) The IFN-activated 2’-5’ OAS binds and activates RNase L, resulting in the dimerisation of RNase L. 
Subsequently, RNase L dimer cleaves the viral RNAs using its endonucleolytic activity. The two fragments 
then undergo the degradation in a 3’ – 5’ decay and a 5’ – 3’ decay. This pathway non-specifically degrades 
both viral and host RNAs. B) The viral dsRNA is proceeded to siRNA by the host’s RNAi machinery. siRNA 
then complementarily binds the target viral RNA, leading to the endonucleolytic cleavage by RISC 
complex. The two fragments consequently undergo the degradation in a 3’ – 5’ decay and a 5’ – 3’ decay. 
This pathway is specific to the viral RNAs due to the RNAi machinery. C) The viral RNA contains ZRE which 
allows ZAP interaction. ZAP then recruits DCPs, deadenylation enzymes and exosome to degrade the viral 
RNAs from both 5’ – 3’ direction and 3’ – 5- direction. 
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RNAi is another anti-viral defence mechanism evoked by the viral infection. The host cell 
utilises the RNAi machinery (details in Chapter 1.3) to degrade viral RNAs. The long 
dsRNA induced by viruses is processed to short interfering RNAs (siRNAs), which 
complementary target viral RNAs, resulting in the endonucleolytic cleavage. 
Consequently, it specifically inhibits the viral replication without destructing the infected 
cells. This pathway is mainly found in plants and invertebrates, and its existence in 
vertebrates was uncertainty until the recent studies demonstrated the existence of RNAi 
pathway contributing to anti-viral response in mammalian cells [47, 48]. Depletion of 
key components of RNAi machinery (Dicer and Drosha) increased HIV-1 replication [49]. 
The B2 protein for Flock house virus has high affinity to dsRNA and inhibits the host 
RNAi-based anti-viral response. It was demonstrated that the depletion of B2 protein 
resulted in the abundant viral siRNAs and consequently increased host RNAi-based anti-
viral response to eliminate viruses [48]. In fact, for human, the somatic cells mainly 
utilise IFN-based anti-viral innate immunity, whereas the embryonic stem cells utilise 
RNAi to defence viruses [44, 48].  
1.3 RNAi mediates gene silencing at the post-transcriptional level  
RNAi, also known as post-transcriptional gene silencing, is a biological phenomenon 
found in fungi, plants, animals, and mammalians that efficiently and specifically 
regulates the gene expression. RNAi is initiated or triggered by non-coding small dsRNA 
which contains three types: miRNAs, siRNA and PIWI-interacting (piRNA). piRNAs are 24-
30 nt long and the main function of piRNAs is to silence transposable elements in 
germline cells [50]. As its difference in biogenesis and associated mRBPs to miRNAs and 
siRNAs, hereafter the introduction and discussion of piRNAs will be excluded in this 
project. Both siRNA and miRNA are endogenously generated from non-coding RNAs; 
siRNA can also be introduced into the cells by transfection. miRNAs and siRNAs have 
approximately 22-nt long with 2-nt overhang at the 3’ end (Figure 1.8). miRNA contains 
the bulge structure within the duplex, whereas siRNA does not. The seed region 
(nucleotide position 2-8 at the 5’ end) is responsible for complementary binding to the 
target mRNA. siRNA-induced endonucleolytic cleavage occurs on the target mRNA at the 
relative site between 10 and 11 nt of siRNA (Figure 1.8). miRNAs induce translational 
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repression and mRNA degradation, and it also leads to the endonucleolytic cleavage 
when it perfect match to the target mRNA. As the gene regulatory function, RNAi has 
become a standard experimental tool to silence a gene of interest for biological research. 
Its potential therapeutic applications are under investigation. The fate of target mRNA 
undergoes either translational repression or degradation. Therefore, to be relevant to 
the main goal of this project, RNAi is described in the following chapters. The main focus 
will be on miRNA and the miRNA-mediated post-transcriptional gene silencing. In this 
chapter, the discovery of RNAi and miRNA will be introduced. 
 
 
Figure 1.8 Structure of mature miRNA and siRNA 
A) The structure of a mature miRNA. The two strands of the miRNA form an approximately 22-nt duplex 
with the bulge structure (mismatches in the center) and 2-nt overhangs at 3’ end. The seed region (2-8 
nt), through which the interaction with the target mRNA, is indicated. Both strands (5p and 3p) can cause 
the silencing of the target mRNA. B) The structure of a mature siRNA. The two strands of the siRNA form 
an approximately 22-nt duplex with 2-nt overhangs at 3’ end. The endonucleolytic cleavage site of the 
complementary target mRNA is indicated with a yellow arrowhead (between 10 and 11 nt from 5’ end). 
The seed region (2-8 nt), through which the interaction with the target mRNA is indicated. 
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1.3.1 The history of miRNA 
lin-4 was the first miRNA discovered in 1993 [51]. LIN-14 is one of the genes to control 
the temporal post-embryonic development in C.elegans, and its expression is negatively 
regulated by lin-4 at the first larval stage [51]. Loss of lin-4 stopped the larval transition 
from the first to the second larval stage, and it also caused some missing structures in 
the adult [51, 52]. No start and stop codons are found in lin-4, indicating lin-4 does not 
encode a protein [51]. In addition, two small transcripts of lin-4 (61nts and 22nts in 
length) were found, whose sequences are complementary to the 3'UTR of lin-14 mRNA. 
These findings indicated lin-4 negatively regulates the LIN-14 translation by RNA-RNA 
interaction [51]. 
Seven years later, in 2000, the second miRNA, let-7 (21nt in length) was discovered in 
C.elegans [53]. Similar to lin-4, let-7 is also one of the heterochronic genes which 
temporally regulate the developmental timing, controlling the transition of the fourth 
larval stage to adult [53]. Loss of let-7 caused the reappearance of larval cell fate during 
the adult development, whereas over-expression of let-7 leads to precocious expression 
during the larval development [53]. let-7 miRNA is complementary to the 3’UTR region 
of lin-41. The mutation of let-7 and the deletion of 3’UTR of lin-41 resulted in the 
ablation of the down-regulation of lin-41 [53, 54]. This indicated that let-7 and 3’UTR of 
the target mRNA are necessary for controlling the gene expression. The let-7 sequence 
is highly conserved not only across the species but also detected at different expression 
levels in the majority of the tissues in humans [55]. let-7 family members share the seed 
region for target recognition, which spans 2 to 8 nt at the end of 5’ end of the miRNAs 
[56, 57]. let-7 family members, therefore, can regulate the same targets.  
1.3.2 The biogenesis of miRNA and siRNA  
miRNA genes are transcribed by RNA polymerase II, and the long primary transcript has 
a local stem-loop structure which contains miRNA sequences. The primary transcript is 
then capped and polyadenylated. Most of miRNAs in human are encoded by introns of 
non-coding or coding transcripts. Some miRNAs share the same promoter of a gene 
where they are located in the intron of a protein-coding gene [58]. There are multiple 
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miRNA loci located genomic contexts, and they often have multiple transcription start 
sites (TSSs) as well [59, 60]. Some of miRNAs are close to each other forming clusters. 
Therefore, these miRNAs are transcribed simultaneously. The mature miRNAs with the 
same seed region belong to the same miRNA family, for example, let-7 family. There is 
only one nucleotide in the difference in miR-141 and miR-200c seed region, but they 
suppress non-overlapping targets [61]. This finding indicated the seed region is essential 
for miRNA function. The nomenclature of miRNA genes is followed by several rules: 1) 
the gene locus and precursor miRNA (pre-miRNA) are referred as mir, while the mature 
miRNA product is referred as miR; 2) if genes encoding miRNAs from the same family, a 
suffix letter after the number of miRNA is used (for example, mir-26a and mir-26b); 3) if 
the same mature miRNA is generated from multiple loci, numeric suffix is then added 
(for example, mir-26a-1 and mir-26a-2) and 4) because two mature miRNAs are 
produced from each locus, 5p and 3p are used to indicate the mature miRNA originated 
from 5’ strand or 3’ strand of the pre-miRNA (for example, miR-26a-5p and miR26a-3p). 
Following the transcription by RNA polymerase II, primary miRNAs (pri-miRNAs) undergo 
several steps for maturation (Figure 1.9A). pri-miRNA contains a stem-loop structure 
which is different in length from the stem-loop for siRNAs. Initially, pri-miRNAs are 
trimmed in the nucleus by Drosha, an RNase III family member, to form a small hairpin-
shaped ~65-nt RNA with a 2-nt overhang at 3’ end, so-called pre-miRNA [62]. The dsRNA-
binding domain (dsRBD) protein DGCR8 is the cofactor associating with Drosha to form 
the microprocessor [63]. Drosha has tandem RNase III domains whose dimerisation 
forms a processing centre. The dsRBD within Drosha together with DGCR8 bind pri-
miRNA. The first RNase III domain precisely cuts the 3’ strand, and the second RNase III 
domain cuts the 5’ strand to produce pre-miRNA [64]. With the help of Exportin-5, pre-
miRNA enters into the cytoplasm where the terminal loop is cropped by Dicer, 
generating the mature 22-nt miRNA duplex (Figure 1.8 and Figure 1.9A). Either strand 
(5p or 3p) can be selected as the guide strand and then associate with 
Dicer/AGO/GW182 forming the functional miRISC to regulate gene silencing. The guide 
strand selection is mediated by the cooperation of Dicer and TAR RNA-binding protein 
(TRBP) and positive regulators of dsRNA-dependent protein kinase R (PKR) 
(PACT/PRKRA), mainly according to the relative thermodynamic stabilities of the two 
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duplex ends [65, 66]. The strand with the less stably base-paired at 5’end and the strand 
with a U at nucleotide position 1 has the high possibility to be the guide strand [67] [68]. 
The unselected strand then undergoes immediate degradation. However, this 
unselected strand can also turn to a guide strand and re-load onto AGO within miRISC 
[69]. Arm switching has been observed depending on different cell types and different 
mRNA targets [70]. For example, miR-34c-3p inhibited both U251 and U87 proliferation, 
whereas miR-34c-5p only inhibited U251 proliferation. miR-34c-3p overexpression 
reduced Notch pathway, whereas miR-34c-5p did not [71]. miRNA biogenesis also arises 









Figure 1.9 The canonical biogenesis of miRNA 
The biogenesis of miRNA. pri-miRNA is transcribed from the genome by RNA polymerase II and cropped 
in the nucleus by Drosha/DGCR8 complex to generate pre-miRNA with the bulged hairpin structure. Pre-
miRNA is then exported to the cytoplasm by binding to Exportin 5 on the 5’ cap structure. In the 
cytoplasm, pre-miRNA is further cleaved by Dicer into miRNA duplex, followed by loading onto AGO and 
unwinding. Either strand (5p or 3p) of miRNA can direct miRISC to the complementary mRNAs for miRNA-
mediated gene silencing. The other strand (not bind to the mRNA) is then reloaded onto miRISC. The 
targeted mRNA undergo either/both the translational repression or/and mRNA decay.  
 
The biogenesis of siRNA is similar to that of miRNA, but there are still some differences, 
which are listed in Table 1.1 [69, 72, 73]. Endogenous siRNAs (endo-siRNAs) precursors 
arise from genomic loci and are derived from transposon transcripts, sense-antisense 
pairs, pseudogene-derived antisense transcripts and stem-loop-structured RNAs [74, 75]. 
In C.elegans and plant, RNA-dependent RNA polymerases (RdRPs) is required for 
generation of endo-siRNAs, while Drosophila and humans present a RdRPs-independent 
manner [76]. Exogenous siRNAs (exo-siRNAs) are introduced as the long dsRNA or siRNA 
duplexes by transfection. In addition, exo-siRNAs can also arise from the viral dsRNA, 
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resulting in the anti-viral defence. In Drosophila, both types of siRNAs are bound and 
processed by Dicer2 into 21-23nts in length, assembling into pre-RISC. The guide strand 
of siRNA assembles into the functional RISC with AGO2, whereas the passenger is 
cleaved by AGO2 resulting in its ejection and degradation [77]. In humans, Dicer, AGO2 
and TRBP associate with each other to form the siRISC-loading complex which binds and 
dices long dsRNAs into siRNAs. The guide strand of siRNAs is then selected to load into 
AGO2 to form a functional siRISC [78]. The selection of the guide strand depends on the 
specific duplex parameters (thermodynamics, 5’ nucleotide identify). The passenger 
strand then undergoes the degradation during RISC assembly [73]. Furthermore, the 
target mRNA cleavage will be impaired if the passenger strand was unable to degrade 
[73].  
 
Table 1.1 Comparison of the biogenesis of miRNA and siRNA. 
Summarised form Guo et al., 2010, Mack et al., 2007, Leuschner et al., 2006 [69, 72, 73]. 






Complementarity within the precursor Partial Perfect 
Configuration Single stranded Double stranded 
Cytoplasmic processing 
Cleaved by Dicer into 21-23nt RNA duplex with 
2nt 3’overhangs 
Length 21-23nt ssRNA (guide strand) 
Associated RNP miRISC RISC 
Fate of the passenger strand 
Loading onto 
another AGO 
Cleaved by AGO2 then 
degradation 
Complementarity to target mRNA Partial Perfect 
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1.3.3 Key components in miRNA pathway 
Although there are differences between miRNA and siRNA with regards to their 
biogenesis, there are still some in common. For example, they have to associate with 
RISCs, relying on three important RISC components to regulate the gene expression: 
Dicer, GW182/TNRC6 and AGO [79-81]. Therefore, these three components will be 
introduced in this chapter, and the main focus will be on AGO. 
1.3.3.1 Dicer 
In 2001, because RNase III enzymes were thought to have dsRNA-specific nucleases 
activity, Bernstein et al. took three types of RNase III family members as the candidates 
to determine which enzyme was responsible for cropping the dsRNA into miRNA/siRNA 
[82]. One of RNase III enzymes containing a DEXDc ATPase domain, a PAZ domain, two 
RNase III domains and a dsRBD were identified presenting the cleavage activity and was 
known as Dicer [82]. Depletion of Dicer caused the loss of dsRNA-induced gene silencing 
of other genes. This indicated that Dicer is of importance for the initiation of RNAi. In 
mammals, there is only one Dicer responsible for the biogenesis of miRNA/siRNA, while 
other organisms have multiple Dicer proteins which have different functions. For 
example, in Drosophila Dicer-1 is responsible for the miRNA biogenesis, while Dicer2 is 
required for the siRNA pathway [83].  
Two domains within Dicer, PAZ and RNase III, are essential for producing siRNAs from 
dsRNA and processing the maturation of miRNA from precursor stem-loops. Similar to 
Drosha, the C-terminal tandem RNase III domains of Dicer dimerise to form a catalytic 
centre. dsRNAs or pre-miRNA are firstly captured by PAZ domain which prefers binding 
to 2-nt at 3’ end. With the assistance of PAZ and dsRBD, the two RNase III domains then 
cleave one of the two strands of dsRNAs, generating 2-nt-long 3’ overhang [84]. 
According to the crystal structure, the region between the PAZ and RNase III domain 
functions as a molecular ruler so that Dicer cleavage sites are located at a fixed distance 
(21-25 nts) from the 3’ end, generating the precise cleavage [64]. Additionally, Dicer also 
cleaves pre-miRNA 22 nts away from the 5’ end [64, 84]. RNase III domain regulates the 
direct interaction with AGO for loading miRNAs [85, 86]. 
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Dicer contributes the biogenesis of miRNA; deletion of Dicer in human cells resulted in 
the reduced level of miRNAs [87]. let-7 miRNA targets human Dicer mRNA which in turn 
leading to a negative feedback loop between Dicer and let-7 miRNA [88]. In addition, 
the Dicer activity can also be regulated by the proteins attached to the terminal loop of 
pre-miRNA. For instance, LIN-28 binds pre-let-7 and inhibits Dicer processing by inducing 
oligouridylation of pre-let-7 [89, 90].  
1.3.3.2 GW182/TNRC6 
GW182 was first identified in a patient serum in 2002 and was named for the presence 
of glycine-tryptophan or tryptophan-glycine repeats (GW/WG) and its molecular weight 
(182 kDa) [91]. There are three paralogs in vertebrates (TNRC6A, TNRC6B and TNRC6C) 
[92], one homolog (DmGW182/Gawky) in Drosophila [93, 94], and one homolog in C. 
elegans, ALG-1 (AIN-1, AIN-2) [95]. They all contain a higher than normal level of GW-
repeats. However, for different family proteins, the number of GW-repeats varies. Most 
GW-repeats lies within the N-terminal region, and few or no GW-repeats lies within the 
middle- and C-terminal region. The GW182 family proteins are structurally conserved. 
GW182/AIN-1/Gawky homolog (GAGH) domain is a conserved domain shared in all of 
this protein family [96]. Except for AIN-1 and AIN-2, GW182 contains an RNA recognition 
motif (RRM) within C-terminal region for mRNA regulation. TNRC6C and DmGW182 also 
contain an ubiquitin-association (UBA) domain whose function is under characterisation.  
GW182 family proteins are critical miRISC components required for miRNA-mediated 
silencing. In Drosophila cells, Behm-Ansmant et al. showed that GW-repeats only within 
the N-terminal region was necessary for the interaction with PIWI domain of AGO 
proteins [97-99]. Depletion of GW182 suppressed the silencing of miRNA targets in 
Drosophila [94]. In human cells, depletion of TNRC6A caused the de-repression of the 
miRNA-targeted gene [100]. These findings indicated that GW182 family proteins 
associate with AGO to trigger silencing rather than AGO alone. The GW182 family 
proteins are one component of processing-bodies (p-bodies) (details in Chapter 1.4) 
[101, 102]. The formation of p-bodies is highly dependent on GW182. Knockdown of 
GW182 in human cells impaired the formation of p-bodies and subsequent miRNA-
mediated gene silencing [100]. In miRNA-mediated silencing, GW182 contributes to 
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target recognition by AGO proteins and recruitment of mRNA decay factors such as DCP2, 
enhancer of decapping 4 (EDC4), and DEAD box protein 6 (DDX6) [99]. GW182 is an 
essential component of miRISC to mediate gene silencing [103]. The depletion of GW182 
affects the miRNA and AGO2 expression, indicating that GW182 is essential for miRNA-
mediated silencing [103].  
As mentioned above, GW182 contains the N-terminal GW repeat-containing region 
which directly interacts AGO proteins [103]. The tryptophan residues contribute to the 
strength of the interaction. The other essential domain of GW182 is the bipartite 
silencing domain (SD), consisting of the middle- and C-terminal regions. In Drosophila 
cells, with the depletion of endogenous GW182, silencing cannot be rescued by GW182 
lacking the middle- and C-terminal regions, indicating the importance of SD to the 
translational repression and degradation of miRNA-targeted mRNA [104]. 
1.3.3.3 Argonaute 
Argonaute (AGO) is highly conserved and expressed in all eukaryotes, functioning a key 
component in the RNAi-mediated gene-silencing process. It was first purified from 
human HeLa cells in 2002 and found to belong to a highly conserved family across 
species [105, 106]. The AGO superfamily can be divided into three groups: the 
Argonaute-like proteins which associate with miRNAs and siRNAs; PIWI-like proteins 
which associate piRNAs and the third group which lacks the endonuclease domain but 
is still important for the RNAi pathway [107]. The Argonaute-like proteins are 
responsible for the regulation of translation by associating with miRNAs and siRNAs in 
the cytoplasm, while the PIWI-like proteins are related to the transcriptional silencing 
mainly expressed in germline cells and located in the nucleus. The first two groups 
present in many species, but most of them are expressed multiple Ago genes. In human 
cells, there are eight Ago genes, among which four are Argonaute-like proteins (AGO1-
4) that are responsible for miRNA and siRNA pathway. In C. elegans and Drosophila, 
there are 5 and 27 in total, respectively.  
Argonaute-like family proteins (hereafter referred to AGO family proteins/AGOs) 
(AGO1-4) contain six domains in the order from the amino-to-carboxy terminus: N-
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terminal, L1 (Linker 1), PIWI-AGO-ZWILLE (PAZ), L2, middle (MID) and PIWI domains 
(Figure 1.10A). AGO1-4 were shown to associate with miRNAs and regulate translational 
repression and mRNA decay by interacting with translational initiation machinery and 
mRNA decay factors [108]. AGO2 is well characterised for its role in binding to small RNA 
and its crystal structure (Figure 1.10B) [109]. Six domains within AGOs form a bilobal 
architecture: the N-terminal lobe is formed with N and PAZ domains, and the C-terminal 
lobe is composed of MID and PIWI domains (Figure 1.10B) [109]. Both miRNAs and 
siRNAs require Dicer to excise, generating 2-nt-long 3’ overhang on the products. The 
5’-monophosphate of RNA is anchored by the pocket structure within the MID domain 
with the preference for U or A [110, 111]. The small RNA threads along the channel 
between MID and PIWI to reach the PAZ domain which tightly binds the 2nt-long 3’ 
overhang of small RNA (Figure 1.10B) [109]. For the machinery of miRNA-mediated 
translational repression, it was reported that the MID domain contained an MC 
sequence region that was believed to be homology to the cap structure binding motif of 
eIF4E [112]. This indicated that AGO might bind to the cap structure to competitively 
inhibit eIF4E binding and then represses the translation [112]. However, the further 
sequencing and mapping of this MC sequence region indicated that there are no 
compatible similarities not only in sequence but also in local structure [113]. 
 
  





Figure 1.10 Structure of human AGO1-4  
A) Human AGO1-4 compose of six domains from N-terminus to C-terminus: the N, L1, PAZ, L2, MID and 
PIWI domains. The PAZ domain is responsible for binding to the 3’ end of guide RNA, and the MID 
domain binds to the 5’ end of guide RNA. The PIWI domain has multiple functions. The two tandem 
tryptophan-binding pockets within the PIWI domain binds to GW182/TNRC6, resulting in the miRNA-
mediated silencing. The PIWI domain also contributes to Dicer binding for loading of small RNAs. 
Moreover, the PIWI domain has an RNase H-like fold, and the slicer activity is mainly observed in AGO2. 
B) The crystal structure of AGO2 (PDB ID: 4OLA) and the guide RNA. AGO2 contains two lobes: the N-
PAZ lobe and the MID-PIWI lobe. The 5’ end of guide RNA binds to the MID domain and threads along 
the channel between MID and PIWI to bind to the PAZ domain. The bound guide RNA is coloured as red. 
The back dashed circle indicates the endonucleolytic active site within the PIWI domain. Figure part B is 
adapted from Schirle et al., 2012 [109] 
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As the key component in the biogenesis of small RNAs, the conserved PIWI box within 
PIWI domain has been shown to interact with Dicer [85]. The loading of small RNAs onto 
AGOs requires the interaction between Dicer and AGO. In addition, the phosphorylation 
of tyrosine 393 (Y393) within L2 domain abolished the Dicer-AGO2 interaction, resulting 
in the reduced mature miRNAs [114]. This study implied L2 domain might also be 
responsible for Dicer binding. In Drosophila, a strict small-RNA-sorting system exists. 
After Dicer processing, miRNA duplexes are sorted into AGO1, while siRNA duplexes are 
sorted into AGO2. miRNAs with a 5’ U preferably loads onto AGO1, while siRNA with a 
5’ C preferably loads onto AGO2. In addition, the structure of miRNA (central 
mismatches) prevents being sorted into AGO2 (Figure 1.8) [115]. However, there is no 
such strict sorting system existing in humans. AGO1-4 can incorporate miRNAs and 
siRNAs. The small RNA duplex loading depends on the heat shock cognate 70 (Hsc70)-
heat shock protein 90 (Hsp90) chaperone complex which binds to AGO and hydrolyses 
ATP to change the AGO conformation. The conformational change opens AGO for small 
RNAs duplex loading and unwinding.  
AGO2 directly interacts with TNRC6A through its C-terminal half and recruits TNRC6A to 
the 3’UTR of mRNA for gene silencing [116]. The crystal structure study showed the 
tandem tryptophan-binding pockets within the PIWI domain are responsible for binding 
TNRC6A or other GW-rich proteins [109]. The structure of PIWI domain is similar to 
RNase H and presents endonucleolytic activity which cleaves the target mRNA [117]. 
Among AGO1-4, AGO2 was believed to be the only human AGO that can slice the target 
mRNA with a perfect complementary match of miRNAs. The cleavage takes place 
between nucleotide position 10 and 11 (relative to the 5’ end of miRNA) [64]. The recent 
study demonstrated that AGO3 also has slicer activity which depends on the guide RNA. 
For example, it showed AGO3 associated with miR-20a cleaved the target mRNAs, while 
let-7a or miR-19b did not [118]. Loading with miRNAs converts AGO3 into a catalytically 
active conformation; the crystal structure was showed AGO3 mimics the 
endonucleolytic active site of AGO2. Swapping of PIWI domain from AGO3 to AGO2 did 
not abolish the slicer activity, indicating that AGO3 contains all residues for slicer activity 
in its PIWI domain [119]. However, crystal structure showed the nucleic acid-binding 
channel within AGO3 is incomplete. The disordered N domain within AGO3 results in the 
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channel exit between the N and PIWI domain wider than that within AGO2 (Figure 1.11) 
[118]. The disordered N domain causes a looser packing region between N and L1/L2 
domains, which is critical for cleavage [118, 120]. Swapping N domain of AGO3 to AGO2 
inhibited AGO2 slicer activity [119]. By contrast, the well-ordered N domain of AGO2 is 
critical for slicer activity. Once swapping N domain of AGO2 to AGO3, AGO3 showed the 
detectable slicer activity [119]. Similar to AGO3, a looser packing region between N and 
L1/L2 was also found in AGO1 [118], indicating the disordered N domain and 
misarranged catalytic domain leads to the deficient in cleavage activity. In fact, AGO1 
cleaved the target when mutations were introduced to the N and PIWI domain, which 
re-arrange these two domains [119].  
 
 
Figure 1.11 The crystal structures of human AGO3 and AGO2 [118] 
The crystal structure of (A) human AGO3 (PDB ID: 5VM9) and (B) AGO2 (PDB ID: 4OLA). The bound guide 
RNAs are coloured in red. Compared with the structure of AGO3 and AGO2, the disordered N domain 
(highlighted in orange circle) within AGO3 leads to a wider channel exit (highlighted in black lines) and 
a looser connection between the N and L1/L2 domain (highlighted in orange arrowheads). These 
structural differences within AGO3 result in the abolished endonucleolytic activity. Figure adapted from 
Park et al., 2017 [118]. 
 
The post-translational modifications of AGO2 affect the functions (Table 1.2) [121]. For 
instance, the stability of AGO2 is affected by the hydroxylation of proline (P) 700 within 
the PIWI domain [122]. The hydroxylation of P700 also increased miRNA activity under 
Chapter 1                                                                  Introduction 
30 
the hypoxic condition [123]. Moreover, the phosphorylation of Y529 within the MID 
domain, which is responsible for the small RNAs binding, reduced the amount of small 
RNAs bound to AGO2 [124]. Besides, the phosphorylation of the multi-site (S824-S834) 
was demonstrated to impair the small RNAs binding [125]. The phosphorylation of 
serine (S) 387 within the L2 domain of AGO2 is mediated by mitogen-activated protein 
kinase (MAPK)-activated protein kinase 2 (MAPKAPK2) or ATK3, promoting AGO2 
localisation to P-bodies and thus translational repression [126, 127]. In addition, another 
phosphorylation site within the L2 domain, Y393, was reported to contribute the 
biogenesis of miRNAs. The phosphorylated AGO2 at Y393 residue resulted in the 
dissociation from Dicer, the reduced loading of miRNA and the reduced level of long-
loop mature miRNAs [114, 128]. Under viral infection or stress, AGOs is modified by poly 
(ADP-ribose) polymerase so that the miRNA-mediated gene silencing is relieved [121, 
129]. AGO2 stability is positively regulated by the cellular availability of mature miRNAs 
and the ubiquitin-proteasome system, and the loading of siRNAs can rescue the stability 
of AGO2 in the absence of miRNA biogenesis [121, 130]. 
 
Table 1.2 The post-translational modification of AGO2. 
Modification Site Function Reference 
Hydroxylation P700 
Increases AGO2 stability and miRNA 
levels 
[122, 123]  
Phosphorylation 
S387 




Dissociates the interaction between Dicer 
and inhibited the maturation of long-loop 
miRNAs under hypoxia;  
[114, 128] 
Y529 Impairs miRNA loading [124] 
S824-
S834 
Impairs miRNA target binding [125] 
Poly ADP-ribosylation 
 Suppresses RNA silencing during stress or 
viral infection 
[121, 129] 
Ubiquitination  AGO2 turnover [121, 130] 
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1.3.4 Gene silencing mediated by miRNA 
The mature miRNA complementarily binds the 3’UTR of the target mRNA. For silencing, 
two different pathways are involved: translational repression and mRNA degradation. 
The machinery of translational repression will be presented in Chapter 1.5. For the 
degradation pathway, TNRC6, a key component of the miRISC complex, recruits PAN2-
PAN3 and CCR4-NOT for deadenylation of the target mRNA, followed by decapping 
process [79]. In addition, AGO2 slices the target mRNA when there is perfect or near-
perfect complementary binding between the miRNA and the target mRNA. After 
cleavage, the mRNA decay machinery factors (exosome, XRN1 and DCPs) degrade the 5’ 
and 3’ fragments.  
1.3.5 Gene silencing mediated by siRNA 
Post-transcriptional siRNA silencing mostly occurs in the cytoplasm. In the siRNA 
pathway, the siRNA guide strand binds to the target mRNA with perfect 
complementarity to deliver RISC to the target. The PIWI domain of AGO has the target-
cleavage activity. This precisely occurs between the 10th and 11th position on the target 
nucleotides when counting from the first base-paired nucleotide at 5’ end with siRNAs 
[131]. After cleavage, the cellular decay machinery factors then degrades the fragments, 
and the functional siRISC is regenerated. In some cases, siRNA can also bind the target 
with imperfect complementarity, resulting in miRNA-like silencing pathway which is 
considered as the “off-target” effects of siRNAs [132]. This is due to the seed region on 
5’-end of siRNAs targeting the mRNA and mismatches make it indistinguishable from 
miRNA silencing pathway [133, 134].  
1.4 The formation of P-bodies is the consequence of RNAi-mediated silencing  
 
1.4.1 P-body is a distinct cytoplasmic ribonucleoprotein granule 
In eukaryotic cells, translationally repressed mRNA (by both mRNA surveillance pathway 
and RNAi mediation) accumulate in the cytoplasmic mRNA ribonucleoprotein (mRNP) 
granules, so-called P-bodies. The P-bodies were first discovered in 1997 when 5’-3’ XRN1 
was found to be localised in small cytoplasmic granular structures, which were later 
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observed to be localised with DCP1-DCP2 [135, 136]. The formation of P-bodies is 
revealed to be dependent on and proportional to the non-translated mRNAs; the 
treatment of ribonuclease A led to P-bodies loss [137]. Lsm1-7 complex, which binds to 
3’ end of mRNA and enhances the decapping complex for mRNA degradation, is one of 
the components found in P-bodies [138, 139]. As a result, the assembly of P-body is 
believed to initiate from the formation of the ‘closed loop’ structure of mRNA by the 
interaction between the decapping complex and the Lsm1-7 complex [139]. The 
aggregation into larger structures are then dependent on the interaction between two 
TNRC6 proteins bound onto the different mRNAs through their glutamine/asparagine 
(Q/N) domain [140]. Evidence showed the depletion of TNRC6A diminished P-bodies 
[141]. 
1.4.2 The formation of P-bodies is the consequence of RNAi-mediated silencing  
A number of proteins involved in miRNA-mediated silencing have been found to be co-
localised to P-bodies including AGO2 [142], TNRC6A [91], eIF4E [143], Lsm1-7 complex 
[144], RCK/p54 [144] and LIMD1 [1], indicating the importance of P-bodies in mRNA-
mediated gene silencing. RCK/p54, is required for miRNA-mediated translational 
repression and facilitates P-bodies formation [144]. Chu et al. demonstrated that the 
depletion of RCK/54 resulted in P-bodies loss and diffusion of AGO2 throughout the 
cytoplasm, but the depletion of RCK/p54 did not affect miRNA- or siRNA-mediated 
silencing [144]. Their findings revealed that the integrity of P-bodies is not necessary for 
RNAi-mediated silencing. Indeed, Ana et al. confirmed that the biogenesis of miRNA is 
connected to P-body formation: the depletion of Drosha reduced P-body sizes and 
numbers [145]. The depletion of Dicer-1 and dmAgo1 (Drosophila Argonaute only 
functions in miRNA-mediated silencing) could also reduce P-body formation [145]. 
Furthermore, studies have shown that the P-body sizes and numbers depended on the 
amount of de-capped mRNAs [146, 147]. Taken together, these studies concluded that 
P-body formation indicates the occurrence of RNAi-mediated silencing.  
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1.4.3 Relationship between P-bodies and stress granules  
There is another cytoplasmic mRNP granule, referred to stress granules (SGs), which also 
aggregate the non-translated mRNAs and whose assembly is also proportional to the 
non-translated mRNAs. However, studies have shown the differences between P-bodies 
and SGs in the following aspects: 1) differences in the shape and size under the 
microscope (P-bodies perform the compact, dense and droplet like structure, whereas 
SGs exhibit the larger, irregular, looser and rather granular structure (Figure 1.12)) and 
2) differences in aggregated proteins (Table 1.3) (P-bodies contain mRNA decay proteins, 
whereas SGs contain translation initiation proteins). Although P-bodies also contain 
eIF4E which is one of the translation initiation factors, it was believed that eIF4E-T binds 
and inhibits eIF4E function resulting in the association between eIF4E and non-
translated mRNAs in P-bodies. As a result, mRNAs in P-bodies are specifically for decay, 
while mRNAs in SGs are not subject to decay immediately. Although XRN1 is found in 
SGs, it has no function on degrading mRNAs due to no DCPs found within SGs. Therefore, 
this property makes SGs as protection of mRNA degradation.  
 
 
Figure 1.12 Structural differences between P-bodies and SGs [148] 
Immunofluorescence image for HeLa cells submitted to an oxidative stress. P-bodies and SGs were 
detected with anti-p54 (green) and anti-eIF3 (red) antibodies, respectively. P-bodies are frequently 
associated with SGs, as indicated by the arrowhead and enlarged in the up-right corner. Figure is adapted 
from Souquere et al., 2009 [148] 




Table 1.3 The list of components of P-bodies and stress granules..  
Summarized from Decker et al., 2012 and Luo et al., 2018 [140, 149]  
Name Function P-bodies Stress granules 
Agonaute proteins miRNA function + + 
Ataxin-2 Translation  + 
CCR4-NOT complex Deadenylase +  
DCP1 Decapping enzyme subunit +  
DCP2 Decapping enzyme +  
DDX3 RNA helicase  + 
EDC1 Decapping activator +  
EDC2 Decapping activator +  
EDC3 Decapping activator +  
eIF2α Translation initiation  + 
eIF3 Translation initiation  + 
eIF4A Translation initiation  + 
eIF4B Translation initiation  + 
eIF4E Translation initiation + + 
eIF4G Translation initiation  + 
eIF4E Translation initiation +  
eIF4E-T Translation repressor +  
eRF1 Translation termination +  
eRF3 Translation termination +  
FMBP Translation, repression/miRNA function  + 
Hedls Decapping activator +  
Lsm1-7 complex Decapping activator +  
Pat1 Translation repressor +  
PUM1 [150, 151] Translation repressor + + 
PUM2 [151, 152] Translation repressor + + 
STAU2 [151, 153] Translation repressor + + 
Rap55 Translation repressor + + 
RCK/p54 Translation repressor/decapping activator + + 
TIA-1 Translation repressor  + 
TNRC6A miRNA function +  
Upf1 Nonsense-mediated decay +  
XRN1 5’ – 3’ exonuclease + + 
YTHDF2 [154, 155] mRNA stability  + + 
40S ribosomal subunit Translation  + 
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P-bodies were shown to have a dual role as mRNA decay sites and storage areas [156]. 
However, the recent study had a conflict that mRNA segregated within P-bodies are not 
decayed [151]. Another independent study also showed that mRNA decay products are 
in cytoplasm not in P-bodies. These findings are very intriguing because the majority 
mRNA decay proteins are found within P-bodies. This raised a question that how mRNA 
decay proteins are inhibited within P-bodies to protect mRNAs from degradation. In 
addition, this recent study implied that mRNA decay would be activated in the cytoplasm, 
which agrees with the previous independent study that depletion of RCK/p54 resulted 
in P-bodies lose, but had no effects on RNAi-mediated silencing [144]. The mechanisms 
remain to be investigated.  
For the perspective of mRNA storage, the repressed mRNAs (not all repressed mRNAs) 
within P-bodies are able to re-engage in translation [156-158]. In fact, mRNAs are 
observed to cycle between polysomes (where translations take place), P-bodies and SGs. 
Inhibiting translation initiation resulted in the loss of mRNAs in polysomes and increased 
mRNAs in P-bodies and SGs [140]. Observations demonstrated that there is a physical 
interaction between P-bodies and SGs; they can dock together for a short period. The 
movement of P-bodies and SGs rely on the microtubule network [159, 160]. Given that, 
the docking can be achieved by the microtubule network. AGO2 with miRNA was 
showed to travel from P-bodies to SGs, indicating the exchange of components between 
P-bodies and SGs [161]. The overexpression of cytoplasmic polyadenylation element 
binding protein (CPEB), which mediates polyadenylation of mRNA, increased docking 
and fusing from one to another [162]. CPEB was shown to be localised to P-bodies and 
might re-adenylate mRNAs and transfer to SGs. Moreover, Tristetraprolin (TTP) 
contributes to increasing the flux of mRNPs from SGs to P-bodies by promoting 
deadenylation. These findings indicated the re-distribution of mRNPs between P-bodies 
and SGs, and it also provides a model of mRNA cycle (Figure 1.13). Depending on the 
fusion, mRNPs within P-bodies and SGs undergo the rearrangement; degradation 
machinery proteins can be replaced with initiation factors by competition which allows 
the repressed mRNAs return to translation. Similarly, mRNPs within SGs can also be 
replaced by degradation machinery proteins, resulting in the mRNA decay. 





Figure 1.13 The dynamic movement of mRNA between polysomes, P-bodies and stress granules 
The translation of normal mRNAs takes place in the polysome, including repeated rounds of translation 
initiation, elongation and termination. Once the surveillance machinery detects the defective mRNAs or 
non-coding RNAs bind their complementary targets, which results in the translational repression, the 
ribosomes drop off and these non-translated mRNAs associated with mRNPs aggregate into the larger 
structure, so-called P-bodies. Therefore, P-bodies mainly contain mRNA decay proteins. On the other 
hand, when the translation initiation is stalled under stresses, mRNAs tend to aggregate into stress 
granules which mainly contain initiation factors. Non-translated mRNAs either in P-bodies or stress 
granules are able to re-enter to polysome for translation once the degradation machinery is replaced 
with the initiation factors. The physical interaction (docking) between P-bodies and stress granules is 
frequently observed. Overexpression of certain proteins can lead to the fusion between P-bodies and 
stress granules, resulting in the re-arrangement of mRNPs. 
 
1.5 Mechanism of translational repression by miRNAs 
In addition to the mRNA decay pathway, miRNA-mediated gene silencing triggers the 
translational repression on the target mRNAs during the translation initiation or post-
initiation [163, 164]. Therefore, to understand the machinery of translational repression, 
the mechanism of mammalian translation initiation is introduced first, followed by the 
translational repression models.  
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1.5.1 The mechanism of mammalian translation initiation 
The maturation of mRNAs is required for the post-transcriptional modification on the 
precursor mRNA in the nucleus, adding a 5’ 7-methylguanosine (m7G) cap structure and 
a 3’polyadenosine (poly(A)) tail to prevent from exonucleolytic degradation [165, 166]. 
The mature mRNA is then translocated into the cytoplasm ready for translation [166, 
167]. The translation consists of three major steps: 1) translation initiation which 
requires ribosomes assembly and the binding to the start codon; 2) peptide elongation 
which creates peptide chain by the translocation of the ribosomes and 3) translation 
termination which releases the ribosome when it reaches the stop codon [168].  
The translation initiation is the process of assembly of elongation-competent 80S 
ribosomes, in which the initial codon is base-paired bound with transfer RNA (tRNA) in 
the ribosome. The 80S complex consists of the 48S initiation complexes and 60S 
ribosomal subunit. The 48S initiation complexes can be further broken down into the 
assembly of multiple eukaryotic initiation factors (eIFs), which play important roles in 
translation initiation (Table 1.4), to form 43S preinitiation complex [168].  
  




Table 1.4 The list of eIFs involved in the translation initiation.  
Adapted from Jackson et al., 2010 [168]. 
Name Function Reference 
eIF1 




Stabilizes the interaction between eIF2-GTP-Met-tRNA and 40S; cooperates with 
eIF1 in promoting the ribosomal scanning  
[169] 
eIF2 Forms the eIF2-GTP-Met-tRNA ternary complex [170] 
eIF2B Promotes GDP-GTP exchange on  eIF2 [171] 
eIF3 
Binds 40S subunits, eIF1, eIF4G and eIF5; promotes ribosome dissociation for the 
recycle of 40S subunits; prevents the re-association of 40S to 60S; facilitates 
binding of eIF2-GTP-Met-tRNA to 40S subunits; and promotes the attachment of 
43S complexes to mRNA  
[172] 
eIF4A 
Unwinds 5’cap-proximal region of mRNA for ribosome attachment by DEAD-box 
ATPase and RNA helicase activity 
[173] 
eIF4B Enhances the helicase activity of eIF4A [174] 
eIF4E Binds to the m7G 5’cap structure of mRNA [175-177] 
eIF4F Consists of eIF4A, eIF4E and eIF4G, forming a cap-binding complex [178] 
eIF4G 
Functions as a scaffold protein to bind eIF3, eIF4A, eIF4E and PABP, and enhances 
the binding of 4E to the 5’cap structure of mRNA 
[173] 
eIF4H Enhances the helicase activity of eIF4A [174] 
eIF5 Induces the hydrolysis of eIF2-bound GTP  [179] 
eIF5B A ribosome-dependent GTPase that mediates ribosomal subunit joining [180] 
eIF6 Binds 60S subunits to prevent 60S joining to 40S subunits [181, 182] 
 
1.5.1.1 The initiation of translation requires multiple factors 
Translation initiation requires the 40S and 60S ribosomal subunits. Translation is a 
cyclical process, and thus the ribosomal subunits that are required for the translation 
initiation are derived by recycling of the post-termination ribosomal complexes (post-
TCs) [183]. The post-TCs consists of the 80S ribosome, tRNA and eukaryotic release 
factors (eRF1 and eRF3) [184]. The main function of eRFs is to release the ribosome from 
mRNA when it reaches the stop codon. eIFs (eIF1, eIF1A and eIF3) dissociate the post-
TCs into the free 60S ribosomal subunits, mRNAs, tRNA and the 40S subunit (Figure 1.14). 
eIF1, eIF1A and eIF3 remain associated with the 40S subunit to prevent its re-association 
with the 60S subunit. Meanwhile, methionine-tRNA (Met-tRNA) is associated with eIF2 
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and GTP form the eIF2-GTP-Met-tRNA ternary complex. Subsequently, 43S preinitiation 
complex is then formed by the assembly of eIF1-eIF1A-eIF3-associated 40S (Figure 1.14).  
 
 
Figure 1.14 The formation of the 43S preinitiation complex by recycling 40S 
eIFs (eIF1, eIF1A and eIF3) dissociate the post-TCs into the free 60S ribosomal subunits, mRNAs, tRNA and 
40S subunits. The recycled 40S then associates with eIF2-GTP-Met-tRNAMet ternary complex to form the 
43S preinitiation complex.  
 
The formation of the 48S complex requires the attachment of the 43S preinitiation 
complex with 5’UTR of mRNA. Due to the secondary structure of 5’UTR, the 5’cap 
structure needs modifications for the sufficient loading of the 43S preinitiation complex. 
eIF4F is a complex consisting of eIF4E, eIF4G and eIF4A, facilitating the association of 
mRNA with the ribosome [178]. eIF4E binds to the 5’cap structure [175, 176]. eIF4G, as 
a scaffold protein, provides a platform for the binding of eIF4E, poly(A)-binding protein 
(PABP), eIF4A and eIF3. Binding to eIF4E, eIF4G is capable of stabilising the 5’cap 
structure [177]. Consequently, the eIF4E-eIF4G-PABP interaction leads mRNA to a 
closed-loop structure [185] (Figure 1.15A). eIF4A, the DEAD-box RNA helicase, with 
eIF4B and eIF4H unwind the 5’cap-proximal region of mRNA for ribosomal attachment 
[174, 178]. Evidence showed that the activity of eIF4A was stimulated by eIF4B and 
eIF4H, preventing mRNA re-annealing, indicating the 5’cap proximal region of mRNA is 
always kept prepared for ribosomal attachment [173]. The attachment of 43S 
Chapter 1                                                                  Introduction 
40 
preinitiation complex to mRNA depends on the interaction between eIF4G and eIF3 
[168]. Subsequently, the 48S complex is formed by the cap-eIF4E-eIF4G-eIF3-43S chain 
of interaction (Figure 1.15B).  
After assembly, with the cooperation by eIF4A, eIF4G and eIF4B, the 43S complex starts 
scanning mRNAs downstream of the cap to the initiation codon (AUG) [168, 186]. Once 
the 43S complex encounters the initiation codon (AUG), the 60S ribosomal subunit is 
recruited mediated by eIF5B [180], resulting in the translation elongation (Figure 1.15). 
For the normal translational machinery, the elongation continues until the ribosome 
reaches the stop codon, and the ribosome then releases from the mRNA to start the 
next round of translation. The translation can be stalled if there are defectives within 
the translated mRNA, which is reviewed in the mRNA degradation pathways (Chapter 
1.2). 
 
Figure 1.15 The formation of the 48S complex and translation elongation 
A) The modification of 5’cap structure of mRNA is processed by binding to eIF4F complex (eIF4A, eIF4E 
and eIF4G). The closed-loop structure is then formed by the binding of eIF4F to PABP; B) With the 
assistance of eIF4B and eIF4H, eIF4G functions as a platform for the assembly of the closed-loop mRNA, 
and the 43S preinitiation complex to form the 48S complex. The 43S complex then starts scanning the 
start codon (AUG). eIF5B subsequently mediates 60S recruitment to 40S, forming 80S subunits for 
translation elongation. 
Chapter 1                                                                  Introduction 
41 
1.5.1.2 Internal ribosome entry sites (IRESs)-mediated translation  
In addition to the cap-dependent initiation reviewed above, an alternative mode of 
translation initiation, which bypasses the requirement for cap-dependent machinery, 
directly recruits the 40S subunit to the start codon. The IRES elements located in the 
5’UTR of mRNA mediate the recruitment of the 40S subunit, therefore so-called IRES-
mediated translation or internal initiation [187]. The long and highly structured 5’UTR is 
not efficient for eIFs binding and scanning, leading to the low level of cap-dependent 
initiation and thus the low level of translated products [188, 189]. Therefore, the 
function of IRES-mediated translation is to support for more translational products. In 
addition, IRES-mediated translation also supports the robust translation of mRNAs when 
the cap-dependent machinery is compromised under physiological, pathophysiological 
and stress conditions [187, 189].  
The IRES elements are diverse in their sequences and/or structures within different 
mRNAs: different mRNAs contain different IRES elements in the sequence and structure. 
Therefore, to determine the existence of an IRES element within in a particular mRNA, 
it requires the experiments for each mRNA. Alternatively, the IRES element of one mRNA 
can be predicted by the online IRES prediction tool, but it needs experiments for further 
determination. The activity of IRES to mediate the internal initiation is with the 
assistance of eIFs or IRES trans-acting factors (ITAFs) [190]. With the assistance of ITAFs, 
IRES changes the conformation which is sufficient for recruitment and preparing a 
landing platform for the ribosomes. In most cases of internal initiation, for example, the 
internal initiation of c-myc and N-myc do not require eIF4E and eIF4G (Figure 1.16A) 
[191]. The two ITAFs, Y-box binding protein 1 (YB-1) and polypyrimidine tract-binding 
protein 1 (PTB-1), bind c-myc IRES and enhance c-myc expression and cell proliferation 
[192]. A different mechanism of IRES-mediated initiation is to stall the cap-initiated 
ribosomes in a short upstream ORF (uORF) (Figure 1.16B) [193]. For example, uORF 
embedded within the IRES of cationic 1 (CAT1) mRNA can activate IRES activity. Under 
the amino acid stress, it enables the structural remodelling of the IRES which results in 
the translation of the main ORF [194]. By contrast, uORF can also inhibit the IRES activity. 
For instance, the expression of human fibroblast growth factor 9 (FGF9) remains at the 
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low level due to uORF-mediated translational repression under the normoxic condition 
(normal level of oxygen), but the expression was up-regulated via IRES-mediated 
translation under the hypoxic condition (low level of oxygen) (Figure 1.16C) [195]. 
Furthermore, RNA G-quadruplex (RG4) structure, which inhibits the cap-dependent 
translation by compromising 5’ cap recognition [196], has been demonstrated to 
regulate IRES-mediated translation (Figure 1.16D) [197]. Inhibiting or stabilising the 
conformation of RG4 within the vascular endothelial growth factor (VEGF) IRES 
repressed the IRES-mediated translation [197].  
 
  





Figure 1.16 The different mechanisms for IRES-mediated translation 
The IRES-mediated translation requires the closed-loop structure of mRNA. In the most cases, eIF4E and 
eIF4G are dispensable. A) ITAFs assist IRES to remodel into an active conformation, providing a landing 
platform for the ribosomes. B) The uORF can promote IRES for ribosomes recruitment. For example, 
under amino acid stress, the uORF embedded within 5’UTR of CAT1 mRNA stalls the 40S subunit and thus 
open the inhibitory structure of IRES. Subsequently, IRES changes its conformation and enables the 
ribosomes recruitment. C) The uORF can also inhibit IRES-mediated initiation. For example, the expression 
of FGF9 keeps at the low level due to the inhibitory function of uORF embedded. However, FGF9 
expression is induced by IRES-mediated translation under the hypoxic condition. D) RG4 embedded within 
IRES (e.g. VEGF) inhibits cap-dependent initiation and promotes the 40S subunit recruitment and thus 
IRES-mediated translation. 
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1.5.2 Translational repression mediated by miRNA 
miRNA-mediated gene silencing controls the expression of the target by the 
translational repression and/or mRNA degradation. Studies have shown that the gene 
repression occurs either at translation initiation or post-initiation [163, 164]. There are 
currently several models for how miRNAs repress the initiation or post-initiation stages 
of translation. The first model proposed the dissociation of ribosomes after the initiation 
of translation, and ribosomes exit prematurely from their associated mRNAs to 
terminate the peptide elongation [164] (Figure 1.17). The research team observed that 
ribosomes associated with the repressed mRNAs dropped off more rapidly than those 
on active mRNAs [164]. In addition, Nottrott et al. showed when let-7a miRNA was used 
to regulate the expression of lin-41 in HeLa cells, the polypeptide elongation in 
repressed mRNAs is at the same rate as it in unrepressed mRNA [198]. This suggested 
that although ribosome dropped off, the translation continued on the repressed mRNAs. 
However, no proteins were detected. Therefore, the translation repression occurs 
during the peptide elongation. During the polypeptide elongation, the components of 
repressed mRNAs (probably miRISCs) initiate the destruction of the peptide by recruiting 
proteases [198] (Figure 1.17). 
 
 
Figure 1.17 The translation repression is caused by ribosome drop-off and protease recruitment by 
miRISC  
miRISC recruits the protease to degrade the nascent peptide during translation elongation. Meanwhile, 
the ribosomes drop off from the repressed mRNA. 
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The second model proposed that the miRISC prevent the assembly of the ribosomes 
(Figure 1.18). In a cell-free system, the amount of 60S subunits was found to decrease 
in miRNA-targeted mRNAs. This indicated translationally repressed mRNAs blocked the 
association of 60S with 40S subunit [199]. In addition, eIF6, which is involved in the 
biogenesis of maturation of the 60S subunit, prevents the assembly of 60S with 40S 
[182]. Depletion of eIF6 ablated the reduction of mRNAs mediated by miRNA-mediated 
silencing in human cells [181]. The evidence also suggested that AGO2 has the direct 
interaction with eIF6 and 60S [181]. Therefore, by competing with 40S ribosomal 
subunits, miRISC binds eIF6-associated 60S subunit and prevents the assembly of 
ribosomes to initiate the translation (Figure 1.18).  
 
 
Figure 1.18 miRISC prevents the assembly of the ribosomes  
miRISC competes with the 40S subunit to bind to eIF6 and 60S subunit. This prevents the maturation of 
60S subunits so that translation is repressed. 
 
The third model addressed the hypothesis that the initiation is repressed by 
deadenylation of mRNA stimulated by miRISC (Figure 1.19). GW182/TNRC6, an 
important component in miRISC, was reported to compete with eIF4G for binding to 
PABP1 [200]. In this case, PABP1 along with poly (A) tail is set for free, and the initiation 
of translation is repressed. Simultaneously, TNRC6A recruits the deadenylase complex 
(CCR4-NOT) and triggers the deadenylation process so that the translational closed-loop 
structure cannot be formed through poly(A) tail [99, 201]. By contrast, for those non-
polyadenylated mRNAs can still be silenced by miRNA, which highly depends on both 
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AGO and GW182 functions [103]. Depletion either will cause the ablation of miRNA 
silencing, while depletion of a component of the deadenylase enzyme causes little 
effects on translation repression [103].  
 
 
Figure 1.19 miRISC regulates the deadenylation of mRNA  
miRISC competes with PABP (not shown) to bind to eIF4G, forming a closed-loop structure. Meanwhile, 
miRISC recruits (CCR4-NOT) complex to degrade poly(A) tail.  
 
Translation is initiated by eIF4E binding to mRNA 5’ cap structure. The methylated base 
of the cap is stacked between two tryptophan residues on eIF4E. A fourth model 
suggested that repression of initiation was due to the formation of an inhibitory closed-
loop by the competition between AGO2 and eIF4E for binding to the 5’ cap structure 
[112]. The two phenylalanine residues (MC sequence region) within the MID domain of 
AGO2 was reported to mimic the eIF4E tryptophan [112]. Mutation of either or both 
phenylalanine caused the abolishment of AGO2 silencing ability. This cap-binding 
function of AGO2, therefore, repressed the initiation by releasing eIF4E from the 5’ cap. 
However, sequence and structural analysis indicated that AGO2 does not contain such 
region that was compatible with eIF4E [113]. The explanation for AGO2 losing silencing 
ability could be that the MID domain structure is destabilised resulted by the mutation 
of both phenylalanine [113]. In fact, the mutation of these residues disrupted the 
interaction between Ago1 and GW182 in Drosophila, resulting in the ablation of 
silencing [103]. The findings from James et al. support this model of an inhibitory 
complex repressing initiation [1]. James et al. demonstrated that LIMD1 is involved in 
miRNA-mediated gene silencing [1] (Figure 1.20). LIMD1 was found to interact miRISC 
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complex and initiation factors with 7-Methylguanosine-5’-triphosphate (m7GTP) 
Sepharose which is used for purification of mRNA cap binding proteins [1]. Therefore, 
the translational repression is caused by the formation of the closed-loop structure 
through a scaffold protein, LIMD1.  
 
 
Figure 1.20 LIMD1 bridges miRISC and eIF4E, repressing the initiation of translation  
An inhibitory complex is formed by the scaffold protein, LIMD1, linking 5’ cap structure and miRISC. 
 
1.6 LIM-domain containing proteins 
LIM-domain containing protein was first identified within in Mechanosensory protein 3 
(MEC-3) in C.elegans in 1988, where a novel cysteine/histidine-rich domain along with 
homeodomain was noticed [202]. Further investigations identified such cysteine-rich 
domain is common to that within cell-lineage protein (lin-11) in C.elegans [203] and 
insulin gene-enhancer-binding protein (Isl1) in rats [204]. Therefore, LIM domain was 
named after the first three LIM domain-containing proteins (lin-11, Isl1 and MEC3). LIM 
domain was initially believed to bind both zinc and iron [205]. However, the further 
studies showed LIM domain only binds to zinc [206]. LIM domain contains a broad 
consensus sequence C(X)2C(X)16-23H/C(X)2/4C/H/E(X)2C(X)2C(X)14-21C/H(X)2/1/3(C/H/D)X, 
forming two zinc fingers (X presents any amino acid; ‘/’ represents ‘or’; numbers at the 
right bottom corner represent the number of amino acid in the sequence) [207, 208] 
(Figure 1.21). Eight highly conserved residues (most are cysteine and histidine) and 
contribute to binding to two zinc atoms forming two zinc fingers. LIM domain was first 
thought to be involved in DNA or RNA recognition due to its zinc-binding motifs [209]. 
But it was then proved to be responsible for protein-protein interaction, rather than 
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protein-DNA/RNA interaction [210, 211]. Therefore, four models of LIM-domain-
regulated biological processes were established: 1) a molecular adaptors, 2) competitor, 
3) conformer and 4) localiser [207]. 
 
 
Figure 1.21 Schematic structure of the LIM-domain 
A) Amino acid sequences within the one LIM-domain, containing eight residues (numbered) contributing 
to zinc binding. Frequently observed amino acid for zinc-binding present in bold. B) Schematic structure 
of the LIM-domain. Eight numbered residues are responsible for the zinc-binding, forming two zinc fingers 
for protein-protein interaction. X represents any amino acid. Figure is adapted from Kadrmas et al., 2004 
[207].  
 
By comparison of amino acid (a.a) sequences among 58 genes containing LIM domains, 
LIM domains can be classified into four broad categories: 1) the nuclear LIM only, which 
acts as transcription factors or co-factors; 2) LIM-homeodomain protein, which is similar 
to the first group but can locate in the nucleus and the cytoplasm; 3) actin-binding LIM 
protein, which contains various protein-protein binding motifs and 4) LIM kinase, which 
shares the similarities with the third group and contains kinase catalytic motif [207, 212]. 
LIMD1 belongs to the ZYXIN family of LIM-domain containing proteins, which belongs to 
the third group. According to the phylogenetic relationships (Figure 1.22), ZYXIN family 
can be further broken down into two sub-family (AJUBA and ZYXIN). AJUBA sub-family 
consists of LIMD1, AJUBA and WTIP. To avoid the confusion caused by using AJUBA as a 
Chapter 1                                                                  Introduction 
49 
specific protein or as a sub-family name, LAW (initials for three family members) is used 
throughout this study to refer AJUBA family. ZYXIN sub-family consists of ZYXIN, LPP and 
TRIP6. As from the same family, all family members contain a variable proline/serine-
rich pre-LIM region (25.42% sequence identity), followed by a highly conserved C-
terminal region containing three LIM domains (63% sequence identity) (Figure 1.22). 
The ZYXIN sub-family members are localised at focal adhesions and involved in the 
cytoskeletal arrangement by docking actin-bundling proteins [213-215]. LAW family 
members were shown as a molecular adaptor (scaffold) to regulate multiple biological 
processes including regulating miRNA-mediated silencing, HIF hypoxia response 
pathway, repressing E2F-driven transcription, and tumour necrosis factor (TNF) receptor 
associated-factor 6 (TRAF6)-mediated signalling [1, 216-218]. 
 
 
Figure 1.22 The ZYXIN family of LIM proteins 
A) The phylogenetic tree shows ZYXIN family can be sub-divided into two groups, AJUBA (AJUBA, LIMD1, 
and WTIP) and ZYXIN (LPP, TRIP6, and ZYXIN). The phylogenetic tree is generated by DNAMAN Windows 
6.0 (Lynnon Biosoft) using default parameters. B) Each family member contains an N-terminal 
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1.6.1 LIMD1 is a tumour suppressor 
LIM domain-containing protein 1 (LIMD1) gene was first identified to be located within 
chromosome 3 common eliminated region 1 (C3CER1) which is frequently eliminated on 
3p21.3 (Mb 43.32 – 45.74) [219]. Chromosome 3p is frequently deleted in 100 % small 
cell lung cancers (SCLCs) and 90% non-small cell lung cancer (NSCLCs) [220]. 
Furthermore, chromosomal deletions and loss of heterozygosity (LOH) of 3p21.3 have 
been reported in the majority of solid tumours, ranging from 70 to 94 % [221]. More 
importantly, these genetic alterations occur at the early stage of lung cancers and show 
the histologic changes of pre-malignant lesions in normal respiratory epithelium [222]. 
In addition, this region contains several tumour suppressor genes (TSGs) such as FUS1 
[223], Ras association domain family member 1 (RASSF1) and BLU [224, 225]. These 
results indicate that chromosome 3p21.3 is responsible for tumour suppression. 
The retinoblastoma (pRB) protein regulates the transcription of multiple genes [226]. 
The transcription factors of the E2F family are the best-known targets of pRB [227]. E2F 
controls the transition from G1 to S phase of cell cycle. pRB binds E2F family proteins to 
repress the initiation of DNA replication by cell cycle progression (G1/S transition) and 
cell proliferation [227]. LIMD1 was reported to bind pRB (Figure 1.23) to increase the 
repression of E2F in the presence of pRB [217]. In addition, LIMD1 was found to inhibit 
cell proliferation when plasmids expressing LIMD1 cDNA were transfected into the 
LIMD1-negative cancer cell line MDA-MB-435 [217]. Over-expression of LIMD1 also 
inhibits the tumour growth when A9 mouse fibrosarcoma cells were injected into nude 
mice [217]. As pRB frequently presents loss-of-function in the early stage of lung cancer 
[228], loss of LIMD1 was postulated to be involved in lung tumourigenesis [217].  
 
  





Figure 1.23 Schematic of the structure of LIMD1 and the binding domains for different partners 
LIMD1 functions as a scaffold protein to bind to PHD2 and VHL through a.a 186-260 (indicated in red) and 
LIM2 (indicated by line) domain respectively, regulating the stability of HIF-1α. Additionally, LIMD1 binds 
pRB through a.a 404-442 (indicated in yellow) to repress E2F.  
 
Further research on LIMD1 has also shown loss of LIMD1 increases tumour incidence 
and sizes of a tumour in vivo [229]. When LIMD1-/- mice were bred with oncogenic K-
RasG12D expressing mice which are an induced lung cancer model, LIMD1-/-: K-RasG12D 
mice developed more and larger tumours than LIMD1+/+: K-RasG12D (wide type) mice did 
[229]. In addition, over the 12-month period, it also exhibited much higher mortality 
rate in LIMD1-/-: K-RasG12D mice (90 %) than LIMD1+/+: K-RasG12D (30%). Therefore, this 
evidence strongly supported that LIMD1 as a bona fide lung tumour suppressor which 
has reduced expression in 80 % of human lung cancers (most on squamous cell 
carcinoma) [217, 229]. 
The LIMD1 expression in human breast cancer is in contrast to that in lung which 
presents a frequent loss of LIMD1 [217, 230, 231]. LIMD1 is expressed in the majority of 
breast cancers [230, 231]. However, when compared to the adjacent normal and distant 
normal tissue, Ian et al. found breast cancer tissue presented a significant reduction of 
LIMD1 expression [230]. LIMD1 expression significantly reduced a significant correlation 
between high cytoplasmic LIMD1 expression with high nuclear LIMD1 expression [230]. 
The further investigation proposed LIMD1 as a prognostic marker for breast cancer that 
low LIMD1 expression correlates with poor prognosis and higher mortality rate [230]. In 
addition, a high frequency of LIMD1 alteration (deletion, methylation, and mutation) 
was found in head and neck squamous cell carcinoma, and its alterations contributed to 
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poor prognosis [232, 233]. Nevertheless, it also revealed a potential tumour suppressive 
function of LIMD1 in the oesophageal cancer cell, the depletion of which caused the 
abnormal cell division [234]. Taken together, these findings demonstrated LIMD1 as a 
tumour suppressor.  
1.6.2 LIMD1 is a negative regulator for the hypoxia-induced factor (HIF) 
Prolyl hydroxylases (PHDs) regulate the HIFs which are transcriptional factors that 
respond to the oxygen tension [235, 236]. In high oxygen tension, PHDs hydroxylate HIF-
1α and allow HIF-1α to bind the von Hippel-Lindau (VHL) as a result that HIF-1α 
undergoes the ubiquitylation and degradation [237, 238]. LIMD1 was found to be a 
scaffold between PHDs and VHL [216]. Forming this PHD-LIMD1-VHL complex, the 
hydroxylation of VHL is promoted, and thus it activates the ubiquitylation and 
degradation of HIF-1α by 26S proteasome (Figure 1.24). Loss of LIMD1 causes the 
stabilisation of HIF-1α and causes pseudo-hypoxia with the enhanced HIF-1α expression 
and activity [216].  
 
 
Figure 1.24 LIMD1 bridges PHD and VHL to regulate the expression of HIF-1α 
A PHD2-LIMD1-VHL complex is formed by the interaction of LIMD1, as a scaffold, with PHD through its 
pre-LIM region (a.a 186-260) and VHL through its LIM2 domain. Thus, LIMD1 promotes the hydroxylation 
by PHD and ubiquitylation by VHL, consequently leading the degradation of HIF-1α by 26S proteasome 
(not shown). The figure is adapted from Foxler et al., 2012 [216] 
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1.6.3 LIMD1 is an important regulator of miRNA-mediated silencing 
James et al. demonstrated that LIMD1 is an important regulator of miRNA-mediated 
silencing [1]. Co-expression of fluorescently-tagged LIMD1 with DCP2, AGO2, DDX6/RCK 
and eIF4E in U2OS cells showed LIMD1 has potential interactions with these proteins. 
This indicated LIMD1 is also a component of P-bodies, suggesting LIMD1 is involved in 
miRNA-mediated silencing pathway. The co-immunoprecipitation of endogenous LIMD1 
confirmed LIMD1 has the physical interactions between the above proteins [1]. Then 
using a reporter assay, LIMD1 was noticed have a regulatory function in miRNA pathway 
but not in siRNA pathway [1]. Finally, using the m7GTP Sepharose affinity resin, LIMD1 
was purified with m7G-bound eIF4E. This indicated and provided the evidence for 
alternative miRNA silencing model that LIMD1 binds 5’cap structure and miRISC 
(AGO2/TNRC6A) to form an inhibitory complex for translational repression [1]. 
1.7 Aims and objectives 
Upon the 2010 publication from Dr Sharp’s group [1], this study therefore aims to 
investigate and characterise the interaction between LIMD1 and AGO2 for a deeper 
understanding of the mechanism of how LIMD1 regulates miRNA-mediated silencing in 
humans. Therefore, the two key aims of this study are as follows: 
• Aim 1: Recombinant LIMD1 and AGO2 proteins carrying point mutations will be 
constructed for investigation of the direct binding between LIMD1 and AGO2. As 
the phosphorylation of S387 was reported to enhance silencing and thus 
translational repression [127], the interaction of AGO2 and LIMD1 with regards 
to the phosphorylation of S387 will be investigated. (Chapter 3)  
• Aim 2: Given that LAW (LIMD1, AJUBA, and WTIP) and AGOs (AGO1-4) are 
involved in miRNA-mediated silencing [1, 108], the co-localisation of each AGO 
family member with LAW will be observed to investigate their associations with 
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2.1.1 Bacterial media 
Luria Bertani (LB) broth The powder (Sigma-Aldrich, L3022-1KG) was dissolved in the 
distilled water (2.5% w/v) and autoclaved at 121°C for 20min. The broth was then stored 
at room temperature, and the required antibiotics were added immediately prior to use.  
LB Broth with agar The powder (Sigma-Aldrich, L2897-1KG) was dissolved in the distilled 
water (3.5% w/v) and autoclaved at 121°C for 20min. After the agar cool to around 50 °C, 
the required antibiotic was added and mixed thoroughly. 20ml LB-Agar was then poured 
into each sterile petri dish and allowed to set at room temperature. The plates were 
then stored at 4°C for up to 1 month. 
Agarose The powder (Sigma-Aldrich, A4718-100G) was stored at room temperature.  
2.1.2 Plasmids 
 
2.1.2.1 Protein expression plasmids for bacterial cells 
pETFPP_2 The pETFPP_2 vector (Figure 2.1) allows for ligation independent cloning (LIC). 
The pETFPP_2 vector provides a 6xHis tag and MBP (maltose binding protein) tag at N-
terminus, and another 6xHis tag at C-terminus. The vector has an HRV 3C (Human 
Rhinovirus 3C) protease recognition site between the tag and the first codon of the sub-
cloned CDS of interest. The C-terminal 6xHis tag no longer exists once CDS of interest is 
subcloned by LIC. Expression of the recombinant protein is driven by the T7 viral 
promoter, and the kanamycin resistance is to select the successfully transformed 
colonies. 
pMCSG10 The pMCSG10 vector (Figure 2.2) allows for LIC. The pMCSG10 vector 
provides a 6xHis tag and a GST tag at the N-terminus. The vector has a TEV (tobacco etch 
virus) protease recognition site between the tag and the first codon of the sub-cloned 
CDS of interest. Expression of the recombinant protein is driven by the T7 viral promoter, 
and the ampicillin resistance is to select the successfully transformed colonies.  




Figure 2.1 Vector map of pETFPP_2-LIMD1 
The pMETFPP_2-LIMD1 vector provides a 6xHis tag and an MBP tag at the N-terminus. The vector has an 
HRV3C protease recognition site between the tags and the first codon of LIMD1 (or LIMD1 deletion 
mutants). The expression of the recombinant protein is driven by the T7 viral promoter, and the ampicillin 
resistance (not shown here) is to select the successfully transformed colonies. 
 
 
Figure 2.2 Vector map of pMCSG10-AGO2 
The pMCSG10-AGO2 vector provides a 6xHis tag and a GST tag at the N-terminus. The vector has a TEV 
protease recognition site between the tags and the first codon of AGO2. The expression of the 
recombinant protein is driven by the T7 viral promoter, and the ampicillin resistance is to select 
successfully transformed colonies. 
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2.1.2.2 Protein expression plasmids for mammalian cells 
pEYFP-C1 The pEYFP-C1 vector provides an N-terminal yellow variant of the EGFP tag 
(EYFP). The constitutive and high-level expression in mammalian cells of the ORF is 
driven by a human CMV (cytomegalovirus) promoter. The kanamycin resistance is to 
select the bacterial successfully transformed colonies, and the neomycin resistance is to 
select the successfully transfected mammalian cells. 
pAsRed2-C1 (mTan) The pAsRed2-C1 vector provides an N-terminal red fluorescent 
protein tag (mTangerine, short ofr mTan). The constitutive and high-level expression in 
mammalian cells of the ORF is driven by a CMV promoter. The kanamycin resistance is 
to select the bacterial successfully transformed colonies, and the neomycin resistance is 
to select the successfully transfected mammalian cells. 
psiCHECK-2 The psiCHECK-2 vector (Figure 2.3) contains the Renilla and Firefly luciferase 
elements. The Renilla luciferase is driven by a SV40 (simian virus 40) promoter, and 
Firefly luciferase is driven by HSV TK (Herpes simplex virus thymidine kinase) promoter. 
The ampicillin resistance is to select the bacterial successfully transformed colonies.  
2.1.3 Cell culture media 
Dulbecco’s Modified Eagle’s Medium (DMEM) DMEM (Sigma-Aldrich, D6429), 
containing 4500mg/L glucose, 2mM L-glutamine and 100mg/L sodium pyruvate, was 
supplemented with 10% (v/v) FBS (Fetal Bovine Serum) and 1% (v/v) Penicillin-
Streptomycin) and stored at 4°C. The media was pre-warmed in a water bath at 37°C 
prior to use. The selection drugs were added immediately prior to use if required. 
2.1.4 Primers for DNA Polymerization 
The primers used in this study for cloning LIMD1 and AGO2 mutants, STK39 3’ reporter 
constructs and qRT-PCR are listed in  
  





Figure 2.3 Vector map of psiCHECK-2-STK39 3’UTR 
The psiCHECK-2 vector contains Renilla and Firefly luciferase elements. The Renilla luciferase is driven by 
a SV40 promoter, and Firefly luciferase is driven by HSV TK promoter. The ampicillin resistance is to select 
the bacterial successfully transformed colonies. 
 
  




Table 2.1 Table of primers used in this study 
Highlighted in Bold represents 12-nt overhangs on each pair which complementarily matched the 
backbone sequences for LIC. The lowercase letters represent the substitution for site-directed 
mutagenesis. 
















































































Table 2.2 Table of primers used in this study 
Primers used for colony PCR and qRT-PCR in this study. 


















1xTrypsin/EDTA Solution The solution (Sigma-Aldrich, T4299-100ML) contained 500 
BAEE units porcine trypsin, 0.2g/100ml EDTA per litre of Dulbecco’s PBS without calcium 
and magnesium. The working solution was stored at 4°C and pre-warmed in a water 
bath at 37°C prior to use. 
Fetal Bovine Serum (FBS) The solution (Gibco, 1050) was aliquoted in 50ml and stored 
at -20°C. FBS was filtered and added to cell medium by using a syringe and a 0.2µm filter 
in a cell culture fume hood.  
1xOpti-MEM® reduced serum medium (Opti-MEM®) Opti-MEM® (GIBCO, 31985-062), 
containing L-glutamine and 2.4g/L sodium bicarbonate, was stored at 4°C and pre-
warmed in a water bath at 37°C prior to use. 
Cell freezing mix sterile dimethyl sulfoxide (DMSO, Sigma-Aldrich, D2438) was mixed 
with FBS 20% (v/v) and stored at -20°C. 
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2.1.5 Antibiotics and selection drugs 
Ampicillin The stock solution (Sigma-Aldrich, A2804-50MG) was prepared at a 
concentration of 100mg/ml in the distilled water and the aliquots were stored at -20°C. 
The standard working concentration was 100µg/ml. 
Kanamycin The stock solution (Bioline, BIO-87028) was prepared at a concentration of 
33mg/ml in the distilled water and the aliquots were stored at -20°C. The standard 
working concentration was 33µg/ml. 
Puromycin The stock solution (Sigma-Aldrich, A2804-50MG) contained 33 mg/ml 
Ampicillin in the distilled water and was stored at -20°C. The standard working 
concentration was 33µg/ml. 
Penicillin/Streptomycin The solution (Sigma-Aldrich, P4333-100ML) contained 10,000 
units of Penicillin and 10mg/ml Streptomycin in 0.9% NaCl. The working aliquots were 
stored at 4°C. The standard working concentration was 1% (v/v). 
2.1.6 Buffers and solutions 
 
2.1.6.1 Stock solutions 
Ethylenediaminetetraacetic acid (EDTA) The stock solution (0.2M) was prepared by 
dissolving 5.845g EDTA (Sigma-Aldrich, E9884) in the distilled water to a final volume of 
100ml and stored at room temperature. 
Imidazole The stock solution (1M) was prepared by dissolving 1.702g imidazole (Sigma-
Aldrich, I202) in the distilled water to a final volume of 100ml. The solution was adjusted 
to pH 8.0 with NaOH and stored at 4 °C. 
NaCl The stock solution (2M) was prepared by dissolving 58.44g NaCl (Sigma-Aldrich, 
S3014-5KG) in the distilled water to a final volume of 500ml and stored at room 
temperature. 
Sodium Phosphate buffer (pH 8.0) The stock solution (0.1 M) was prepared by dissolving 
1.65g NaH2PO4 (Sigma-Aldrich, S0751) and Na2HPO4 (Sigma-Aldrich, S5136) in the 
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distilled water to a final volume of 500ml and pH was adjusted to pH 8.0. The stock 
solution was stored at 4°C for up to 1 month. 
Phosphate buffered saline (PBS, 1x) The powder (Severn, 20-7461-01) was dissolved in 
10L distilled water and autoclaved at 121°C for 20min for cell culture purpose. The 
1xsolution was stored at room temperature. 
Paraformaldehyde (PFA, 4%) The solution was prepared by diluting 16% PFA (Pierce, 
28908) with 30 ml 1xPBS and stored at room temperature 
Tris-HCl (pH 8.0) 1M stock solution (pre-autoclaved) was obtained from Severn Biotech 
Ltd. (20-7901-01) and stored at room temperature. 
Tris-HCl (pH 6.8) 1M stock solution (pre-autoclaved) was obtained from Severn Biotech 
Ltd. (20-7901-10) and stored at room temperature. 
His binding buffer 50mM Tris-HCl (pH 8.0), 500mM NaCl and 5mM imidazole were 
dissolved in the distilled water to make the final volume to 50ml and stored at 4°C. 
His elution buffer 50mM Tris-HCl (pH 8.0), 500mM NaCl and 50mM imidazole were 
dissolved in the distilled water to make the final volume to 50ml and stored at 4°C. 
2.1.6.2 DNA buffers 
Tris-borate-EDTA (TBE, 50x) The stock solution (Severn, 206000) was stored at room 
temperature. The working solution was prepared by diluting the stock into 1x, and the 
unused solution was stored at room temperature. 
DNA Agarose Gel Loading Buffer (10x) 50% (v/v) glycerol and 0.25% (w/v) Bromophenol 
Blue were dissolved in 1xTBE and stored at room temperature. The working 
concentration was 1x. 
DNA Agarose Gel 0.8-1.2% (w/v) agarose was added to 1xTBE and dissolved by heating 
in a microwave till the solution changed from cloudy to clear. The agarose was then left 
to cool to approximately 50°C, and RedSafeTM (iNtRON, 21141) was added and mixed. 
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The mixture was poured into the module and left to set. The percentage weight of 
agarose was varied depending on the size of DNA to be analysed. The smaller the 
percentage is, the better and the bigger size of DNA can be analysed.  
2.1.6.3 Cell lysis/washing buffers 
Passive Lysis Buffer (PLB) (5x): 5x PLB (Promega, E1941) was stored at -20°C and diluted 
to 1x with the distilled water immediately prior to use. 
NP-40 Lysis buffer 50mM Tris-HCl pH 8.0, 150mM NaCl, 1% (v/v) and IGEPAL CA-630 
(Sigma-Aldrich, I8896) were dissolved in the distilled water to make the final volume to 
500ml.   
RIPA Lysis buffer 50mM Tris-HCl pH 8.0, 150mM NaCl, 0.5% (w/v) sodium deoxycholate 
(Sigma-Aldrich, D6750), 0.1% (w/v) sodium dodecyl sulphate (SDS, Thermo Fisher 
BP166), and 1% (v/v) IGEPAL CA-630 were dissolved in the distilled water to make the 
final volume to 500ml. The buffer was stored at 4°C. 
Buffer A 150mM NaCl, 20mM Tris (pH 8.0), 1mM MgCl2 (Severn Biotech Ltd., 20-xxxx-
01), 0.1% (v/v) IGEPAL CA-630 and 10% (v/v) glycerol (VWR, 200-289-5) were dissolved 
in the distilled water to make the final volume to 500ml. The buffer was stored at 4°C. 
Bovine serum albumin (BSA) solution 5% (w/v) of BSA (ACROS, 268131000) was 
dissolved in the distilled water prior to use.  
Protease & phosphatase inhibitor cocktail (1x) The working solution was prepared by 
dissolving one cOmplete ULTRA Mini EDTA-free protease inhibitor cocktail tablet (Roche, 
05892791001) and one PhosSTOP phosphatase inhibitor cocktail tablet (Roche, 
04906837001) per 10ml of any lysis buffers for mammalian and bacterial cell lysis 
immediately prior to use. The unused buffer was aliquoted and stored at -20°C for up to 
1 month. 
MG-132 proteasome inhibitor (1000x) 10mM stock solution was prepared by dissolving 
1mg MG-132 (Calbiochem, 474790) in the distilled water. The stock aliquots were stored 
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at -20°C and diluted to 1x in any lysis buffers for the mammalian cell lysis immediately 
prior to use. 
2.1.6.4 Protein purification buffers 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) The stock solution (1M) was prepared by 
dissolving 2.383g IPTG (ICN, 102101) in 10ml distilled water and stored at -20°C. 
Glutathione resin for the capture of GST-tagged proteins Glutathione Sepharose® 4B 
resin (GE Healthcare, 17-0756-01) was washed once in PBS by vortex gently and 
centrifuged for 1 min at 800g, 4°C to remove any ethanol in the storage buffer. The 
supernatant was discarded after centrifugation. 
Nickel resin for the capture of His-tagged proteins HIS-Select® Nickel Affinity Gel (Sigma-
Aldrich, P6611-5ML) was washed once in PBS by vortex gently and centrifuged for 1 min 
at 800g, 4°C to remove any ethanol in the storage buffer. The supernatant was aspirated 
after centrifugation. 
anti-MBP magnetic resin for the capture of MBP-tagged proteins anti-MBP Magnetic 
Resin (New England Biolabs, E8037S) was washed in 0.1M Sodium phosphate buffer (pH 
8.0), and the magnet was then applied for 30s to pull resin to the side of the tube. The 
supernatant was aspirated.  
2.1.6.5 Solutions for sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blotting 
SDS-PAGE Sample buffer (5x) Tris-HCl (pH 6.8), 50% (v/v) glycerol, 5% (w/v) SDS, 5% (v/v) 
β-mercaptoethanol (Sigma-Aldrich, M7522) and 0.5% (w/v) Bromophenol Blue (Sigma-
Aldrich, 204-086-2) were dissolved in the distilled water to make the final volume to 
500ml. The preparation of this buffer should be performed in the fume hood. The dry 
components were allowed to fully dissolve before the addition of glycerol. The buffer 
was aliquoted and stored at -20 °C. 
SDS-PAGE resolving gel ProtoGel® 30% acrylamide: bisacrylamide (37.5: 1) solution 
(National Diagnostics, EC-890), 4xresolving buffer (1.5M Tris-HCl, pH 8.8, National 
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Diagnostics, EC-892), 0.1% (w/v) ammonium persulphate (APS, Sigma-Aldrich, A3678) 
and 0.1% (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED, Sigma-Aldrich, T9281) 
were dissolved in the distilled water to make a gel containing 8-12% acrylamide. APS 
and TEMED were immediately added and inverted gently before pouring into Mini-
PROTEAN® casting plates (Bio-Rad), leaving around 1cm space on the top for the stacking 
gel. 100% ethanol was added to cover the top of the gel solution in the casting plates to 
eliminate bubbles and ensure a horizontal edge. The gel was allowed to set around 
20min at room temperature. The ethanol was then completely removed by using filter 
paper. 
SDS-PAGE stacking gel ProtoGel® 30 % acrylamide: bisacrylamide (37.5:1) solution, 
4xstacking buffer (1.0 M Tris-HCl, pH 6.8, National Diagnostics #EC-893), 0.1% (w/v) APS 
and 0.2% (v/v) TEMED were dissolved in the distilled water to make a gel containing 4% 
acrylamide. APS and TEMED were immediately added and inverted gently before 
pouring into casting plates. The comb was then immediately inserted before the gel 
began to set. The gel was allowed to set around 30min at room temperature. The gels 
were used immediately or stored at 4°C by wrapping with damp tissue paper and cling 
film to prevent drying out.  
Precision Plus Protein™ all blue molecular weight marker The marker (Bio-Rad, 
1610373) was stored at -20°C. 
Tris/glycine/SDS Running Buffer (10x) 1xworking solution was made by diluting 10xTris 
Glycine SDS (Severn Biotech Ltd., 20-6400-50). Unused 1xsolution was stored at room 
temperature. 
Tris/glycine Transfer Buffer (10x) 1xworking solution was made by diluting 10xTris 
Glycine (Severn Biotech Ltd., 20-6300-50). Unused 1xsolution was stored at room 
temperature. 
PBS-Tween (1x) 0.05% (v/v) Tween® 20 (Sigma-Aldrich, P1379-250ml) was added to 
1xPBS and stored at room temperature. 
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Blocking Solution 5% marvel skim milk powder (Sigma-Aldrich, 70166-500G) was 
immediately dissolved in 1xPBS-Tween prior to use and stored at 4°C for up to 1 day. 
Coomassie Blue Protein Staining 0.12% (w/v) Coomassie Brilliant Blue R (Sigma-Aldrich, 
6104-59-2), 50% (v/v) methanol (Fisher, M/3950/17) and 20% (v/v) acetic acid (Sigma-
Aldrich, 33209-2.5L) were dissolved in the distilled water to make the final volume to 1L. 
The solution was then filtered through 3mm filter paper and stored at room 
temperature. 
Coomassie Blue de-staining solution 20% (v/v) methanol and 10% (v/v) acetic acid were 
dissolved in the distilled water to make the final volume to 1L and stored at room 
temperature. 
2.1.6.6 Dual-luciferase reporter assay solutions 
Dual-Luciferase Reporter Assay System The kit (Promega, E1960) contains a Luciferase 
Assay Buffer and Stop&Glo® Reagent for the measurement of firefly and renilla luciferase 
signals respectively. The kit was stored at -20°C. The reagent was mixed with the distilled 
water at 1:1 ratio prior to use. The Luciferase assay buffer was firstly used for detection 
of Firefly luciferase activity. The Stop&Glo reagent was then added for detection of 
renilla luciferase activity. 
2.2 Methods 
 
2.2.1 Bacterial culture methods 
 
2.2.1.1 PCR amplification 
Purified plasmid DNA was used as a template in the 25μl reaction for PCR amplification. 
Phusion® Hot Start Flex 2xMaster Mix (NEB, M0536S), 3% DMSO [240] and the pair of 
DNA primers ( 
 
Table 2.1) were mixed. PCR protocols for thermocycler were set according to the 
manufacturer's guidelines. dsDNA templates were initially denatured for 30s at 98°C. 30 
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cycles of denaturation (10s at 98°C), annealing (30s at a primer-dependent temperature), 
and extension (periods according to the product size at 72°C). A final extension step was 
10min at 72°C. The extension time was set to 30s/kb for the target gene. 
2.2.1.2 Sequence specific digestion of DNA by restriction enzymes 
The purified plasmid DNA or PCR products were digested in a total volume of 20µl, using 
1µl of each required restriction enzyme in the appropriate buffer and incubated at 37°C 
for 2h, no longer than 4h. The enzyme was inactivated by incubating at 80°C for 20min 
(Table 2.3). 
BseRI (New England Biolabs, R0581S) and SspI (New England Biolabs, R3132) was stored 
at -20°C. 
 
Table 2.3 Table of conditions of restriction enzyme digestions used in this study  
BseRI was used to linearise pETFPP_2 vector, and SspI was used to linearise pMCSG10 vector. Heat 
inactivation time was 20min for both enzymes 
Enzyme Buffer Incubation time Inactivation temperature 
BseRI 1x CutSmart® Buffer 2h 80°C  
SspI NEBuffer2 2h 65°C  
 
2.2.1.3 Agarose gel electrophoresis and gel extraction of DNA fragments 
Agarose gel contains 0.7-1.2% agarose and 1xRedSafe. The percentage of gels depends 
on the size of the desired separation DNA. Gels were run at a constant voltage of 100V 
in TBE buffer until the desired DNA was separated detected by G: Box system (SYNGENE). 
For gel extraction, DNA bands were visualised and excised on a UV-light box under the 
proper protection. DNA then was extracted and purified by following the manufacturer’s 
instructions (Qiagen, 28704).  
2.2.1.4 Ligation independent cloning (LIC) 
LIC is an alternative technique allowing efficient creation of various recombinant 
plasmids. Due to the long 3’ complementary overhangs on the insert and vector, it 
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maximises the specificity of annealing and correction of insertion with a lower chance 
of self-circularization of vector [241]. Compared to ligation dependent cloning, the 
procedure does not require the use of T4 ligase, or alkaline phosphatase. It depends on 
the action of endo (3’-5’) of T4 DNA polymerase with the presence of the single dNTP to 
generate the complementary overhangs between the target vector and PCR products.  
For generating LIMD1 mutants constructs in this project, gene of interest was PCR 
amplified using the pair of primers designed to contain 12nts on 5’ end (Figure 2.4A). 
This 12-nt overhang is the same as to the sequence on the vector backbone. After PCR 
amplification, the products were treated with T4 DNA polymerase (New England Biolabs, 
M0203S) with the presence of dATP (Bioline, BIO-39036) (Figure 2.4A). In the presence 
of dATP, the polymerase activity and the 3’-5’ exonuclease activity of T4 DNA 
Polymerase are balanced and generate long overhangs on the 5’ends (Figure 2.4A). The 
pETFPP_2 vector was linearised by BseRI and then was treated with T4 DNA polymerase 
with the presence of dTTP (Bioline, BIO-39039), generating long overhangs on the 3’ends 
(Figure 2.4B). On the other hand, for pMCSG10 vector, SspI was used for vector 
linearization, and dCTP (Bioline, BIO-39038) and dGTP (Bioline, BIO-39037) were used 
for T4 DNA polymerase treatment. The reaction was performed at room temperature 
for 90min, followed by 75°C for 20min to deactivate T4 DNA polymerase. The treated 
vector and PCR products were then mixed for annealing (Figure 2.4C) at room 
temperature for 5min, followed by an optional procedure that 5-min incubation at room 
temperature with 25mM EDTA (Severn, 20-5300-01). EDTA is a metal chelator to 
diminish the metal reactivity on which the activity of metal-dependent enzymes such as 
polymerase relies. Although heat deactivation was carried out before annealing, the 
trace polymerase activity might still exist. Therefore, by adding EDTA, it can decrease 
the likelihood of unsuccessful annealing. Besides, it can also protect DNA from being 
damaged by potential nuclease contamination. The annealing mixture was then 
performed for transformation.  
  





Figure 2.4 A flowchart for Ligation independent cloning 
A) Gene of interest was PCR amplified using the pair of primers designed to contain the additional 
nucleotides on the 5’ end, which was the same as to the sequence on the vector backbone. The PCR 
product was then treated with T4 DNA polymerase in the presence of dATP, creating long overhangs on 
the 5’ends. B) The vector was linearised by a restriction enzyme and then treated with T4 DNA polymerase 
in the presence of dTTP, creating long overhangs on the 3’ends. C) The overhangs generated by the T4 
DNA polymerase on both PCR product and vector are complementarty. The treated vector and PCR 
product were then mixed for annealing in the presence of EDTA. 
 
2.2.1.5 Site-directed mutagenesis of plasmids 
Q5® Site-Directed Mutagenesis was used to generate the internal deletion mutants and 
the point mutation in this project. To create pMCSG10-AGO2 N-L1-PAZ truncation 
mutant, a pair of DNA primers flanking the CDS of L2-MID-PIWI was designed and used 
PCR for amplifying the linear DNA sequences without the undesired sequences (Figure 
2.5A). To create a point mutation in this project (EYFP-AGO2 Y393), the desired 
nucleotide changes are designed in the forward primer, including long complementary 
nucleotides on the downstream of the mutation to allow a sufficient annealing (Figure 
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2.5C). PCR was used to amplify the linear DNA sequences with the desired point 
mutation. After PCR amplification, a small portion of the linear PCR product was 
visualised by agarose gel electrophoresis to check a single product of the expected size 
of the band was amplified, and the majority was applied for column purification to 
remove any polymerase. The purified DNA was then treated with KLD Mastermix for 
5min at room temperature (Figure 2.5B and Figure 2.5D). Under the treatment of KLD, 
kinase phosphorylates the 5’-hydroxyl terminus and in turn allows 5’-phosphate group 
for ligation by ligase to circularise the linear PCR product. DpnI degrades the methylated 
template DNA produced by E.coli. The mixture was then prepareded for transformation.  
 
 
Figure 2.5 A flowchart for site-directed mutagenesis 
A) The sequence of pMCSG10-AGO2 N-L1-PAZ and the vector bone were linearly amplified by using a pair 
of DNA primers flanking the undesired CDS of L2-MID-PIWI (highlighted in yellow). B) The PCR product 
was treated with KLD to circularise the linear DNA and remove the circular template DNA. C) The 
sequence of EYFP-AGO2 point mutation was linear amplified. The desired point mutation is indicated in 
a yellow star. D) The PCR product was treated with KLD to circularise the linear DNA and remove the 
circular template DNA. 
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2.2.1.6 Transformation of E.coli strains for plasmid DNA production 
Chemically competent DH5α bacteria (NEB, C2988J) were thawed on ice immediately 
prior to use and gently tapped to ensure complete resuspension (avoid pipetting). 5µl 
of annealed DNA or 1µl of plasmid DNA was added to 40µl bacteria and gently tapped 
again to ensure mix well, followed by the incubation on ice for 30min. The bacteria were 
then heat shocked in a water bath (42°C, 35s) and placed on ice to recover for 2min. 
500µl of sterile SOC broth (New England Biolabs, B9020S) was added before the 
incubation at 37°C with vigorous shaking (220rpm) for 60min. 100µl of the bacteria were 
spread onto LB-agar plates containing the appropriate antibiotic and incubated 
overnight at 37°C. Plates were removed from the incubator on the following morning 
(no more than 16h incubation) and stored at 4°C for up to 1 month. The individual 
bacterial colony was picked by a sterile 10µl pipette tip and inoculated in 5ml of LB broth 
containing the same appropriate antibiotic overnight at 37°C with vigorous shaking 
(220rpm). The bacterial pellet was collected on the following morning by centrifugation 
(5000g, 5min).  
To store the inoculated E.coli, 800µl solution was mixed with 200µl glycerol and stored 
at -20°C. For recovery, a sterile 10µl pipette tip was used to pick the frozen solution and 
spread onto LB-agar plates. 
2.2.1.7 Preparation of plasmid DNA 
The inoculated E.coli solution was centrifuged at 5000rpm, 4°C for 5min to collect the 
bacterial pellet. The plasmid DNA was then extracted from the bacterial pellet by using 
High Pure Plasmid Isolation Kit (Roche, 11754785001), or Genopure Plasmid Midi Kit 
(Roche, 03143414001) on different experimental purpose by following the 
manufacturer's instruction.  
2.2.1.8 Quantification of DNA concentrations 
DNA concentration was measured using a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies Inc.). The pedestals were wiped with 100% ethanol and the 
distilled water after each measurement. The instrument was blanked with 1µl of the 
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same buffer in which DNA eluted. 1µl of the DNA sample was used per measurement 
with both a 260nm and 280nm light absorbance values. The ratio of 260/280 between 
1.8-2.0 means DNA is pure. The ratio 260/230 between 2.0-2.2 means no protein 
contamination. The concentration was measured twice for each DNA sample, and an 
average value was taken. 
2.2.1.9 DNA sequencing 
DNA sequencing was performed by Source BioScience on an Applied Biosystems 3730 
DNA Analyzer. The sequencing result was analysed by Multiple Sequence Comparison 
by Log-Expectation (MUSCLE) [242].  
2.2.1.10 Transformation of E.coli strains for protein production and expression of the 
recombinant proteins 
Rosetta™ (DE3) pLysS cells (Novagen, 70956) were thawed on ice and gently tapped to 
ensure complete resuspension. 0.5µl of plasmid DNA was added to 2µl the bacteria and 
gently tapped again to ensure mix well, followed by the incubation on ice for 5min. The 
bacteria were heat shocked in a water bath (42°C, 35s) and then incubated on ice to 
recover for 2min. 500µl of sterile SOC broth was added to the bacteria before being 
incubated at 37°C with vigorous shaking (220rpm) for 60min. 100µl of the bacteria were 
spread onto LB-agar plates containing the appropriate antibiotic and incubated 
overnight at 37°C. Plates were removed from the incubator on the following morning 
(no more than 16h incubation) and stored at 4°C for up to 1 month.  
The individual bacterial colony was picked by a sterile 10µl pipette tip and inoculated in 
5ml of LB broth containing the same appropriate antibiotic overnight at 37°C with 
vigorous shaking (220rpm). For large-scale culture, the inoculated culture was diluted (1: 
50) into sterile LB broth containing the same appropriate antibiotic on early afternoon. 
The culture was incubated at 37°C with vigorous shaking (150rpm) for 90min, followed 
by incubation at 18°C with vigorous shaking (130rpm) for 17 h. About 60min later, the 
optical density at 600nm reached 0.6-0.8. IPTG, which is an allolactose mimic negatively 
regulating the lac repressor, was then added to reach a final concentration of 1mM to 
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induce the protein expression for overnight. The cultures were held at 4°C after the 
overnight incubation.  
After overnight inoculation, the bacterial pellets were collected and frozen on dry ice. 
The pellets were then thawed on ice and dissolved in 2.8ml/g of RIPA buffer (50mM Tris-
HCl, pH 8.0, 150mM NaCl, 0.5% (w/v) SDS, 1% (v/v) IGEPAL CA-630) with protease 
inhibitor and phosphatase inhibitor. The suspension was frozen on dry ice and thawed 
again, followed by sonication in a 30s burst for three times until the suspension became 
watery. The 10s pause was taken between each burst to prevent the suspension 
overheat. The lysates were then centrifuged at 4°C for 15min at 21,500g, and the 
supernatant was collected and stored at -80°C for later use. 
2.2.1.11 Recombinant protein purification and elution of His-tagged proteins 
MBP-tagged protein expressed in pETFPP_2 vector system also has His tags. As a result, 
HIS-Select® Nickel Affinity Gel can be used to purify and elute the protein for later use. 
25μl of pre-washed gel was incubated with 500μl cell lysates at 4°C with rotation for at 
least 30min. The gel was then washed three times with His binding buffer with vortex 
and centrifugation at 4°C for 1min, 500g, followed by eluting with His elution buffer with 
rotation at 4°C overnight. After overnight incubation, the supernatant was collected 
after centrifugation at 4°C for 1min at 500g. The imidazole in the eluted proteins was 
removed by Amiconultra (Amicon, UFC501024). The purified protein was then stored at 
-20°C for later use. 
2.2.2 Cell culture methods 
 
2.2.2.1 Cell culture 
All cell lines used in this study and their regular cultures are listed in the Table 2.4. 
Human lung epithelial cancer cell line A549 (shSCR and shLIMD1) and Human breast 
cancer cell line MDA-MB-435 (FH-VO and FH-LIMD1) were lentivirally-transduced for 
stable knowdown or re-expressing LIMD1, respectively. Human cervical epithelial cancer 
cell line HeLa (Cas9 Control and LIMD1-/-) LIMD1 knockout CRISPR-Cas9 edited cell lines 
were generated using the lenti-CRISPR v2 plasmid (Appendix Figure 11.1) [243], 
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acquired from Addgene (plasmid, 52961). Therefore, three pairs of isogenic cell lines 
with regards to expressing LIMD1 or not were generated. Besides all cell lines mentioned 
above, human bone osteosarcoma U2OS, human bronchoalveolar lung carcinoma cell 
line H358M, human lung adenocarcinoma cell line H838 and H522, human squamous 
cell carcinoma H520, human biphasic mesothelioma MSTO-211H, and human lung 
mesothelioma H28 were cultured in the humidified incubator with 5% CO2, 20% O2 using 
DMEM with required selective drugs. DMEM was supplemented with 10% (v/v) FBS) and 
1% (v/v) Penicillin-Streptomycin. Human small airway epithelial cell (SAEC) was cultured 
in the humidified incubator with 5% CO2, 20% O2 using a specific media.  
 
Table 2.4 Table of cells used in this study  
Cell Organism Tissue Cell type Disease 
Mycoplasma 
tested or not 
A549 Human Lung Epithelial Carcinoma Yes 
MDA-MB-435 Human Breast Epithelial Carcinoma Yes 
HeLa Human Cervix Epithelial Adenocarcinoma Yes 
U2OS Human Bone Epithelial Osteosarcoma Yes 
H358M Human Lung Epithelial Carcinoma Yes 
H838 Human Lung Epithelial Adenocarcinoma Yes 
H522 Human Lung Epithelial Adenocarcinoma Yes 
H520 Human Lung Epithelial Carcinoma Yes 
MSTO-211H Human Lung Fibroblast Mesothelioma Yes 
H28 Human Lung Epithelial Mesothelioma Yes 
SAEC Human Lung Epithelial  Yes 
 
2.2.2.2 Splitting and seeding of the cells 
Only adherent cell lines were used in this project. Once the adherent cells form a 
confluent monolayer, the colour of the media, indicating pH, changes from red to yellow. 
The old media was removed, and the cells were washed gently with 5ml auto-cleaved 
PBS. 3ml (for T75 flask) of trypsin-EDTA was added, and the cells were incubated at 37°C 
for 5min to detach the cells from the bottom of the culture flask. 7ml pre-warmed 
DMEM was added to neutralise trypsin-EDTA, and the cell suspension was transferred 
into a 15ml Falcon tube, followed by centrifugation at 1200rpm for 3min. The 
supernatant was then discarded, and the cell pellet was re-suspended in 5-13ml DMEM. 
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1/5-1/20 of the cell suspension was transferred to a new flask depending on the 
proliferation rate of the cell line and then topped with pre-warmed DMEM to 10ml.  
To seed an exact number of cells, the concentration of cell suspension was then counted 
using a TC10™ Automated Cell Counter (Bio-Rad). 
2.2.2.3 Freezing the cells for storage 
After the routine split, the leftover of cell suspension was centrifuged at 1200rpm for 
3min, to remove the supernatant. The pellet was then washed with PBS and centrifuged 
at 1200rpm for 3min. The supernatant was discarded. The pellet was then re-suspended 
in the cell freezing mix and aliquoted into a 1ml vial, stored at -80°C for short-term 
storage and in liquid nitrogen for long-term storage.  
2.2.2.4 Hypoxic treatment of the cells 
The proper number of cells was seeded in 12-well plate to reach 80% confluent after 
72h incubation. One plate of cells was left in normoxia (20% O2) for 72h. The second 
plate was moved to the hypoxia (1% O2) at 68h and allowed to set in hypoxia for 4h. The 
third plate was moved to the hypoxia (1% O2) at 48h and allowed to set in hypoxia for 
24h. All plates of cells were collected at the endpoint (72h). The protein was extracted 
for the downstream analysis.  
2.2.2.5 General transfection of DNA 
The proper number of cells was seeded 24h before transfection to achieve 30-50% 
confluent. For DNA transfection, Viafect (Promega, E2692) was used, and the ratio was 
3μl Viafect per μg of plasmid DNA. For each well of 12-well plate, 100μl of Opti-MEM 
was mixed well with the proper amount of Viafect by vortex and pulse centrifugation. 
The transfection reagent mixture was then incubated at room temperature for 5min, 
followed by adding the plasmid DNA. The mixture was then mixed well and incubated at 
room temperature for 20min. After incubation, the transfection complexes were gently 
added dropwise to the cells. The cells were then incubated for 48h for the downstream 
usage. 
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2.2.2.6 Preparation of mammalian cell lysates for direct binding 
2 hours before lysing the cells, MG-132 (Sigma-Aldrich, 1211833-36-9), a reversible and 
cell-permeable proteasome inhibitor, was added to the cell media to make the final 
concentration to 10mM. After 2h incubation with MG-132, the cells were washed three 
times with ice cold PBS and lysed in 500μl NP-40 with the protease inhibitor and 
phosphatase inhibitor. The cells were then scraped by the reverse end of P1000 pipette 
tip, and cell lysates were transferred to 1.5ml Eppendorf, followed by vortex 3s for three 
times. Between each vortex, cell lysates were incubated on ice for 3s. Cell debris was 
discarded after centrifugation at 4°C, 13,000rpm for 10min and the supernatant was 
transferred into new Eppendorf and stored on ice for immediate use for the MBP pull-
down assay.  
2.2.2.7 Human Kinome siRNA Library screening and cell viability assay 
Mock transfection and optimisation INTERFERin and Lipofectamine RNAiMAX 
(hereafter refer to Lipofectamine) were used for the mock transfections to evaluate and 
optimise the cytotoxicity and transfection efficiency. Both INTERFERin and 
Lipofectamine are non-liposomal cationic transfection reagents whose activity 
depend on the basic structure of cationic lipids containing a positively charged head 
group. Nucleic acids are negatively charged because of the polyphosphate backbone, 
resulting in the interaction with the positively charged cationic lipids to form 
transfection complexes. These transfection complexes are positively charged due to 
the structure of lipids, allowing to interact with the negatively charged cell membrane. 
Once interacted, cells uptake these complexes into the cytoplasm via an endocytosis 
process. These transfection complexes then release nucleic acids which diffuse through 
the cytoplasm and function. 
Library screening For library screening, cell viability assay for validation and 
investigation, the seeding number (Table 2.5) for the cells was optimised to achieve 90-
100% confluent at the endpoint (Day 5). To achieve 50μM siRNA for the final 
concentration, the cells were seeded on 96-well plate on Day 1. Transfection was 
performed after 24h seeding the plate. 0.5μl of transfection reagents was mixed well 
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with 50μl of Opti-MEM by vortex and pulse centrifugation. The transfection reagent 
mixture was then incubated at room temperature for 5min, followed by mixing well with 
the proper amount of siRNA to meet the experiment requirement. For library screening, 
the final concentration of SMARTPool siRNA (Table 2.6). The mixture was then incubated 
at room temperature for 20min. Because the screening was to find out the synthetic 
lethality, the isogenic pair of each cell line was used. To keep the same siRNA was 
transfected into two cell lines, 50μl of transfection complexes was aliquoted to each cell 
line after the cells media was removed, followed by adding 75μl cell media. The cells 
were then incubated in the incubator for 24h before the cell media was changed on Day 
3. The cells were then incubated for another 48h (Day 5) for endpoint measurement and 
analysis.  
 
Table 2.5 Table of seeding numbers of each cell line in 96 well plate format in this study 
The exact seeding number in 96 well plate of each cell line used in this study for target validation and cell 
viability assay. 
Cell line 













1000 cells/well SAEC 2000 cells/well 
A549 2000 cells/well H28 2000 cells/well 
H520 2000 cells/well H522 2000 cells/well 
H838 3000 cells/well H358M 1500 cells/well 
MSTO-211H 2000 cells/well   
 
Cell viability was measured five days after transfection using the 96-well plate CellTiter-
Glo Luminescent Cell Viability Assay kit (Promega, G7570) according to the 
manufacturer's instructions. Luminescence readings from each well were log 
transformed and normalised according to the median signal on each plate and then 







































































Table 2.6 Table of siRNAs used the library screening and target validation 
Kinome library siRNA screen was used siGENOME® SMARTPool® siRNA Library targeting Human Protein Kinase. siNTC is non-targeting siRNA control pool. All siRNAs are for 
Homo sapiens. 
Target Gene Symbol Gene ID Gene Accession Alias Sequence Length Pool Catalog Number Manufactory 
Human Protein Kinases - - - - 19 G-003505 Dharmacon 
- - - siNTC/siSCR - 19 D-001206-13-20 Dharmacon 
PLK1 5347 NM_005030 siPLK1 SMARTPool Pool of the following 4 19 M-003290-01 Dharmacon 
AAK1 22848 NM_014911 siAAK1 SMARTPool Pool of the following 4 19 M-005300-01 Dharmacon 
AAK1 22848 NM_014911 siAAK1 #1 GACAUGCACUGCCUAAUUA 19 D-005300-01 Dharmacon 
AAK1 22848 NM_014911 siAAK1 #2 GUACAGAACUCUCCCAUUC 19 D-005300-02 Dharmacon 
AAK1 22848 NM_014911 siAAK1 #3 GAUGAAAUGUGCCUUGAAA 19 D-005300-03 Dharmacon 
AAK1 22848 NM_014911 siAAK1 #4 GAAGGUGGAUUUGCUAUUG 19 D-005300-04 Dharmacon 
ACVR2B 93 NM_001106 siACVR2B SMARTPool Pool of the following 4 19 M-004927-01 Dharmacon 
ACVR2B 93 NM_001106 siACVR2B #1 GAACGAACUGUGUCAUGUA 19 D-004927-01 Dharmacon 
ACVR2B 93 NM_001106 siACVR2B #2 AAAGAUCACUGGUUGAAAC 19 D-004927-02 Dharmacon 
ACVR2B 93 NM_001106 siACVR2B #3 ACGAGAACCUGCUACAGUU 19 D-004927-04 Dharmacon 
ACVR2B 93 NM_001106 siACVR2B #4 CUGAAUAGGCAAAGCGAUU 19 D-004927-17 Dharmacon 
AURKB 9212 NM_004217 siAURKB SMARTPool Pool of the following 4 19 M-003326-08 Dharmacon 
AURKB 9212 NM_004217 siAURKB #1 CAGAAGAGCUGCACAUUUG 19 D-003326-07 Dharmacon 
AURKB 9212 NM_004217 siAURKB #2 CCAAACUGCUCAGGCAUAA 19 D-003326-08 Dharmacon 
AURKB 9212 NM_004217 siAURKB #3 ACGCGGCACUUCACAAUUG 19 D-003326-09 Dharmacon 
AURKB 9212 NM_004217 siAURKB #4 UGGGACACCCGACAUCUUA 19 D-003326-10 Dharmacon 
BMPR1A 657 NM_004329 siBMPR1A SMARTPool Pool of the following 4 19 M-004933-04 Dharmacon 
BMPR1A 657 NM_004329 siBMPR1A #1 GGACUCAGCUCUAUUUGAU 19 D-004933-03 Dharmacon 
BMPR1A 657 NM_004329 siBMPR1A #2 CAGCUACGCCGGACAAUAG 19 D-004933-07 Dharmacon 
BMPR1A 657 NM_004329 siBMPR1A #3 CGAGUGAUCCGUCAUACGA 19 D-004933-08 Dharmacon 
BMPR1A 657 NM_004329 siBMPR1A #4 CCGCAAUUGCUCAUCGAGA 19 D-004933-24 Dharmacon 
DCK 1633 NM_000788 siDCK SMARTPool Pool of the following 4 19 M-006710-00 Dharmacon 
DCK 1633 NM_000788 siDCK #1 CCAGAGACAUGCUUACAUA 19 D-006710-01 Dharmacon 
DCK 1633 NM_000788 siDCK #2 GCAGGGAAGUCAACAUUUG 19 D-006710-02 Dharmacon 
DCK 1633 NM_000788 siDCK #3 UGAAUUGGAUGGAAUCAUU 19 D-006710-03 Dharmacon 





































































DUSP21 63904 NM_022076 siDUSP21 SMARTPool Pool of the following 4 19 M-007893-02 Dharmacon 
DUSP21 63904 NM_022076 siDUSP21 #1 GGGAACAGCUCAUCAAUUA 19 D-007893-01 Dharmacon 
DUSP21 63904 NM_022076 siDUSP21 #2 UUGCGUACCUCAUGAAAUA 19 D-007893-03 Dharmacon 
DUSP21 63904 NM_022076 siDUSP21 #3 CAAAUAACCAGAAGCUUGU 19 D-007893-04 Dharmacon 
DUSP21 63904 NM_022076 siDUSP21 #4 CGGUGGAAGUGGUCAACGU 19 D-007893-18 Dharmacon 
EFNB3 1949 NM_001406 siEFNB3 SMARTPool Pool of the following 4 19 M-011261-00 Dharmacon 
EFNB3 1949 NM_001406 siEFNB #1 CAAACCUCCUUCUCACUUG 19 D-011261-01 Dharmacon 
EFNB3 1949 NM_001406 siEFNB #2 GUAUAGCCCUAAUCUCUGG 19 D-011261-02 Dharmacon 
EFNB3 1949 NM_001406 siEFNB #3 GCUCGCACCACGAUUACUA 19 D-011261-03 Dharmacon 
EFNB3 1949 NM_001406 siEFNB #4 CUCCAAACAUCUACUACAA 19 D-011261-04 Dharmacon 
ERBB4 2066 NM_001042599 siERBB4 SMARTPool Pool of the following 4 19 M-003128-03 Dharmacon 
ERBB4 2066 NM_001042599 siERBB4 #1 GCAGGAAACAUCUAUAUUA 19 D-003128-06 Dharmacon 
ERBB4 2066 NM_001042599 siERBB4 #2 GAUCACAACUGCUGCUUAA 19 D-003128-07 Dharmacon 
ERBB4 2066 NM_001042599 siERBB4 #3 GCUCUGGAGUGUAUACAUU 19 D-003128-09 Dharmacon 
ERBB4 2066 NM_001042599 siERBB4 #4 GGAAUUCCAACGCGAGAAA 19 D-003128-22 Dharmacon 
HIPK2 28996 NM_022740 siHIPK2 SMARTPool Pool of the following 4 19 M-003266-03 Dharmacon 
HIPK2 28996 NM_022740 siHIPK2 #1 GAGAAUCACUCCAAUCGAA 19 D-003266-06 Dharmacon 
HIPK2 28996 NM_022740 siHIPK2 #2 AGACAGGGAUUAAGUCAAA 19 D-003266-07 Dharmacon 
HIPK2 28996 NM_022740 siHIPK2 #3 GGACAAAGACAACUAGGUU 19 D-003266-08 Dharmacon 
HIPK2 28996 NM_022740 siHIPK2 #4 GCACACACGUCAAAUCAUG 19 D-003266-09 Dharmacon 
MAGI3 260425 NM_152900 siMAGI3 SMARTPool Pool of the following 4 19 M-009453-02 Dharmacon 
MAGI3 260425 NM_152900 siMAGI3 #1 GGACAGAAGUGCCCUAGAA 19 D-009453-01 Dharmacon 
MAGI3 260425 NM_152900 siMAGI3 #2 GAAGAUAAACCACCAAACA 19 D-009453-04 Dharmacon 
MAGI3 260425 NM_152900 siMAGI3 #3 CCUGACCAGUCUAUAUAUA 19 D-009453-05 Dharmacon 
MAGI3 260425 NM_152900 siMAGI3 #4 GCUGAUGUACCAUUGCUUA 19 D-009453-06 Dharmacon 
NEK1 4750 NM_012224 siNEK1 SMARTPool Pool of the following 4 19 M-004864-01 Dharmacon 
NEK1 4750 NM_012224 siNEK1 #1 GAAAUAAACCCAUCAGCUA 19 D-004864-01 Dharmacon 
NEK1 4750 NM_012224 siNEK1 #2 GAGAGAAGUUGCAGUAUUG 19 D-004864-02 Dharmacon 
NEK1 4750 NM_012224 siNEK1 #3 GAAUUUGGCUUAUCAGAAU 19 D-004864-03 Dharmacon 
NEK1 4750 NM_012224 siNEK1 #4 GGGAAGCUAUGCAGAAUAA 19 D-004864-04 Dharmacon 
NRBP2 340371 NM_178564 siNRBP2 SMARTPool Pool of the following 4 19 M-005340-02 Dharmacon 





































































NRBP2 340371 NM_178564 siNRBP2 #2 GGAAUCUACCCACUGAUGA 19 D-005340-05 Dharmacon 
NRBP2 340371 NM_178564 siNRBP2 #3 AUGCGGGAGUUCAUCCUUU 19 D-005340-06 Dharmacon 
NRBP2 340371 NM_178564 siNRBP2 #4 GGUCACAGAGGAGGCCAUU 19 D-005340-07 Dharmacon 
STK39 27347 NM_013233 siSTK39 SMARTPool Pool of the following 4 19 M-004875-02 Dharmacon 
STK39 27347 NM_013233 siSTK39 #1 GAACAGAGAGUACCUGAUU 19 D-004875-01 Dharmacon 
STK39 27347 NM_013233 siSTK39 #2 GCACGACUGUUGCUCAUUU 19 D-004875-02 Dharmacon 
STK39 27347 NM_013233 siSTK39 #3 CAGGUGGUCUUAUUUAUUG 19 D-004875-04 Dharmacon 
STK39 27347 NM_013233 siSTK39 #4 AAACAGGGGUAGAGGAUAA 19 D-004875-05 Dharmacon 
TSSK1B/STK22D 83942 NM_032028 siTSSK1B/STK22D SMARTPool Pool of the following 4 19 M-005038-02 Dharmacon 
TSSK1B/STK22D 83942 NM_032028 siTSSK1B/STK22D #1 GGACGAAGCUCGCAAGAAG 19 D-005038-05 Dharmacon 
TSSK1B/STK22D 83942 NM_032028 siTSSK1B/STK22D #2 GGAUGACAGUGGUCGAAUG 19 D-005038-07 Dharmacon 
TSSK1B/STK22D 83942 NM_032028 siTSSK1B/STK22D #3 CCAGCAAGCCGUCGACUAU 19 D-005038-08 Dharmacon 
TSSK1B/STK22D 83942 NM_032028 siTSSK1B/STK22D #4 CAUCACAUGGCAAGGUCUA 19 D-005038-09 Dharmacon 
TWF2/PTK9L 11344 NM_007284 siTWF2/PTK9L SMARTPool Pool of the following 4 19 M-003169-01 Dharmacon 
TWF2/PTK9L 11344 NM_007284 siTWF2/PTK9L #1 AGAGAGAGCUCCAGCAGAU 19 D-003169-05 Dharmacon 
TWF2/PTK9L 11344 NM_007284 siTWF2/PTK9L #2 UUAACGAGGUGAAGACAGA 19 D-003169-06 Dharmacon 
TWF2/PTK9L 11344 NM_007284 siTWF2/PTK9L #3 ACACAGAGCCCACGGAUGU 19 D-003169-07 Dharmacon 
TWF2/PTK9L 11344 NM_007284 siTWF2/PTK9L #4 GCUGGGAUCAGGACUAUGA 19 D-003169-08 Dharmacon 
WEE1 7465 NM_003390 siWEE1 SMARTPool Pool of the following 4 19 M-005050-02 Dharmacon 
WEE1 7465 NM_003390 siWEE1 #1 GCAGAACAAUUACGAAUAG 19 D-005050-01 Dharmacon 
WEE1 7465 NM_003390 siWEE1 #2 UAGAACAUCUCGACUUAUU 19 D-005050-02 Dharmacon 
WEE1 7465 NM_003390 siWEE1 #3 GAUCAUAUGCUUAUACAGA 19 D-005050-03 Dharmacon 
WEE1 7465 NM_003390 siWEE1 #4 GGGAAUUUGAUGUGCGACA 19 D-005050-22 Dharmacon 
WNK1 65125 NM_018979 siWNK1 SMARTPool Pool of the following 4 19 M-005362-01 Dharmacon 
WNK1 65125 NM_018979 siWNK1 #1 GCAGGAGUGUCUAGUUAUA 19 D-005362-01 Dharmacon 
WNK1 65125 NM_018979 siWNK1 #2 UAUCGAAGAUGAAGACUUA 19 D-005362-02 Dharmacon 
WNK1 65125 NM_018979 siWNK1 #3 GGAAGGCGGUUUAUAGUGA 19 D-005362-03 Dharmacon 
WNK1 65125 NM_018979 siWNK1 #4 GCAGUUGUCUCAAUAUCUA 19 D-005362-04 Dharmacon 
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2.2.2.8 Protein extraction 
The cells were washed three times with ice cold PBS and lysed in RIPA with the protease 
inhibitor and phosphatase inhibitor. The cells were then scraped, and the cell lysates 
were transferred to 1.5ml Eppendorf, followed by the 3s vortex for three times. Between 
each vortex, cell lysates were incubated on ice for 3s. Cell debris was discarded after 
centrifugation at 4°C, 13,000rpm for 10min, and the supernatant was transferred into 
the new Eppendorf and stored on ice for immediate use for western blot or stored at -
80°C.  
2.2.3 Direct binding assay 
 
2.2.3.1 MBP pull-down of exogenously expressed proteins in mammalian cell 
Cell lysates were incubated with 20μl of pre-washed anti-MBP magnetic resin at 4°C with 
rotation for 30min to conjugate the MBP-tagged proteins onto the resin. The resin was 
then washed three times with 200μl of 0.1M sodium phosphate buffer (pH 8.0) with 
vortex and applied to a magnet for 30s to pull resin to the side of the tube, followed by 
the incubation with mammalian cell lysates at 4°C with rotation for 2h. After incubation, 
the resin was washed three times with 500μl RIPA with vortex and applied to a magnet 
for 30s to pull resin to the side of the tube. Proteins were eluted in 20μl 2xSDS-PAGE 
sample loading buffer and then analysed by Western Blot. 
2.2.3.2 GST pull-down with bacterial expressing recombinant proteins 
Glutathione Sepharose 4B resin was blocked in 200μl of 5% BSA at 4°C with rotation for 
overnight. Bacterial cell lysates were incubated with 20μl of the resin at 4°C with 
rotation for 30min. The resin was then washed three times with 200μl RIPA with gentle 
vortex and centrifugation at 4°C for 1min, 500g, followed by incubating with the purified 
MBP-tagged protein in buffer A at 4°C with rotation for 2h. After incubation, the resin 
was washed five times with 500μl the binding buffer with vortex and centrifugation at 
4°C for 1min, 500g. Proteins were eluted in 20μl 2xSDS-PAGE sample loading buffer and 
then analysed by Western Blot. 
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2.2.3.3 MBP pull-down with bacterial expressing recombinant proteins  
Cell lysates were incubated with 10μl of pre-washed anti-MBP magnetic resin at 4°C with 
rotation for 30min to conjugate the MBP-tagged proteins onto the bead. The resin was 
then washed three times with 200μl RIPA buffer with vortex and applied to a magnet 
for 30s to pull resin to the side of the tube. The supernatant was then removed, followed 
by incubating with required protein lysates at 4°C with rotation for 2h. After incubation, 
the resin was washed three times with 500μl binding buffer with vortex. Proteins were 
eluted in 20μl 2xSDS-PAGE sample loading buffer and then analysed by Western Blot. 
2.2.4 Cell viability assay 
Cells were seeded in the 96well plates on Day 1 (Figure 2.6). Cells were transfected with 
siRNAs from Human Kinome siRNA library on Day 2. The cell media was changed on Day 
3 or changed at 4h post-transfection if there were a dramatic cell death. Transfected 
cells were allowed to grow for 2 days till the endpoint (Day 6, Figure 2.6). On day 6, the 
cells were measured the cell viability by using CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega, G7573). The cells were washed with 100ml PBS and then 100ml of 
diluted CellTiter-Glo® solution (1:3 with ddH2O) was added. The cells were then shaken 
for 2min and allowed to incubate for 10min, followed by the measurement of 
luminescence using plate reader (PerkinElmer, 1420). 
 
  





Figure 2.6 A flowchart of measuring the cell viability under the siRNAs treatment. 
Cells were seeded in 96well plate on Day 1 and treated with siRNAs from Human Kinome siRNA library on 
Day 2. The media was then changed at 24h post-transfection or 4h post-transfection if dramatic cell death 
was caused. The cell viability of each well was measured using the commercial assay kit after two-day 
growth.  
 
2.2.5 Clonogenic assay for validation siRNA targets from the screening 
After 24h transfection in a 96-well-plate format, the cells were trypsinised with 50μl 
trypsin and incubated for 3min in the incubator. 200μl media was added to neutralise 
the activity of trypsin. 20µl of complete suspended cell suspension was transferred to 
one well of 6-well plate. Triplicate on 6-well plate was made for each siRNA transfected 
sample. 2ml media was added to each well of 6-well plate, and the cells were incubated 
for ten days. After ten days, the cells were washed once with PBS and fixed with 100% 
ice cold ethanol overnight at 4°C. The cells were then stained with 10% (v/v) crystal 
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violet at room temperature for 40min, followed by washed with tap water and allowed 
to dry at room temperature. The colony number was counted manually.  
2.2.6 RNA extraction and quantification 
RNA was extracted from the cells by using Reliaprep RNAminiprep (Promega, Z6012), 
following the manufacturer's instruction. RNA concentration was measured using a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies Inc.).  
2.2.7 Total RNA extraction  
The cells were allowed to grow to confluent in monolayer. The culture media was 
removed. 1ml/1x107 cells of TRIzol reagent (Sigma-Aldrich, T9424-100ML) was directly 
added to the culture dis. The cell lysate was transferred to a 1.5ml Eppendorf and then 
was passed through a sterile, disposable 21g needle for three times to fragment the 
high-molecular weight cellular components, which minimise their presence in the 
aqueous phase. The homogenate was incubated at room temperature for 5min. 200ml 
chloroform (Sigma-Aldrich, C2432-25ML) was added and mixed vigorously. The 
homogenate was then incubated at room temperature for 3min, followed by 
centrifugation at 4°C for 15min, 12,000g. The homogenate was then equilibrated to the 
room temperature. The upper aqueous RNA solution was transferred to a new 1.5ml 
Eppendorf. 1 volume of isopropanol was added to the aqueous RNA solution and mixed 
gently. The mixture was incubated on ice for 1h, followed by the centrifugation at 4°C 
for 30min, 12,000g. The supernatant was then carefully discarded to prevent perturbing 
the RNA pellet. The RNA pellet was then washed with 1 volume of 70% chilled ethanol 
and mixed well. The solution was centrifuged at 4°C for 15min, 12,000g and incubated 
at room temperature for 15min. The solution was then centrifuged at 4°C for 5min, 
12,000g and the supernatant was discarded carefully. The RNA pellet was air-dried at 
room temperature for 10min and dissolved in 200ml RNase-free water. The extracted 
RNA was stored at -80°C for the downstream assays.  
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2.2.8 RNA quantification 
The pedestals were wiped clean 100% ethanol and the distilled water after each 
measurement. The instrument was blanked with 1µl of the same buffer in which RNA 
eluted. 1µl of the DNA sample was used per measurement with both a 260nm and 
280nm light absorbance values. The ratio of 260/280 between 1.8-2.0 means RNA is 
pure. The ratio 260/230 between 2.0-2.2 means no protein contamination. The 
concentration was measured twice for each RNA sample, and an average value was 
taken.  
2.2.9 Reverse transcription and qRT-PCR for miRNA 
The total RNA (1ug) was first treated with DNase 1 (Sigma-Aldrich, AMPD1-1KT) to 
eliminate the residue DNA during the extraction and precipitation processes. 500ng 
DNase-treated total RNA was then reverse transcribed to cDNA with 20µl of the 
following reaction system using miScript II RT Kit (QIAGEN, 218161): 4µl 5xmiScript 
HiFlex Buffer, 10xmiScript Nucleics Mix, 7µl RNase-free water and 2µl miScript Reverse 
Transcriptase Mix. The reaction mixture was incubated at 37°C for 60min, followed by 
the incubation at 95°C for 5min to inactivate miScript Reverse Transcriptase Mix. 
2.5ng of cDNA was used for 25µl of the following qRT-PCR reaction system: 12.5µl 
2xQuantiTect SYBR Green PCR Master Mix (QIAGEN, 218073), 2.5µl 10xmiScript 
Universal Primer, 2.5µl 10xmiScript miR-26 Primer and RNase-free water. The initial 
denaturation was performed for 15min at 95°C. 30 cycles of denaturation (15s at 94°C), 
annealing (30s at 55°C), and extension (30s at 70°C). Data were normalised to the 
reference non-coding small nuclear RNA (U6), and the relative amount of targets were 
quantified using the 2-ΔΔCt method. 
2.2.10 qRT-PCR for mRNA 
RNA was diluted to 10ng for each sample and added to GoTaq 1-step qRT-PCR (Promega, 
A6020) reactions along with the specific primers. qRT-PCR was performed in triplicate 
on the Applied Biosystems 7500 Real-Time PCR System. Data were normalised to the 
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housekeeping gene RNA polymerase II (RPII), and the relative amount of targets were 
quantified using the 2-ΔΔCt method.  
2.2.11 Annexin V/PI staining for FITC apoptosis detection by the flow cytometry 
Apoptotic cells can be identified based on the phosphatidylserine transition on the cell 
surface-chromosomal and the DNA fragmentation. Annexin V is used to stain the cells 
to indicate cell membrane changes which occur in the early stage of apoptosis. Once 
apoptosis is initiated, the phosphatidylserine present in the inner cell membrane 
migrates through the cell membrane of the lipid bilayer. Annexin V specifically binds to 
phosphatidylserine in the presence of protein-dependent Ca ion. Propidium iodide (PI) 
bind with DNA and is only permeant to dead cells. Therefore, by using fluorescent 
labelled Annexin V and PI, it is possible to perform double staining simultaneously and 
identify the living cells and apoptotic cells by the flow cytometry (Figure 2.7).  
 
 
Figure 2.7 An example of apoptosis detection by Annexin V/PI staining using the flow cytometry 
One example to demonstrate in which area that the cells represent viable, early apoptosis, or late 
apoptosis using Annexin V/PI double staining. 
 
The cells were seeded in 6well plate and transfected with 50nM siRNAs. After 48h, the 
supernatant was discarded. The cells were washed with 1ml PBS twice, followed by 
detaching with Trypsin-EDTA. The cells pellets were collected by centrifugation at 
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1200rpm for 3min and were washed with PBS twice. 1xAnnexin V binding solution 
(Dojindo, AD01-02) was used to make final cell concentration of 1x106 cells/ml. 100ul of 
cell suspension was transferred, and 5µl PI was added for incubation at room 
temperature for 15min, protected from light. 400µl 1xAnnexin V was added and applied 
for flow cytometry analysis. 
2.2.12 Western blot protein expression analysis 
 
2.2.12.1 SDS-PAGE 
SDS-PAGE gels were assembled into a mini-PROTEAN® Tetra Cell (Bio-Rad) and filled with 
1xrunning buffer. 5µl protein marker and samples were carefully loaded into the bottom 
of each well of the gel. Gels were then run at a constant voltage of 80V until the blue 
dye reached and concentrated at the top of the resolving gel, which usually takes 15min. 
A constant voltage of 120V-180V was then used until the blue dye front reached the 
bottom of the resolving gel. 
2.2.12.2 Coomassie Staining and Destaining 
The SDS-PAGE gel was stained with Coomassie blue staining solution at room 
temperature with shaking gently for 1-2h. The gel was washed with tap water for three 
times and then destained in Coomassie blue de-staining solution for overnight at room 
temperature. 
2.2.12.3 Immunoblot 
During SDS-PAGE, PVDF membrane (Roche, 0301004001) were completely soaked in 
100% methanol with shaking at room temperature for 5min, followed by gradually 
diluting 100% methanol to 0% methanol by adding the distilled water. The membrane 
was then soaked in the transfer buffer with shaking at room temperature until use. After 
the electrophoresis, SDS-PAGE gels along with the membrane and filter paper were 
assembled according to the manufactory’s instruction and transferred at a constant 20V 
for 20min using Trans-Blot® Turbo™ transfer cell (Bio-Rad). The membrane was then 
incubated in the blocking solution at room temperature for at least 1h. Membranes can 
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be cut into small size if multiple antibodies were applied. The required primary antibody 
was diluted in the blocking solution (Table 2.7). After blocking, the membrane was 
incubated in the antibody solutions overnight with gentle agitation at 4°C. The 
membrane was then washed with PBS-T three times for 5min at room temperature with 
shaking. Horseradish peroxidase (HRP)-conjugated secondary antibodies were diluted at 
a ratio of 1:5000 in blocking solution. The membranes were incubated with the 
secondary antibody with shaking at room temperature for 1h. The membrane was then 
washed with PBS-T for three times for 5min at room temperature with shaking before 
incubation with an Enhanced Chemi-luminescence Reagent (ECL2) Western Blotting 
Detection Solution (Thermo Scientific, PI80196) for 5min to initiate an HRP-catalysed 
luminescent reaction. The membrane was finally exposed to Chemi-luminescent 
Detection Film (Roche Applied Science) for different time according to the intensity of 








Table 2.7 Table of the primary and secondary antibodies used for immunoblotting in this study 
The table contains the information of the working dilutions, host species, predicted molecular weight, 
manufacturing company and catalogue number indicated. 
Primary antibodies 








AGO1 1: 1000 Rabbit 97 Cell Signalling 5053S 
AGO2 1: 1000 Rabbit 97 Cell Signalling 2897S 
AGO3 1: 1000 Rabbit 97 Cell Signalling 5054S 
AGO4 1: 1000 Rabbit 97 Cell Signalling 6913S 
β-actin 1: 25,000 Mouse 42 Sigma-Aldrich A1978 
DnaK (hHSP70) 1: 1000 Mouse 70 Cell Signalling ab69617 
EGFP/EYFP tag 1: 2,000 Mouse 26.9 Roche 11814 460001 
GW182 1: 1000 Mouse 182 Santa Cruz sc-56314 
HIF-1α 1: 1000 Mouse 120 BD Biosciences 610959 
LIMD1 
(N-terminus) 
1 : 500 Mouse 72 Sharp et al.(2004) 
Clone 3F2/C6 
N/A 





1: 200 Rabbit 97 Prof. Paµl Graves N/A 
p38 1:1000 Rabbit 43 Cell Signalling 9212S 
Phospho-p38 1:1000 Mouse 43 Cell Signalling 9216S 
STK39 1:1000 Rabbit 65 Cell Signalling 2281S 
HRP-conjugated Secondary antibodies 
Antigen Dilution Host species Company 
Catalogue 
Number 
Mouse 1: 5,000 Goat Dako P0447 
Rabbit 1: 5,000 Goat Dako P0448 
 
2.2.13 Immunofluorescence assay 
Immunofluorescence assay (IFA) was employed to investigate the co-localisation 
between two proteins, detected by the confocal microscope. The assay normally uses 
the specificity of antibody conjugated with fluorescent dyes against the endogenous 
proteins and allows to visualise and analyse the distribution of the endogenous proteins 
[244]. Two or more proteins of interest respectively bind their specific antibody 
conjugated with different colours of fluorophores. Because different fluorophores have 
their fluorescence emission wavelengths, the confocal microscope measures these 
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different wavelengths by using temporally separated laser sources. Consequently, 
different colours for each labelled protein will be observed, which in turn provide the 
localisation of each protein within the cells. Therefore, if there is an association between 
different proteins, it will be observed that these different proteins are within proximate 
distant and subsequently causing the merged colour to be captured by the microscope.  
U2OS was used for IFA due to its large shape. The cells are ideally approximately 60% 
confluent at the end point. 2.5 x 104 cells/well were seeded in 12-well plate with 
polylysine-coated coverslips (Corning, 354085) in it. After 24h incubation, the cells were 
co-transfected with two plasmids DNA containing genes of interest (500ng/well for 
each). The cells were then incubated at 37°C, 5% CO2 for 48h. Media was changed if the 
cells were dying because of the toxicity of transfection reagent or DNA to be transfected. 
After 48h incubation, the cells were washed three times with PBS and fixed in 1ml 4% 
paraformaldehyde at room temperature for 3min. The cells were then washed for three 
times with PBS. 10µl of mounting medium with DAPI (Biotium, 23004) was added onto 
a microscope slide. The coverslips were removed from the 12 well plate using a blade 
and tweezers and flipped over onto the mounting medium. The coverslips were then 
allowed to set at room temperature and stored at 4°C without light. The cells can be 
analysed under a confocal microscope.  
The quantification of each pair of co-localisation in this study (in Chapter 4) was 
generated from two or three independent biological repeats (n=2 or 3). For each 
individual repeat, the number of co-localised foci out of 80-100 cells was counted 
manually under the microscope, and then the percentage of co-localisation was 
calculated. 
2.3 Statistical Analysis 
Standard score (Z-score) was calculated according to the cell viability in Human Kinome 
siRNA Library screening. The formula is  𝑧𝑖 =
𝑥𝑖−𝑥
𝑆
, where 𝑥𝑖  represents each value in 
the data set; 𝑥 represents the mean of all values in the data set and 𝑆 represents the 
standard deviation of the dataset. Z-score, which represents the distance between the 
raw value and the population mean in units of the standard deviation, was calculated 
Chapter 2                                                         Materials and Methods 
91 
for each kinase for each cell line according to the cell viability [245]. In the library 
screening, Z-score described that how many standard deviations of cell viability treated 
with one siRNA lies above or below the mean of all cell viability treated with the whole 
Human Kinome siRNA library. A Z-score above the mean had a positive value, whereas 
it bellow the mean had a negative value. The positive value indicated the increasing 
growth of the cells, while the negative value indicated an inhibitory or cytotoxicity on 
the cells. Therefore, the greater the absolute Z-score value was, the greater effect on 
the cells due to the depletion of the gene by siRNAs. ΔZ-score was the difference in Z-
score between the isogenic pair of cell lines: 𝛥𝑍 = 𝑍− − 𝑍+, where 𝑍−  represents 
LIMD1 negative cell line and 𝑍+ represents LIMD1 positive cell line. The smaller ΔZ-
score was, the more potent synthetic lethality the siRNA caused. 
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3 Characterisation of the interaction interfaces between LIMD1 and AGO2  
To initiate miRNA-mediated silencing, AGO proteins recruit TNRC6 proteins and the 
downstream effector proteins (DCPs), DDX6, and CCR4-NOT4 to form miRISC [99]. It has 
been reported that the depletion of LIMD1 reduced the efficacy of miRNA-mediated 
gene silencing through disruption of miRISC [1]. It was demonstrated that LIMD1 is a 
critical component required for miRNA-mediated silencing, binding to AGO2 through the 
unstructured the pre-LIM region (amino acid (a.a) 1-464) [1]. Pre-LIM domain has been 
reported to interact with multiple protein partners, including PHD2 via a.a 186-260 and 
pRB between via 404-442 (Figure 1.23) [216, 217]. However, the precise interaction 
region for AGO2 binding remained unknown. Moreover, the specific domain within pre-
LIM domain for AGO2 binding was also required to be investigated. The characterisation 
of the interaction interfaces on both AGO2 and LIMD1 would help for deep 
understanding the role and function of LIMD1 in miRISC assembly, and thus the 
mechanism of miRNA-mediated silencing.  
Initially, to map the interaction interface on LIMD1, a set of internal deletion mutants 
within pre-LIM domain together with Xpress (Xpr)-tagged LIMD1 FL (full-length) were 
expressed and subjected to co-immunoprecipitation (co-IP) with EYFP-AGO2 from 
HEK293T cells. The co-IP result showed that the deletion of a.a 140-166 within pre-LIM 
region abrogated the interaction with AGO2 (Figure 3.1). This result suggested that a.a 
140-166 within LIMD1 is a critical domain that contributes to the interaction with AGO2.  
 
  





Figure 3.1 Amino acids 140-166 within LIMD1 are required for association with AGO2 in vitro 
A) Co-IP of Xpr-LIMD1 and the internal deletion mutants with EYFP-AGO2 from HEK293T lysate. The 
deletion of a.a 140-166 within LIMD1 abolishes association with EYFP-AGO2. Experiments were 
performed by Dr Katherine S. Bridge. B) Schematic of LIMD1 internal deletion mutants and summary of 
binding to EYFP-AGO2. Xpr, Xpress. 
 
3.1 Construction of the expression plasmids to investigate the interaction interfaces 
between LIMD1 and AGO2 
Given that a.a 186-260 is responsible for the binding to PHD2, the deletion of which does 
not affect the association between LIMD1 and AGO2(Figure 3.1A), it implied in addition 
to a.a.140-166, a.a 112-140 may also may also contribute to AGO2 binding. As a result, 
not only a.a 140-166 but also the larger specific domains of pre-LIM were designed for 
the fusion-tag technology to investigate the direct interaction region with AGO2 (Figure 
3.2A).  
AGO2 contains six domains as depicted in Figure 1.10: the N, L1, PAZ, L2, MID and PIWI 
domains. Therefore, to map the interaction domain on AGO2, truncation mutants with 
each domain sequentially deleted from either the N- or C-terminus were designed 
(Figure 3.2B). Because bacteria (E.coli), as a host, has the unparalleled fast growth 
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leading to a high cell density [246], bacterial recombinant expression plasmids were 
used for the production of the purified proteins required for in vitro identification of the 
interaction interfaces on LIMD1 and AGO2.  
 
 
Figure 3.2 Schematic of LIMD1 and AGO2 constructs used in this project 
A) LIMD1 FL (full length) or the truncation mutants was designed to fuse with an N-terminal HisMBP-tag. 
B) Full length of AGO2 or a serial set of sequential truncation mutants from either the N- or C-terminus 
were designed to fuse with an N-terminal GST-tag. *, the constructs were made by Dr Sybil C.K. Wong. 
 
3.1.1 Construction of expression plasmids for LIMD1 FL and truncation mutants by 
LIC 
Maltose-binding protein (MBP) is a common protein expression tag that natively 
expresses in E.coli. Because MBP, as a molecular chaperone, prevents the aggregation 
of the incompletely folded fusion protein, fusion of a target protein to MBP allows to 
significantly increase the expression level and solubility [247]. In addition, MBP-tagged 
proteins can be readily purified for the downstream analysis and experiments. The 
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pETFPP_2 vector system was selected because it provides an N-terminal MBP-tag 
(Figure 2.1) and utilises ligation independent cloning (LIC) (details described in Chapter 
2.2.1.4). Moreover, due to the long 3’ complementary overhangs on the insert and 
vector, LIC maximises the specificity of annealing and correction of insertion with a 
lower chance of self-circularisation of the vector [241]. 
The required cDNA sequence of LIMD1 encoding a.a 110-166 was prepared by PCR 
amplification using Xpr-LIMD1 as a template. A single PCR product of the expected size 
was successfully amplified (Figure 3.3A). The empty parental pETFPP_2 vector (pETFPP-
VO) was linearised by the treatment of BseRI (Figure 3.3B). The PCR product and the 
purified linearised vector were annealed after the treatment of T4 DNA Polymerase 
(details described in Chapter 2.2.1.4). The colony PCR was performed by using T7 
primers for verifying whether there was an insert to the parental vector backbone. The 
results showed the size of the PCR product of the colony #4 was bigger than that in the 
empty parental vector (Figure 3.3C). However, the colony #1 showed a PCR product at 
the same size of the empty parental vector (Figure 3.3C). The results indicated only 
colony #4 had an insert due to a larger size of the PCR product (with the required 
sequences). The alignment of the experimental DNA sequence of the colony #4 to the 
NCBI Database CDS for LIMD1 (NM_014240.2) then confirmed the insert was in frame 
with the tag sequences (Figure 3.3D). The same procedure was used to insert the CDS 
of LIMD1 a.a 120-166, 130-166, 140-166, and FL into pETFPP_2-VO for expressing MBP-
LIMD1 120-166, 130-166, 140-166, and LIMD1 FL (Figure 3.2A). The sequencing results 
showed coding sequences of the desired cDNAs in all plasmids were in frame with the 
tag sequences (Figure 3.4 and Figure 3.5).  
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The pETFPP_2-VO plasmid expressing MBP-VO and MBP-tagged LIMD1 plasmids with 
the correct insert described above were transformed into E.coli. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was used to induce the expression of MBP-VO and MBP-
tagged LIMD1 proteins (Chapter 2.2.1.10). The constructs also encode an N-terminal 
poly-histidine tag (Figure 2.1). Hence the recombinant proteins can be purified by Ni-
NTA resin, which provides high specificity and affinity to histidine residues. The purified 
proteins were eluted from the resin by using imidazole, which is a competitive inhibitor 
for His-tag [248], and analysed by both Coomassie staining and Western blot. All desired 
recombinant proteins were expressed at the correct molecular weight (Figure 3.6). For 
MBP-VO, there were double bands detected by Western blot (Figure 3.6A). The 
sequencing result of the parental pETFPP_2-VO showed there was no stop codon after 
MBP, and thus gives an additional 45 amino acids which in turn causes the size of the 
product is bigger than the actual size (larger size of the band in Figure 3.6D). The smaller 
size of the band for MBP-VO is degradation product but still encodes MBP. As a result, 
the difference in the size of bands between MBP-VO and MBP-tagged LIMD1 truncation 
mutants in Western blot did not represent the real difference in predicted molecular 
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3.1.2 Construction of expression plasmids for AGO2 C-terminal truncation mutants 
To investigate the interaction domain on AGO2, a serial set of constructs expressing 
sequential truncation mutants of AGO2 were designed (Figure 3.2B). Glutathione S-
transferase (GST) is a widely used tag due to its positive influence of the GST-tagged 
proteins on solubility, expression and purification for the study of protein-protein 
interaction [249]. Therefore, the pMCSG10 vector expressing an N-terminal GST-tag was 
selected (Figure 2.2). The FL and N-terminal truncations MID-PIWI, L2-MID-PIWI and 
PAZ-L2-MID-PIWI of AGO2 were previously cloned into pMCSG10 vector by Dr Sybil C.K. 
Wong. The LIC method was used to generate N-L1-PAZ-L2 truncation mutant in the 
pMCSG10 vector. pMCSG10-AGO2 was used as a template for PCR amplification of the 
CDS of N-L1-PAZ-L2. For colony PCR verifying the correct insert, the size of colony PCR 
product of truncation mutant should be smaller than that of pMCSG10-AGO2 FL. The 
colony #1 and #3 were not successfully cloned because of their sizes of PCR products 
were the same as that of pMCSG10-AGO2 FL, while the highlighted band indicated a 
successful cloning of colony 5 (Figure 3.7A), indicating there was no internal deletion. 
The plasmid DNA of the highlighted colony was sequenced by using pGEX5 forward 
primer or T7 reverse primer (Figure 3.7B and Figure 3.7C). The sequencing result 
confirmed that the insert matched to the CDS of AGO2 (NM_012154.3) and was in frame 
with GST sequences (Figure 3.7D). 
  





Figure 3.7 Cloning of bacterial expression plasmids for pMCSG10-AGO2 N-L1-PAZ-L2 by LIC 
A) The colony PCR of 5 colonies was performed to indicate the successful cloning using T7 primers. The 
expected size of the correct insert is 3607bp. PCR band chosen for sequencing was highlighted by the red 
arrowhead. B&C) pGEX5 forward primer or T7 reverse primer was used for sequencing. D) The alignment 
of the Sanger sequencing read to the database AGO2 CDS (NM_012154.3) performed by MUSCLE. Only 
partial of codons downstream or upstream of the CDS start or stop were displayed.  
 
Site-directed mutagenesis was used to generate the pMCSG10-AGO2 N-L1-PAZ 
truncation mutant (details described in Chapter 2.2.1.5). A pair of DNA primers flanking 
the CDS of L2-MID-PIWI of AGO2 were designed for PCR amplification of the linearised 
DNA sequencing of N-L1-PAZ (Figure 3.8A). The single PCR product of the expected size 
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(7021bp) of AGO2 N-L1-PAZ was successfully amplified, analysed by agarose gel 
electrophoresis (Figure 3.8A). The colony PCR was then performed to confirm the 
mutagenesis worked. PCR product from pMCSG10-AGO2 FL was used as a reference for 
no internal deletion. The result showed both colony #2 and #3 had PCR products whose 
size are the same as to pMCSG10-AGO2 FL (Figure 3.8B). This indicated the mutagenesis 
did work on colony #2 and #3 to delete the undesired cDNA sequence (L2-MID-PIWI). In 
contrast, the mutagenesis successfully worked on colony #1; the PCR product showed a 
smaller size at 2083bp (Figure 3.8B). The sequencing result and alignment confirmed 
the cDNA sequences matched to the CDS of AGO2 and was in frame with GST sequences 
(Figure 3.8E).  
 
  





Figure 3.8 Cloning of bacterial expression plasmid for pMCSG10-AGO2 N-L1-PAZ truncation mutant 
from pMCSG10-AGO2 by Q5® site-directed mutagenesis 
A) Agarose gel electrophoresis for visualising the PCR product of the required DNA sequence of pMCSG10-
AGO2 N-L1-PAZ, amplified using pMCSG10-AGO2 as a template and a pair of primers flanking the region 
L2-MID-PIWI. B) The colony PCR of 4 colonies was performed to indicate the successful cloning using T7 
primers. The PCR product of pETFPP_2 VO was used as a reference for the expected size of the backbone 
band. PCR band chosen for sequencing was highlighted by the red arrowhead. C) pGEX5 forward primer 
or T7 reverse primer was used for sequencing. The alignment of the Sanger sequencing read to the 
database AGO2 CDS (NM_012154.3) performed by MUSCLE. Only partial of codons downstream of the 
CDS start or upstream of L2 domain were displayed. 
 
To check the expression of the GST-AGO2 constructs generated above, plasmids were 
transformed in E.coli, and the expression of the recombinant proteins was induced by 
IPTG. The recombinant proteins were purified using the glutathione resin from the 
bacterial cell lysates and adjusted to the similar concentration of protein purified on the 
resin. The result showed the desired GST-AGO2 N-L1-PAZ-L2 and N-L1-PAZ were 
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successfully expressed and confirmed by Western blot, and the similar concentration of 
the indicated recombinant proteins was purified on the glutathione resin (Figure 3.9).  
 
 
Figure 3.9 Verification of GST-tagged AGO2 full length (FL) and truncation mutants expression 
pMCSG10-VO and pMCSG10-AGO2 truncation mutants were transformed and induced by IPTG to 
overexpress the recombinant GST-tagged proteins. The Glutathione agarose resin was used for 
purification, analysed by A) Coomassie staining and B) Western blot. C) The predicted molecular weight 
of GST-AGO2 FL and its C-terminal truncation mutants. 
 
3.1.3 Optimisation of the conditions and reagents for in vitro direct binding assays  
The pull-down assay, which is an in vitro direct binding assay to confirm the existence 
physical interaction between two proteins, was employed to determine the minimal 
binding domains within both AGO2 and LIMD1. GST-VO and MBP-VO were used as the 
negative controls for the pull-down assay to examine whether there was any non-
specific binding between GST-VO and MBP-VO. The pilot pull-down assay showed a non-
specific interaction between GST-VO and MBP-VO by incubating both proteins either on 
the MBP magnetic resin or the glutathione resin (Figure 3.10A and Figure 3.10B). 
However, MBP-VO could not be immobilised on the glutathione resin (Figure 3.10C). 
Therefore, these results indicated that the non-specific interaction was between GST-
VO and MBP-VO rather than the affinity between MBP-VO with the glutathione resin.  





Figure 3.10 A pilot pull-down assay to examine the non-specific binding between negative controls 
A) MBP-VO was immobilised on the MBP magnetic resin and incubated with GST-VO, detected by 
Coomassie staining. Two highlighted bands represent for MBP-VO (42.5 kDa) and GST-VO (26 kDa) 
respectively. B) GST-VO was immobilised on the glutathione resin and incubated with MBP-VO, detected 
by Western blot. C) MBP-VO was incubated with glutathione resin to confirm that there was no 
interaction between MBP and the glutathione resin, detected by Western blot. 
 
To reduce/remove this non-specific binding between GST-VO and MBP-VO, further 
optimisations of pull-down were carried out. Initially, the effect of different incubation 
times (1, 2, 4h, and O/N) were investigated. Through optimisations of time, the result 
showed 1, 2, and 4h incubations were optimal for reducing the non-specific binding 
(Figure 3.11A). To allow sufficient time for detecting the specific binding, 4h was used 
throughout this project. Given that the protein-protein interaction can be affected by 
the buffer conditions (salt concentration and/or the type of detergent), three different 
conditions of the incubation buffers were optimised (conditions described in Chapter 
2.1.6.3). The optimisation showed Buffer A was optimal for reducing the specific 
interaction between AGO2 and LIMD1 140-166 (Figure 3.11B). Taken together, 4h 
incubation and Buffer A were optimal for GST pull-down in this project.  
 





Figure 3.11 Optimisation of conditions for reducing the non-specific binding in GST pull-down assay 
A) GST-VO was incubated with immobilised GST-VO on the glutathione resin with different incubation 
time periods: 1h, 2h, 4h, and O/N. The sample was assayed by Western blot. O/N: overnight. B) Western 
blot analysis for the GST pull-down in different binding/washing buffers. GST-tagged proteins were 
purified on the glutathione resin and incubated with the pre-purified and eluted MBP-VO or MBP-LIMD1 
140-166 respectively.  
 
3.2 Investigation of the direct interaction between AGO2 and LIMD1 
 
3.2.1 LIMD1 binds to AGO2 via LIMD1 140-166 
The deletion of LIMD1 140-166 caused the loss of binding with AGO2 according to the 
co-IP results (Figure 3.1). Because co-IP from cell extracts does not necessarily indicate 
a direct interaction, an in vitro direct binding assay (GST pull-down) was employed to 
investigate the direct interaction. Bacterial proteins GST-VO and GST-AGO2 were 
purified on the glutathione resin. It was adjusted that the concentration of GST-VO, as 
an experimental control for non-specific binding, no less than that of GST-AGO2 (Figure 
3.12A). GST-AGO2 FL is highlighted, and the smaller bands were degradation products, 
as confirmed by Western blot (Figure 3.12B). The eluted MBP-VO and MBP-LIMD1 140-
166 were then incubated using the optimal conditions, which are 4h incubation and 
buffer A as binding/washing buffer. The result indicated GST-AGO2 directly bound to 
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Figure 3.12 LIMD1 binds AGO2 via a.a 140-166 
A) GST-VO and GST-AGO2 were purified on the resin and incubated with MBP-VO and MBP-LIMD1 140-
166 respectively, analysed by Western blot. The purified GST-VO and GST-AGO2 were analysed by 
Coomassie staining to visualise the concentration of GST-tagged protein for pull-down. B) The purified 
GST-AGO2 was analysed by Western blot to confirm the smaller size of bands as the degradation products 
of GST-AGO2. 
 
GST-AGO2 purified from E.coli underwent extensive degradation. The research group of 
Ian J.MacRae kindly provided the purified untagged crystallography grade human AGO2 
(hAGO2), which has been used for the study of the crystal structure of hAGO2 [109]. 
hAGO2 [250] purified from Spodoptera Frugiperda cell sf-9 was stabilised, showing there 
were not any degradation products even large amount of protein was loaded (Figure 
3.13). To rule out the possibility that the impurities in the homemade AGO2 in E.coli 
affected the interaction with LIMD1, hAGO2 was then used in the MBP pull-down. MBP-
VO, MBP-LIMD1 and MBP-LIMD1 140-166 were expressed in E.coli and purified on the 
MBP magnetic resin. hAGO2 was then added for the incubation, analysed by Western 
blot. The purified MBP-tagged proteins were visualised by Coomassie staining to confirm 
the concentration of protein for the pull-down assay (Figure 3.13). The result of MBP 
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pull-down matched the previous co-IP data from our group that there was an interaction 
between AGO2 and LIMD1 [1]. By using different tags for direct binding assay, the robust 
result showed that 140-166 is a specific interaction domain for AGO2 binding (Figure 
3.12 and Figure 3.14).  
 
 
Figure 3.13 A serial dilution of the crystallography grade hAGO2  
Purified untagged crystallography grade hAGO2 kindly provided from Dr Ian J.MacRae’s research group 
[250], showss no degradation products compared to that in Figure 3.12A. 18ug, 9ug, and 4.5ug hAGO2 
were analysed by Coomassie staining.  
 
 
Figure 3.14 MBP pull-down with MBP-VO, MBP-LIMD1, or MBP-LIMD1 140-166 
A) The purified untagged crystallography grade hAGO2 was used for MBP pull-down. B) MBP-VO, MBP-
LIMD1, and MBP-LIMD1 140-166 were purified on the MBP magnetic resin and incubated with hAGO2, 
analysed by Western blot (highlighted by black arrowheads). 
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3.2.2 LIMD1 binds to the L2 domain of AGO2. 
To map the precise interaction interface on AGO2 with LIMD1, the sequential truncation 
mutants from either N- or C-terminus was fused to GST and expressed in E.coli 
highlighted by black arrowheads in Figure 3.15A. The truncation mutations made within 
AGO2 systematically removed one domain at a time. Thus, these could be used to 
identify the domain required for the binding to LIMD1 140-166. The expression and the 
concentration of GST-VO and GST-AGO2 truncation mutants purified on the glutathione 
resin were analysed by Coomassie staining. The concentration of protein was adjusted 
to the similar level (Figure 3.15A). The GST pull-down showed that GST-AGO2 FL and all 
AGO2 truncation mutants with the L2 domain binding to MBP-LIMD1 140-166 (Figure 
3.15A). Either N- or C-terminal truncation mutants without the L2 domain abolished the 
interaction with LIMD1 (Figure 3.15B). The result indicated that L2 domain was 
necessary for the direct interaction between GST-AGO2 and MBP-LIMD1 140-166 
(Figure 3.15). As a result, the L2 domain of AGO2 was revealed to be responsible for the 
direct interaction with LIMD1. 
  





Figure 3.15 LIMD1 binds to the L2 domain of AGO2 
A) GST-VO and GST-AGO2 truncation mutants were purified on the resin and incubated with MBP-VO and 
MBP-LIMD1 140-166 respectively, analysed by Western blot. The purified GST-VO and GST-AGO2 
truncation mutants were analysed by Coomassie staining to visualise the concentration of the purified 
GST-tagged protein for pull-down. B) Schematic of GST-AGO2 truncation mutants and a summary of 
binding to LIMD1 140-166.  
 
3.3 Phosphorylation status of S387 within the L2 domain affects the direct 
interaction with LIMD1 
It has been proposed that Akt3-dependent phosphorylation of S387 within the L2 
domain of AGO2 diverts its activity from mRNA cleavage to (or toward) miRNA-mediated 
silencing [127]. Therefore, it raised the question as to whether the phosphorylation of 
S387 within the L2 domain would trigger the association between AGO2 and LIMD1. 
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According to the chemical structure of amino acids (Figure 11.2), the constructs 
expressing phospho-deficient (unphosphorylatable alanine mutant AGO2 S387A) or 
phospho-mimic (AGO2 S387E) of EYFP-AGO2 FL version were generated by Dr Sybil C.K. 
Wong. The point mutation of S387 represents the ability to be phosphorylated, which 
inferred the phosphorylation status of S387.  
3.3.1 Construction of expression plasmids for GST-AGO2 L2 domain only  
It has shown that the loss of L2 domain abrogated the interaction between AGO2 and 
LIMD1 (Figure 3.15). To corroborate this mapping result, the construct expressing GST-
AGO2 L2 domain was generated using LIC. In addition, to investigate how the 
phosphorylating ability on S387 within L2 domain would affect the interaction with 
LIMD1, the construct expressing GST-AGO2 L2 S387E was also generated using site-
directed mutagenesis. The colony PCR results showed the colony #1 and #3 containing 
potential correct L2 domain inserts, and the sequencing results confirmed the cDNA 
sequences matched to the database and all inserts were in frame with GST sequences 
(Figure 3.16A and Figure 3.16B). The construct expressing GST-AGO2 L2 was then used 
a template to generate S387E mutant of GST-AGO2 L2 version. The sequencing results 
of the colony #3, which has a potential correct L2 S387E insert, showed serine was 
substituted by glutamic acid (Figure 3.16C and Figure 3.16D).  
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To examine the expression of GST-AGO2 L2 and GST-AGO2 L2 S387E, both plasmids, as 
well as GST-VO, were transformed in E.coli, and the protein expression was induced by 
IPTG. The recombinant proteins were purified by the glutathione resin and analysed by 
Coomassie staining (Figure 3.17A). The predicted size of GST-AGO2 L2 and L2 S387E are 
37kDa (highlighted in Figure 3.17A). However, there were additional larger bands (band 
2 and 6 in Figure 3.17A), indicating impurities were co-purified. The mass spectrometric 
analysis was performed upon the purified GST-Ago2 L2/L2 S387E, which confirmed that 
the majority of lower bands (band 4, 5, 8 and 9) were GST-AGO2 degradation products. 
This analysis also identified that the purified samples contained the bacterial version of 
chaperone protein Hsp70 (DnaK). As the heat shock proteins were demonstrated to 
chaperone AGOs and facilitate the loading of small RNA duplexes [251], DnaK may 
function in the same mechanism to associate with and be co-purified with the 
recombinant AGO2 proteins.  
 
  





Figure 3.17 Verification of the expression of GST-AGO2 L2 and GST-AGO2 L2 S387E 
A) GST-AGO2 L2 and L2 S387E were purified on the glutathione resin and analysed by Western blot. The 
expected size of GST-AGO2 L2/ L2 S387) is 37kDa (highlighted by the arrowhead). Degradation products 
of GST-AGO2 L2/ L2 S387E were identified by B) Mass spectrometry analysis. The Mass spectrometry 
analysis was performed by the group of Dr Michael Plevin.  
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3.3.2 DnaK does not affect the interaction between LIMD1 and AGO2  
As shown in Figure 3.17, DnaK was co-purified from the lysates made from E.coli. There 
were 70kDa bands shown by Coomassie staining (Figure 3.15) across all GST-AGO2 
truncation mutants, resulting in the impurities in GST-AGO2 purified samples. In 
addition, the heat shock proteins have been shown to associate with AGO2 for loading 
small RNA onto AGO2 [251, 252]. Therefore, it raised a question whether the LIMD1-
AGO2 interaction would be indirect (bridged by DnaK). To prove this is not a case, 
Western blot was performed to analyse the samples of GST pull-down. The result 
demonstrated that DnaK levels were equal across the samples, including the AGO2 
truncation mutants that did and did not interact with LIMD1 (Figure 3.18). This result 
indicated that the presence of DnaK was thus not conferring any interaction between 
AGO2 and LIMD1.  
 
 
Figure 3.18 DnaK identified as present in purified GST-AGO2 truncation mutants does not affect binding 
to LIMD1 
The purified GST-AGO2 C-terminal truncation mutants were blot with the indicated antibodies. DnaK 
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3.3.3 The interaction of AGO2 and LIMD1 depends on the phosphorylating ability of 
S387 within the L2 domain.  
The phosphorylation of S387 within AGO2 increased the association with TNRC6A to 
promote its miRNA silencing, but the mechanism of this association remained unknown 
[127]. As S387 is located within the L2 domain of AGO2, which is required for LIMD1 
interaction (Figure 3.15), it was examined whether the phosphorylation of S387 could 
affect the interaction with LIMD1. To address this, EYFP-AGO2,-AGO2-S387A, or -AGO2-
S387E was co-expressed with Xpr-LIMD1 respectively in HEK293T cells, and co-IPs were 
performed to investigate their interacting ability with LIMD1. AGO2 S387A reduced the 
interaction with LIMD1 by 74%, whereas the phospho-mimic version of AGO2 (AGO2 
S387E) rescued/enhanced the interaction with LIMD1 (Figure 3.19).  
 
 
Figure 3.19 Interaction between LIMD1 and AGO2 is dependent on S387 phosphorylation 
Co-IP of Xpr-LIMD1 with EYFP-AGO2 WT, -AGO2 S387A (phospho-deficient), and -AGO2 S387E (phospho-
mimic) point mutants from HEK293T lysate. Quantification of LIMD1 binding relative to co-IP with EYFP-
AGO2 was shown in numbers. This experiment was performed by Dr Katherine S. Bridge. 
 
The importance of S387 phosphorylation for LIMD1 binding was further confirmed by 
the GST pull-down. GST-AGO2 WT and -AGO2 S387E were overexpressed in E.coli and 
purified on the glutathione resin. MBP-LIMD1 140-166, which was previously identified 
as a minimal interaction interface for AGO2 (Figure 3.11), was then added. The result 
revealed an enhanced interaction by 3-fold between the AGO2 S387E (phospho-mimic) 
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and LIMD1 140-166 (Figure 3.20). This result corroborated the co-IP result (Figure 3.19) 
that the phospho-mimic version of AGO2 (S387E) enhanced the interaction with LIMD1.  
 
 
Figure 3.20 Phospho-mimic mutation of S387 enhances the interaction with MBP-LIMD1 140-166 
A) GST-VO, -AGO2 and -AGO2 S387E point mutants were purified on the resin and incubated with MBP-
VO and MBP-LIMD1 140-166 respectively, analysed by Western blot. The purified GST-VO, -AGO2 WT and 
-AGO2 S387E point mutants were analysed by Coomassie staining. B) Quantification of LIMD1 binding 
relative to AGO2 WT. Data shown are mean ±SEM, n=3, * p<0.05.  
 
It has been revealed that the L2 domain of AGO2 was the binding domain for LIMD1 
(Figure 3.15) and the phosphorylation of S387 within the L2 domain increases the 
interaction with LIMD1 (Figure 3.20). To further confirm these findings, the recombinant 
protein AGO2 L2 domain only and the S387E point mutant were generated and 
performed for the GST pull-down with MBP-LIMD1 FL and MBP-LIMD1 140-166 (Figure 
3.21). The result confirmed that L2 domain was responsible for the interaction with 
LIMD1, and the phospho-mimic mutation, S387E, enhanced the interaction.  
 
 





Figure 3.21 S387 phosphorylation within the L2 domain only mutants enhances the interaction with 
MBP-LIMD1 140-166 
GST-VO, -AGO2 L2 and -AGO2 L2 S387E point mutant were purified on the resin and incubated with MBP-
VO and MBP-LIMD1 140-166 respectively, analysed by Western blot. The purified GST-VO, -AGO2 L2 and 
-AGO2 L2 S387E point mutants were analysed by Coomassie staining to visualize the concentration of 
GST-tagged protein for pull-down. The expected size of GST-AGO2 L2 is 37kDa, which is highlighted by 
black arrowheads. 
 
The phospho-mimic version of AGO2 (S387E) enhanced the interacting ability with 
LIMD1 (Figure 3.20 and Figure 3.21). In addition, as S387 was reported to be 
phosphorylated by Akt3 and was Akt3-signalling dependent [127], HA-Akt3 was co-
expressed with EYFP-AGO2 in HEK293T cells to facilitate Akt3-driven phosphorylation at 
S387 residue on EYFP-AGO2 WT. The pull-down assays were then performed to examine 
whether MBP-LIMD1 140-166 could interact with Akt3-driven phosphorylated AGO2. 
The optimisation of the binding buffer showed NP-40 was the optimal buffer for 
detecting the interaction between the phosphorylated EYFP-AGO2 and MBP-LIMD1 140-
166 (Figure 3.22).  
 
 





Figure 3.22 Optimisation of binding/washing buffers for MBP pull-down 
MBP-VO and MBP-LIMD1 140-166 were purified on the MBP resin and incubated with HEK293T cell 
lysates, which were co-transfected with HA-Akt3 and EYFP-AGO2. Buffer A, RIPA, and NP-40 were used 
to optimise the binding and washing buffer. The samples were analysed by Western blot. 
 
To examine the binding ability of Akt3-driven phosphorylation at S387, three pairs of 
constructs (HA-VO/EYFP-AGO2, HA-Akt3/EYFP-AGO2, and HA-VO/ EYFP-AGO2 S387E) 
were co-expressed in HEK293T cells. Without over-expressing Akt3, the endogenous 
Akt3 was not sufficient to phosphorylate EYFP-AGO2, resulting in S387 on EYFP-AGO2 
remaining hypo-phosphorylated (Figure 3.23A). Therefore there was no interaction 
between EYFP-AGO2 and MBP-LIMD1 140-166 observed. Not surprisingly, once S387 
was phosphorylated by over-expressed HA-Akt3, EYFP-AGO2 interacted with MBP-
LIMD1 140-166 (Figure 3.23B). Over-expressing the phospho-mimic version of EYFP-
AGO2 (S387E) also facilitated the interaction between AGO2 and LIMD1 140-166 (Figure 
3.23C). These results indicated S387 phosphorylation was of importance to regulate the 
AGO2-LIMD1 interaction. Intriguingly, there was no interaction between EYFP-AGO2 
and MBP-LIMD1 110-166 (Figure 3.23).  
 





Figure 3.23 MBP pull-down assay for Akt3-driven phosphorylation of EYFP-AGO2 
A) MBP-VO and MBP-LIMD1 140-166 were purified on the MBP resin and incubated with HEK293T cell 
lysates, which were co-transfected with HA-VO and EYFP-AGO2. B) MBP-VO and MBP-LIMD1 140-166 
were purified on the MBP resin and incubated with HEK293T cell lysates, which were co-transfected with 
HA-Akt3 and EYFP-AGO2. C) MBP-VO and MBP-LIMD1 140-166 were purified on the MBP resin and 
incubated with HEK293T cell lysates, which were co-transfected with HA-VO and EYFP-AGO2 S387E.  
 
3.4 Summary 
Within the pre-LIM region of LIMD1, loss of a.a 140-166 completely abrogated the 
association with AGO2 (Figure 3.1). The further investigation identified and 
corroborated that a.a 140-166 was an essential domain and was sufficient for the direct 
interaction with AGO2 (Figure 3.12). Within AGO2, loss of L2 domain abolished the 
direct interaction with LIMD1 a.a 140-166 (Figure 3.15). This observation was 
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corroborated by the result of in vitro direct binding assay that L2 domain was sufficient 
for interaction with LIMD1 (Figure 3.21). Although DnaK was identified to be co-purified 
with GST-AGO2, it did not contribute to the direct binding of AGO2 to LIMD1 (Figure 
3.18). The direct interaction between AGO2 and LIMD1 depended on the 
phosphorylating ability of S387 within the L2 domain of AGO2 (Figure 3.20 and Figure 
3.21). Akt3-mediated phosphorylation on S387 of AGO2 enhanced the interaction with 
LIMD1 (Figure 3.23). These results demonstrated that the phosphorylation at S387 
regulated the direct interaction with LIMD1 via the L2 domain and a.a 140-166 on both 
proteins, providing a novel aspect that LIMD1-involved miRNA-mediated silencing was 
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4 Investigation of the co-localisation between AGOs and LAW  
The human AGOs (AGO1-4) are evolutionally conserved, and AGOs have been 
demonstrated as large redundant with regards to miRNA loading and target recognition 
[108]. Therefore, the AGO2-LIMD1 interaction might anticipate all four human AGOs 
could bind to LIMD1. To address this hypothesis, GST-AGO1, -AGO3, and -AGO4 were 
respectively immobilised and incubated with MBP-LIMD1 140-166 (Figure 4.1). The 
result showed that MBP-LIMD1 140-166 had the direct interaction with all four AGOs 
(Figure 4.1A), whose expressions were confirmed by Western blot using the specific 
antibodies (Figure 4.1B). This implied that all four human AGOs had the direct 
interaction with LIMD1.  
 
 
Figure 4.1 LIMD1 binds four AGOs through LIMD1 140-166 
A) GST-VO and GST-AGOs were performed GST pull-down with MBP-VO and MBP-LIMD1 140-166 
respectively, analysed by Western blot. The purified GST-VO and GST-AGOs proteins were analysed by 
Coomassie staining and (B) Western blot. 
 
The alignment analysis of the L2 domain within human AGOs showed the existence of a 
significant structural homology (84.6% identity) (Figure 4.2). In addition, L2 domain of 
AGO2 has been revealed to be responsible for the interaction with LIMD1 (Chapter 
3.2.2). Therefore, it required investigating whether the L2 domain of other AGOs 
contributes to LIMD1 binding. To address this question, GST-AGO1 N-terminal 
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truncation mutants were made and performed for GST pull-down. As with AGO2, all 
truncation mutants, except the mutants without L2 domain had the direct interactions 
with LIMD1 (Figure 4.3). This indicated that the L2 domain on AGO1 was a critical 
domain for the interaction with LIMD1. The investigation was only performed on AGO1, 
but it was inferred that L2 domain within the other AGO proteins (AGO3 and AGO4) 
could also be essential for LIMD1 interaction. It will be demonstrated in Chapter 4.1.2 
that how the phosphorylating ability of the conserved S387 residue within L2 domain 
affects the association of AGO proteins with LIMD1.  
 
 
Figure 4.2 Multiple sequence alignment of the L2 domain of human AGOs 
The alignment of the protein sequences for the L2 domain of AGO1 (NP_036331.1), AGO2 (NP_036286.2), 
AGO3 (NP_079128.2) and AGO4 (NP_060099.2) was performed by DNAMAN Windows 6.0 (Lynnon 
Biosoft) using default parameters, and the identity was also calculated by DNAMAN. The conservation 
symbols were added manually. *, positions with complete identity; :, positions with strongly conserved 
residues (PAM250 score > 0.5); ., positions with weakly conserved residues (0 < PAM250 ≤ 0.5). The 
conserved serines were highlighted in red; the glutamic acid which is 2-a.a downstream of the conserved 
serine within AGO3 was highlighted in green.  
 
 
Figure 4.3 AGO1 binds LIMD1 via L2 domain 
GST-VO and GST-AGO1 N-terminal truncation mutants were purified on the resin and incubated with His-
LIMD1 FL, analysed by Coomassie staining. The purified GST-VO and GST-AGO1 N-terminal truncation 
mutants were analysed by Ponceau staining to visualise the concentration of GST-tagged protein for pull-
down. This experiment was performed by Dr Sybil C.K. Wong.  
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4.1 Investigation of the co-localisation of AGO proteins and LIMD1 
Akt3-mediated phosphorylation of AGO2 (S387) within L2 domain promoted a phospho-
dependent interaction with LIMD1 (Chapter 3.3). The alignment of the L2 domain of all 
four human AGOs revealed that a conserved serine residue also present in AGO1 (S385) 
and AGO4 (S377) (Highlighted in Red, Figure 4.2). AGO3 lacks this conserved serine 
residue but instead contains a phospho-mimic glutamic acid residue (E390) (Highlighted 
in Green, Figure 4.2). Therefore, it was hypothesised whether the 
interaction/association of AGOs with LIMD1 was also phospho-dependent within the L2 
domain.  
To address the question whether the conserved serine residue was responsible for 
LIMD1 association, immunofluorescence co-localisation experiments were employed to 
visualise the subcellular localisation of EGFP-AGO2 (including the version of point 
mutations on the conserved serine) and mTangerine (mTan)-LIMD1. P-bodies, which are 
cytoplasmic foci where mRNA storage, decapping or decay can take place [101, 102], 
contains key components of miRNA silencing pathway: AGOs. The formation of P-bodies 
is the consequence of the miRNA-mediated silencing [145]. LIMD1 was previously 
demonstrated to regulate miRNA-mediated silencing and revealed as a P-body 
component interacting with AGO2 [1]. Therefore, by using fluorescently tagged proteins 
and the confocal microscope, the degree of co-localisation of AGO2 with LIMD1 could 
be visualised and calculated.  
4.1.1 Optimisation of the reagents and conditions for immunofluorescence assay  
To investigate the co-localisation, U2OS cell line was selected as it expresses 
characteristics of monolayer and larger shape which offer a clear vision of the cell 
context, especially for the co-localisation. Therefore, U2OS cells were co-transfected 
with the pair of EYFP-tagged protein and mTan-tagged protein using ViaFect™ 
Transfection Reagent, which is a cationic delivery reagent in aqueous solution. Given 
that the amount of DNA, DNA: ViaFect™ ratio, incubation time, and type of cells are 
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critical aspects for transfection efficiency, the ratio of DNA: ViaFect™ and the amount of 
DNA were optimised to achieve a successful transfection for the optimal results for co-
localisation to be observed. The detail of optimisation was listed in Table 4.1.  
 
Table 4.1 Table of the optimisations for DNA amount and the ratio of DNA: ViaFectTM  
Primary optimisation for the ratio of DNA: ViaFectTM 
 Ratio of DNA: ViaFectTM 
1:2 1:3 
DNA amount 750ng 750ng 
Volume of ViaFectTM 1.5µl 2.25µl 
Secondary optimisation for the amount of DNA 
 Ratio of DNA: ViaFectTM 
1:3 1:3 1:3 1:3 
DNA amount 500ng 750ng 1000ng 1500ng 
Volume of ViaFectTM 1.5µl 2.25µl 3µl 4.5µl 
 
The primary optimisation was performed in U2OS transfected with the same amount of 
mTan-LIMD1 (750ng) using different DNA: ViaFect™ ratio (1:2 and 1:3), and the 
fluorescent signals were visualised to determine the transfection efficiency (Figure 4.4). 
Cells were transfected with mTan-LIMD1 resulting in cells expressing the fluorescent 
signals under the microscope. Depending on the transfection efficiency, more cells 
would show red signals if the transfection efficiency was higher. Therefore, the more 
the number of cells expressing red signals, the higher transfection efficiency is (Figure 
4.4). The result indicates that the ratio 1:3 of DNA: ViaFectTM provided a higher 
transfection efficiency when transfected with the same amount of DNA (Figure 4.4B).  
  





Figure 4.4 The primary optimisation of the ratio of DNA: ViaFectTM using the same amount of DNA 
U2OS was transfected with 750ng of mTan-LIMD1 using the ratio (A) 1:2 or (B) 1:3of DNA:ViaFectTM. The 
amount of fluorescent signals were used to determine the transfection efficiency. The magnification was 
400x.  
 
Then for the secondary optimisation, the ratio 1:3 was used to optimise the amount of 
DNA. Four amounts of DNA (500ng, 750ng, 1000ng, and 1500ng) were transfected into 
the cells respectively. As expected, increasing the amount of DNA transfected correlated 
to an increase in transfected cells (amount of the red signals), up to 1000ng (Figure 4.5). 
Above this (1500ng), the DNA/transfection reagent complex was toxic to cells, resulting 
in cells that were fluorescent but not viable (Figure 4.5C and Figure 4.5D). Therefore, 
1000ng of DNA was considered as an optimal amount of DNA transfected into U2OS 
with the ratio 1:3 of DNA: ViaFectTM for immunofluorescence assay in this project.  
  





Figure 4.5 The secondary optimisation of the amount of DNA using the same ratio of DNA: ViaFectTM 
U2OS was transfected with (A) 500ng mTan-LIMD1, (B) 750ng mTan-LIMD1, (C) 1000ng mTan-LIMD1 and 
(D) 1500ng mTan-LIMD1, using the same ratio of DNA: ViaFectTM. The amount of fluorescent signals were 
used to determine the transfection efficiency. Although (D) shows the greatest number of the fluorescent 
signals, the cells were dying as they started floating. The magnification was 400x. 
 
4.1.2 Phosphorylation of the conserved serine within L2 domain affects the co-
localisation of AGO proteins with LIMD1 
To corroborate the direct binding studies between LIMD1 and AGO proteins (Figure 4.1 
and Figure 4.3) and the phosphorylation-dependent interaction between AGO2 and 
LIMD1 (Chapter 3.3.3), EYFP-AGO2 and mTan-LIMD1 were over-expressed in U2OS cells 
with the siRNA-mediated knockdown of Akt3. The result showed a 9-fold reduction in 
co-localisation between EYFP-AGO2 and mTan-LIMD1 (Figure 4.6A and Figure 4.6B). The 
dependency on S387 for LIMD1 association was also examined in U2OS cells transfected 
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with mTan-LIMD1 and the EYFP-AGO2 constructs expressing the point mutations on 
S387. Compared to AGO2 WT, AGO2 S387A and S387E showed a 9.4-fold decrease and 
2.1-fold increase in co-localisation with LIMD1, respectively. These data indicated that 
the interaction between AGO2 with LIMD1 was dependent on the phosphorylating 
ability of AGO2 S387. 
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Figure 4.6 The co-localisation of LIMD1 and AGO2 depends on Akt3-mediated phosphorylation 
A) Co-expression of EYFP-AGO2 with mTan-LIMD1 in U2OS cells treated with non-targeting (SCR) or Akt3 
siRNA. B) Co-expression of EYFP-AGO2 S387 point mutants with mTan-LIMD1 in U2OS cells. C) 
Quantification of number of AGO2 P-bodies co-localised with LIMD1 in (A). D) Quantification of number 
of AGO2 P-bodies co-localised with LIMD1 in (C). Data shown are mean ±SEM, n=3, * p<0.05, ** p<0.001. 
Nuclear outlines in white. Scale bars are 10µm. This experiment was performed by Dr Katherine S.Bridge. 
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To investigate whether the interaction between AGO proteins and LIMD1 was 
dependent on the phosphorylation of the equivalent conserved serine, the point 
mutants of EYFP-AGO1 (S385A and S385E) and -AGO4 (S377A and S377E) were 
generated. However, AGO3 does not have an equivalent serine but contains a glutamic 
acid residue two amino acids downstream (Figure 4.2). Therefore, E390 residue was 
substituted by alanine as a phospho-deficient mutant (E390A) to evaluate whether E390 
was responsible for the association with LIMD1. The results demonstrated that with the 
treatment of Akt3 siRNA, there was a trend of disassociation of AGO1 and LIMD1 (Figure 
4.7A and Figure 4.7B). These data implied that Akt3-mediated phosphorylation 
contributed to AGO1-LIMD1 association. For the point mutants of AGOs, as with AGO2 
that the phospho-deficient mutants of AGO1 and AGO4 significantly decreased the 
association with LIMD1, whereas the phospho-mimic mutants of AGO1 and AGO4 
enhanced the co-localisation with LIMD1 (Figure 4.7C, Figure 4.7D and Figure 4.8). 
Interestingly, as AGO3 containing a naturally existing phospho-mimic residue E390, the 
AGO3-LIMD1 interaction was not affected by the treatment of Akt3 siRNA (Figure 4.9A 
and Figure 4.9B). This indicated that AGO3-LIMD1 association was not Akt3 signal-
dependent. In addition, E390A mutants showed a significant reduction in co-localisation 
(Figure 4.9C and Figure 4.9D). Therefore, AGO3-LIMD1 interaction was independent on 
Akt3 signalling due to the naturally existing phospho-mimic residue E390. Taken 
together, these data revealed a fundamental mechanism of the interaction between 
AGO proteins and LIMD1, which depended on Akt3-mediated phosphorylation on the 
conserved serine within L2 domain. For the naturally existing phospho-mimic residue on 
AGO3, the interaction with LIMD1 was not Akt3-dependent.  
  




Figure 4.7 The co-localisation of LIMD1 and AGO1 depends on Akt3-mediated phosphorylation 
A) Co-expression of EYFP-AGO1 with mTan-LIMD1 in U2OS cells treated with non-targeting (SCR) or Akt3 
siRNA. B) Co-expression of EYFP-AGO1 S385 point mutants with mTan-LIMD1 in U2OS cells. C) 
Quantification of number of AGO1 P-bodies co-localised with LIMD1 in (A). D) Quantification of number 
of AGO1 P-bodies co-localised with LIMD1 in (C). Data shown are mean ±SEM, n=3, * p<0.05, ** p<0.001. 
Nuclear outlines in white. Scale bars are 10µm. 





Figure 4.8 The co-localisation of LIMD1 and AGO4 depends on the phosphorylation of S377 
A) Co-expression of EYFP-AGO4 S377 point mutants with mTan-LIMD1 in U2OS cells. B) Quantification of 
number of AGO4 P-bodies co-localised with LIMD1 in (A). Data shown are mean ±SEM, n=3, * p<0.05. 
Nuclear outlines in white. Scale bars are 10µm. 
 
  




Figure 4.9 The co-localisation between AGO3 E390, a natural phospho-mimic, and LIMD1 is not Akt3 
dependent.  
A) Co-expression of EYFP-AGO3 with mTan-LIMD1 in U2OS cells treated with non-targeting (SCR) or Akt3 
siRNA. B) Co-expression of EYFP-AGO3 E390 point mutant with mTan-LIMD1 in U2OS cells. C) 
Quantification of number of AGO3 P-bodies co-localised with LIMD1 in (A). D) Quantification of number 
of AGO3 P-bodies co-localised with LIMD1 in (C). Data shown are mean ±SEM, n=3, ** p<0.001. Nuclear 
outlines in white. Scale bars are 10µm. 
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4.2 Characterisation of the association between AGOs and LAW  
It has been demonstrated that LAW family members (LIMD1, AJUBA and WTIP) were 
critical regulators for miRNA-mediated silencing [1]. To date, the focus of miRNA-
mechanism has been focused on the role of LIMD1 within miRISC. Our attention was 
next turned to the family member proteins AJUBA and WTIP to examine whether they 
co-localise with the AGOs and whether the S387 point mutations within AGO2 and the 
conserved serine within AGO proteins were important for the association. Therefore, 
mTan-AJUBA was co-expressed with EYFP-AGOs (containing serine point mutants) in 
U2OS cells to examine the co-localisation. The results confirmed the hypothesis that 
there was an association between AJUBA and AGOs (AGO1-3). The AGO1 S385A mutant 
showed a significant 7-fold reduction in co-localisation with AJUBA, while it showed an 
increasing trend when it was S385E mutant (Figure 4.10). For AGO3, the same results as 
LIMD1 were observed; E390A abolished the most of the co-localisation with AJUBA 
(Figure 4.11). Compared to AGO2 WT, AGO2 S387A and S387E showed an increasing 
trend (2-fold and 1.5-fold respectively) in co-localisation with AJUBA, although the 









Figure 4.10 The co-localisation of AGO1 and AJUBA depends on the phosphorylation of S385 
A) Co-expression of EYFP-AGO1 S387 point mutants with mTan-AJUBA in U2OS cells. B) Quantification of 
number of AGO1 p-bodies co-localised with AJUBA in (A). Data shown are mean ±SEM, n=2, * p<0.05. 
Nuclear outlines in white. Scale bars are 10µm. 
 
  





Figure 4.11 The co-localisation of AGO3 and AJUBA depends on E390, a natural phospho-mimic 
A) Co-expression of EYFP-AGO3 E390 point mutants with mTan-AJUBA in U2OS cells; B) Quantification of 
number of AGO3 p-bodies co-localised with AJUBA in (A). Data shown are mean ±SEM, n=2, ** p<0.001. 
Nuclear outlines in white. Scale bars are 10µm. Published data. 
 
  





Figure 4.12 The co-localisation of AGO2 and AJUBA is affected by the phosphorylation of S387 
A) Co-expression of EYFP-AGO2 S387 point mutants with mTan-AJUBA in U2OS cells. B) Quantification of 
number of AGO2 p-bodies co-localised with AJUBA in (A). Data shown are mean ±SEM, n=2. Nuclear 
outlines in white. Scale bars are 10µm. 
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The association between WTIP and AGOs (AGO1-3) was then examined with regards to 
the point mutants of the conserved serine. The co-localisation data showed AGO1-WTIP 
association was dependent on the conserved S385. Compared to AGO1 WT, the 
phospho-deficient mutant (S385A) showed a reduction on the co-localisation, whereas 
the phospho-mimic mutant (S385E) increased the AGO1-WTIP co-localisation (Figure 
4.13). In addition, the association between AGO3 and WTIP decreased if the point 
mutation was introduced (E390A) (Figure 4.14). Unlike AGO1-WTIP association 
regulated by the point mutations on the conserved serine, either S387A or S387E 
mutations showed the increased co-localisation of AGO2 and WTIP (Figure 4.15).  
In summary, these data demonstrated that the association between AGO proteins 
(AGO1 and AGO2) and LAW depended on the ability of the conserved serine to be 
phosphorylated (Figures 4.10, 4.12, 4.13, and 4.15). Lacking of the conserved serine on 
AGO3, the naturally existing phospho-mimic residue E390 contributed to AGO3 
constitutive association with LAW (Figure 4.11 and 4.14).  
 
  





Figure 4.13 The co-localisation of AGO1 and WTIP depends on the phosphorylation of S385 
A) Co-expression of EYFP-AGO1 S385 point mutants with mTan-WTIP in U2OS cells. B) Quantification of 
number of AGO1 p-bodies co-localised with WTIP in (A). Data shown are mean ±SEM, n=2. Nuclear 
outlines in white. Scale bars are 10µm. 
 
  





Figure 4.14 Co-localisation of AGO3 and WTIP depends on the E390, a natural phospho-mimic 
A) Co-expression of EYFP-AGO3 E390 point mutants with mTan-WTIP in U2OS cells. B) Quantification of 
number of AGO3 P-bodies co-localised with WTIP in (A). Data shown are mean ±SEM, n=2. Nuclear 
outlines in white. Scale bars are 10µm. 
 
  





Figure 4.15 The co-localisation of AGO2 and WTIP is affected by the phosphorylation of S387 
A) Co-expression of EYFP-AGO2 S387 point mutants with mTan-WTIP in U2OS cells. B) Quantification of 
number of AGO2 P-bodies co-localised with WTIP in (A). Data shown are mean ±SEM, n=2. Nuclear 
outlines in white. Scale bars are 10µm. 
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4.3 Investigation of the co-localisation of AGO2 and LIMD1 with regards to the 
phosphorylating ability of Y393 within L2 domain  
In addition to S387, EGFR-mediated phosphorylation at tyrosine 393 (Y393) on AGO2 
was reported to reduce the interaction with Dicer to inhibit the biogenesis of miRNAs 
[114]. The phosphorylation at Y393 was also reported to inhibit miRNAs loading onto 
AGO2 and in turn resulted in the inhibition of miRNA-mediated silencing [128]. These 
reports suggested that Y393 was another important phosphorylation site involved in 
miRNA-mediated silencing pathway. Given that Y393 is also located within the L2 
domain, it raised a question whether the phosphorylation at Y393 affected the 
association with LIMD1.  
4.3.1 Construction of the expression plasmids for EYFP-AGO2 Y393 point mutants 
To examine whether the residue Y393 was also important and could contribute to AGO2-
LIMD1 association, one set of constructs expressing phospho-mimic (Y393D) or 
phospho-deficient (Y393F) of EYFP-AGO2 S387 version needed to be generated 
according to the chemically-similarity of amino acids (Figure 11.3). In addition, the 
interaction of AGO2 and LIMD1 depended on Akt3-mediated phosphorylation of S387 
(Chapter 3.3). To rule out the effect by S387, another set of constructs expressing the 
point mutation at Y393 residue (Y393D and Y393F) of EYFP-AGO2 S387A version were 
also required. Therefore, to generate two sets of EYFP-AGO2 Y393 point mutants with 
regards to S387/S387A, site-directed mutagenesis was performed by using EYFP-AGO2 
S387 or EYFP-AGO2 S387A as a template (details described in Chapter 2.2.1.5). The 
sequencing was directly performed after mutagenesis treatment. The results showed 
except for EYFP-AGO2 Y393F, other constructs including EYFP-AGO2 Y393D and EYFP-
AGO2 S387A contained the required substitutions on Y393 (Figure 4.16 and Figure 4.17). 
The sequencing result showed there were two peak readings at Y393 (highlighted by a 
red arrowhead, Figure 4.16). This indicated that there was a technique error on picking 
colonies sent to sequencing, resulting in the vial of this construct contains two plasmids, 
EYFP-AGO2 Y393 and EYFP-AGO2 Y393F.  





Figure 4.16 The preparation of Y393 point mutations on EYFP-AGO2 S387 WT by Q5® site-directed 
mutagenesis 
A&C) The alignment of the Sanger sequencing read to the database AGO2 CDS (NM_012154.3) performed 
by MUSCLE. B&D) The chromatograms showed distinct peaks for each nucleotide in the corresponding 
region, indicating the required point mutations. The Red arrowhead indicates that there are two readings 
at the required mutagenesis site. 
 
  





Figure 4.17 Preparation of Y393 point mutations on EYFP-AGO2 S387A by Q5® site-directed 
mutagenesis 
A&C) The alignment of the Sanger sequencing read to the database AGO2 CDS (NM_012154.3) performed 
by MUSCLE. B&D) The chromatograms showed distinct peaks for each nucleotide in the corresponding 
region, indicating the required point mutations. 
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4.3.2 Phosphorylating ability of Y393 within the L2 domain of AGO2 affects the co-
localisation with LIMD1 
It is of note that the mutated AGO2 was over-expressed to investigate its co-localisation 
with LIMD1 according to the ability of phosphorylation on Y393. Therefore, the co-
localisation experimental results did not directly examine the phosphorylation status of 
Y393. By co-transfecting EYFP-AGO2 WT set of Y393 point mutants with mTan-LIMD1, 
the results showed that EYFP-AGO2 Y393D (phospho-mimic) had 6-fold less co-
localisation with LIMD1 compared to EYFP-AGO2 WT, whereas the co-localisation 
between EYFP-AGO2 Y393F (phospho-deficient) with LIMD1 increased (Figure 4.18). 
These results implied the association with LIMD1 was dependent on the 
phosphorylation of Y393. Unlikely with the function of S387 examined in Chapter 4.1 
that the phosphorylation enhances the interaction with LIMD1, the phosphorylation of 
Y393 might inhibit the association with LIMD1 and hypo-phosphorylation of Y393 
enhanced this association. With regards to the technique error on EYFP-AGO2 Y393F, 
this would underestimate the effect of Y393F on enhancing the association with LIMD1, 
and this could explain the high error bar on Y393F among the independent biological 
repeats (Figure 4.18). 
 
  





Figure 4.18 The point mutation of Y393 within L2 domain affects the association with LIMD1 
A) Co-expression of EYFP-AGO2 Y393 point mutants with mTan-LIMD1 in U2OS cells. B) Quantification of 
number of AGO2 P-bodies co-localised with LIMD1 in (A). Data shown are mean ±SEM, n=2, *, p<0.05. 
Nuclear outlines in white. Scale bars are 10µm.  
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Given that S387A within AGO2 abrogated the association with LIMD1 (Figure 4.6), it 
raised the question how it affected AGO2-LIMD1 interaction with regards to the 
combined phosphorylation at these two resides. By examining the co-localisation of 
EYFP-AGO2 S387A/Y393 point mutants, S387A mutant was found to achieve a low co-
localisation with LIMD1 (Figure 4.19), which agreed with our previous observations 
above where hypo-phosphorylation at S387 disrupted the interaction with LIMD1 
(Chapter 3.3). With the dual-mutation on S387A/Y393D, the co-localisation could not be 
rescued and remained low (10%) at a similar level to the S387A mutation only. 
S387A/Y393F dual-mutation, however, increased the co-localisation with LIMD1 (Figure 
4.19). Within AGO2 S387A set, the phospho-mimic mutant Y393D did not change the 
association with LIMD1, but as observed previously the phospho-deficient mutant Y393F 
increased the association with LIMD1. This further confirmed the association of AGO2 
and LIMD1 was also dependent on the phosphorylation of Y393.  
 
  





Figure 4.19 The point mutation of Y393 within L2 domain affects the association with LIMD1 
A) Co-expression of EYFP-AGO2 S387A Y393 point mutants with mTan-LIMD1 in U2OS cells. B) 
Quantification of number of AGO2 P-bodies co-localised with LIMD1 in (A). Data shown are mean ±SEM, 
n=2. Nuclear outlines in white. Scale bars are 10µm.  
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4.4 Summary 
In summary, the conserved serine within the L2 domain of all four human AGOs was 
demonstrated to be responsible for LIDM1 association (Chapter 4.1). Moreover, it 
showed there were associations between AGOs and LAW family members. These 
associations were regulated by the phosphorylation at the conserved serine (expect 
AGO3 with naturally existing glutamic acid (Figure 4.11 and Figure 4.14)) (Chapter 4.2). 
In addition to S387 contributing to regulating the AGO2-LIMD1 interaction, the AGO2-
LIMD1 association might also depend on another phosphorylation site (Y393) within the 
L2 domain (Figure 4.18 and Figure 4.19). The phosphorylation of S387 and Y393 function 
as a molecular ‘switch’ to regulate the association of AGO2 with LIMD1. For simplicity, 
‘ON’ or ‘OFF’ was used to define whether there is an association or not, respectively 
(Table 4.2 and Figure 4.20). For example, S387/Y393 (EYFP-AGO2 WT) was considered 
as an ‘ON’ model that LIMD1 and AGO2 showed a high co-localisation (Figure 4.19C, 
Figure 4.20 and Table 4.2). Phospho-mimic mutant Y393D decreased the interaction 
(‘OFF’), whereas phospho-deficient mutant Y393F rescued the association (‘ON’). On the 
other hand, S387A/Y393 resulted in a low co-localisation (‘OFF’) between AGO2 and 
LIMD1 (Table 4.2, Figure 4.19C and Figure 4.20). Phospho-mimic mutant Y393D 
remained the low degree of interaction, whereas phosphor-deficient mutant Y393F 
rescued the degree of interaction (Table 4.2 and Figure 4.20B). These observations 
provided a potential fundamental mechanism through which the phosphorylation of 
Y393 regulated AGO2-LIMD1 association, which was not addressed in the previous 
studies. It helped to understand how AGO2 is regulated to interact with LIMD1 (also 









Table 4.2 Simplified AGO2-LIMD1 association with regards to different combinatorial point mutants on 
S387 and Y393 











Figure 4.20 Summary of AGO2-LIMD1 association with regards to the combined point mutations of S387 
and Y393 
AGO2-LIMD1 association was regulated by the combined point mutations of S387 and Y393. S387A 
















This study was designed to 1) characterise the direct binding interfaces between LIMD1 
and AGO2 for a better understanding for the role of LIMD1 as a regulator in miRNA-
mediated silencing and 2) investigate the association between AGOs and LAW to expand 
our knowledge of AGOs utilisation with regards to different LAW family proteins. 
Therefore, this chapter will discuss the overall mechanistic implications of the findings 
presented so far and postulate the proposed/hypothesised model of the pathway that 
LIMD1 involved in the above study. 
5.1 The specific domains responsible for the AGO2-LIMD1 interaction  
The previously published study from our group demonstrated that LIMD1 associates 
with miRISC to facilitate the miRNA-mediated silencing [1]. This present study not only 
determined that LIMD1 binds directly to AGO2, one of the key component of miRISC, 
but also revealed their specific interaction domains: a.a 140-166, which was defined as 
an AGO-binding motif (AB-motif) of LIMD1 in our latest publication [253], binds to the 
L2 domain of AGO2 (Chapter 3.2). It is of note that the crystal structure analysis revealed 
the PIWI domain of AGO2 with tandem tryptophan-binding pockets is responsible for 
direct binding with TNRC6A tryptophan residues [109]. This present study confirmed 
that this domain does not interact with LIMD1 (Figure 3.15). LIM domains were 
determined by our latest publication to directly interact with TNRC6A, another key 
component of miRISC, via the Argonaute-binding domain (ABD) (Figure 5.1A). The loss 
of LIMD1 significantly impaired AGO2-TNRC6A/miRISC association and miRNA-mediated 
silencing activity (Figures 1A-1C and 2 of [253], p269-p270).  
The phosphorylation has been demonstrated to contribute to the protein-protein 
interaction, and the phosphorylation site tend to be located on the interaction 
interfaces [254]. A previous study has shown that the phosphorylation of S387 on AGO2 
by Akt3 increased miRNA-mediated silencing and decrease siRNA-mediated 
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endonucleolytic activity [127]. Evidence has been showed that the N and L1/L2 domain 
on AGO3 is looser than that on AGO2 (Figure 1.11), and thus AGO3 lacks its 
endonucleolytic activity [118]. Therefore, it is reasonable to postulate the 
phosphorylation of S387 or the phospho-mimic mutant, S387E might change the 
conformation of AGO2: open the space between the N and L1/L2 domain. This not only 
increased the interaction with LIMD1 and miRNA-mediated silencing.  
This present study indicated that the Akt3-mediated phosphorylation on S387 promotes 
AGO2-LIMD1 interaction (Figure 4.6 and Figure 5.1B). The phosphorylation may 
modulate the binding energy and thus change the molecular structure [254], which 
ultimately enhance the binding of AGO2 with LIMD1. Our latest publication has 
elaborated this finding that phosphorylation at S387 subsequently enhances miRNA-
mediated silencing. In agreement with our findings, La Rocca et al. recently identified 
phosphorylation-dependent activation of miRNA silencing by PI3K, a kinase that lies 
upstream of Akt3 [255]. In addition, the interaction between AGO2 and TNRC6A is 
independent of LIMD1 binding [256], suggesting AGO2 can interact TNRC6A without 
LIMD1. Taken all together, the phosphorylation of S387 on AGO2 enhances the 
interaction with LIMD1, and in turn, LIMD1 is proposed to function as a molecular ‘clamp’ 
by binding to both AGO and TNRC6A proteins simultaneously. Therefore, the enhanced 
AGO2-LIMD1 interaction secure the association among three proteins, which 
subsequently facilitates miRNA-mediated silencing. 
  





Figure 5.1 Schematic of the interfaces of LIMD1, AGO2 and TNRC6A for binding to each other 
A) The graphical representation of domain interaction of AGO2, LIMD1, and TNRC6A. The AB-motif of 
LIMD1 (a.a 140-166) directly binds to the L2 domain of AGO2, and the LIM domains of LIMD1 bind to the 
N-terminal ABD of TNRC6A. B) The phosphorylation of S387 on AGO2 facilities its interaction with AB-
motif of LIMD1. ABD, Argonaute-binding domain. SD, silencing domain.  
 
5.2 AGO-LAW association occurs via a common phosphorylation-dependent 
mechanism 
The L2 domain connecting the PAZ and MID domains is evolutionally conserved across 
all four human AGOs with 84.6% sequence identity (Figure 4.2). This study suggested 
the direct interaction of human AGO1-4 with LIMD1 via the L2 domain (Figure 4.1 and 
Figure 4.3). In addition, the S387 residue within the L2 domain of AGO2, which is 
phosphorylated by Akt3, is conserved in human AGO1 and 4 (highlighted in Figure 4.2). 
This study showed that the association of LIMD1 with AGO1 and 4 is also dependent on 
the phosphorylation at this conserved serine residue (Figure 4.7 and Figure 4.8). Given 
that a previous study demonstrating that AGO1 can be phosphorylated [124], these data 
imply a hypothesis of a common AGO-activating mechanism whereby the conserved 
serine residue is phosphorylated by Akt3 and/or other unidentified kinases. AGO3 does 
not contain this conserved serine residue but contains a phospho-mimic glutamic acid 
residue (E390) instead (Figure 4.2). E390 on AGO3 directs the association with LIMD1 
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independently of Akt signalling (Figure 4.9). Horman et al. postulated that the 
phosphorylation of S387 represented a molecular switch between the siRNA and miRNA 
function of AGO2 [127]. To expand upon this concept, this study indicates the Akt3-
mediated phosphorylation on AGO1, 2 (and possibly AGO4) could also be considered as 
a switch from OFF to ON for miRNA-silencing function. Furthermore, this study also 
suggests LAW family members (LIMD1, AJUBA and WTIP) can associate with all human 
AGOs (Chapter 4.1) and were previously demonstrated to be required for the miRNA-
mediated silencing [1, 253]. The co-localisation results do not imply that all four AGOs 
associating with LAW depend on the same ‘phospho-serine-switch-ON/OFF’ mechanism 
as with AGO2-LIMD1. However, it is similar that the presence of a glutamic acid residue 
(E390) within the L2 domain allows AGO3 to associate with LAW irrespective of Akt-
signalling. As a result, this study reveals a possible compensatory silencing pathway via 
AGO3-LAW when there is no Akt3 signalling to activate any or all of the other AGOs by 
phosphorylation.  
Although Wang et al. demonstrated that AGO2 is the most abundant and in turn most 
contributes to miRNA-mediated silencing [257], LAW family proteins are important 
determinants of AGO utilisation [253]. By cross-comparing all co-localisation results in 
Chapter 4 with regards to the wild-type conserved serine within L2 domain of AGO1-3, 
AGO3-AJUBA is the dominant complex in U2OS (Figure 5.2).  
 
 
Figure 5.2 Cross comparison of AGO-LAW association  
Data summarised from the previous IFA results and focused on AGO with the wild-type serine. 
Quantification of the number of AGOs P-bodies co-localised with LAW in U2OS cells co-expressed EYFP-
AGOs (1-3) with mTan-LAW. Data shown are mean ±SEM, n=2. 
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Taken together with the result that AGO3-WTIP complex switches to function in miRNA-
mediated silencing when AGO2-LIMD1 complex is depleted [253], this present study 
implied the common existence of a differential AGO-LAW complexes (AGO3-AJUBA) and 
were involved in miRNA-mediated silencing. Furthermore, in the LIMD1-/- HeLa cell line, 
it was WTIP rather than AJUBA that forms a complex with AGO3 and resulted in 
significant repression of the miR-99/100 reporter [253]. Such results are not 
contradictive to the dominant AGO3-AJUBA complex observed in this present study 
(Figure 5.2), but instead, it proved that the differential AGO-LAW complexes exist and 
are dependent on the context of the cell type and abundance of each AGO. As discussed 
previously, LIMD1 as a molecular ‘clamp’ to secure AGO2-LIMD1-TNRC6A complexes to 
facilitate miRNA-mediated silencing. The recent study demonstrated that one molecule 
of TNRC6A can recruit up to three human AGO proteins via its GW motifs [258]. The 
cooperative repression was observed by different miRNAs when their seeding sites are 
within 13-35 nts [259]. In addition, it has shown that AGOs function cooperatively to 
silence the target mRNA by the cooperativity in binding: the recruitment of the first 
miRISC to the 3’UTR of mRNA enhances the recruitment of the other miRISC complexes 
through the physical interaction between miRISCs [260]. Recently, Flamand et al. 
revealed the interaction interfaces between AGOs within two miRISCs in C.elegans 
(Figure 5.3A), and such interaction allowed the conformation change of AGO and TNRC6, 
resulting in the recruitment of CCR4-NOT deadenylases complex [261]. Therefore, taken 
together with these studies, this present study would put forward the proposed model 
for miRNA-mediated silencing with regards to AGO-LAW-TNRC6 complex (Figure 5.3B). 
If the miRNA seed sites are within a close distance, one molecule of TNRC6 can bind to 
three different AGOs. The interaction between AGOs and TNRC6 is clamped by the 
association with LAW and AGO-AGO interaction. Consequently, it results in the 
cooperative repression of the target mRNA. This present study elaborates the theory 
that the determination of AGO utilisation, the cooperation of different AGO proteins 
and the specific pairing with LAW maybe context-dependent with regards to the 
distribution of a particular miRNA among AGO proteins [108, 262], the abundance of 
AGO proteins and differential LAW expression in the cells. Further investigations need 
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Figure 5.3 Proposed model of AGO-LAW-TNRC6 association regulating miRNA-mediated silencing 
A) Interaction between tow ALG-2 (the homology of human AGO2) within two miRISCs (not shown) 
loaded with miR-80 (indicated in green) and miR-35 (indicated in yellow), which target the 3’UTR of Toh-
1 (indicated in grey). The dashed box indicates the proposed interaction interface. B) One molecule of 
TNRC6 (indicated in light blue) can interact up to three AGO proteins. The determination of AGO 
utilisation and its specific pairing with LAW depend on the distribution of miRNA among AGO proteins, 
the abundant of AGO proteins and LAW expression in the cells. Figure part (A) is adapted from Flamand 
et al., 2017 [261]. 
 
It is of note that this study has examined only the phosphorylating ability but not the 
phosphorylation status of the conserved serine within the L2 domain. Although AGO1 
can be phosphorylated [124], there is no specific evidence to show the conserved serine 
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on AGO1 and 4 can be phosphorylated. Therefore, the results were based on the 
assumption that the conserved serine is phosphorylated by Akt3 and/or other 
unidentified kinases. Further investigations are required to examine the possible 
phosphorylation. In addition, all the co-localisations observed in this study was 
conducted by the confocal microscope. Although the confocal microscope scans across 
the sample and generates high-resolution images, the diffraction limit is less than 
240nm. Therefore, proteins within 240nm are visualised as co-localised. Proximity 
ligation assay (PLA) [263], is an immunohistochemical tool for the precise protein 
analysis, including protein-protein interactions and protein modifications. The principle 
of PLA is to use one pair of short DNA oligonucleotides labelled antibodies which bind 
to different epitopes of two proteins. If two proteins are in close proximity (40nm apart), 
DNA oligonucleotides on the antibodies then form a circular ssDNA molecule and 
continue the rolling cycle amplification. Therefore, the amplified signals can be detected 
by the confocal microscope. PLA has been employed to show AGO2-LIMD1, LIMD1-
TNRC6A and TNRC6A-CNOT9 signals, but not TNRC6A-CNOT1 signal [253]. As a result, 
PLA is necessary to reveal the AGO-LAW association accurately.  
5.3 The residue Y393 also regulates AGO2-LIMD1 association 
Besides S387, this study also reveals another residue, Y393, within the L2 domain of 
AGO2, the phosphorylation of which can also regulate AGO2 association with LIMD1; 
phospho-mimic mutant (Y393D) impairs the AGO2-LIMD1 association, whereas 
phospho-deficient mutant (Y393F) restores/enhances the AGO2-LIMD1 association. In 
agreement with the previous study demonstrating the dephosphorylation of Y393 on 
AGO2 is required to promote miRNAs loading onto AGO2 and thus miRNA-mediated 
silencing [128], this present study implied LIMD1 participates in this pathway that the 
dephosphorylation of Y393 results in the interaction of AGO2 with LIMD1 and thus 
miRNA-mediated silencing. In addition, as similar to the conserved serine (S387 in AGO2), 
Y393 is also conserved across all four human AGOs (Figure 5.4). More interestingly, 
AGO3 not only contains a naturally existing phospho-mimic (E390) residue which is 
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independent of Akt3-signalling but also contains a naturally existing phospho-deficient 
(F394) residue. Therefore, AGO3 may be the most dominant AGO required for miRISC 
complexes, which is in agreement with the IFA data (Figure 5.2). However, the 
endogenous AGO3 expression is extremely low due to the high proportion of rarely used 
codons in its mRNA [264]. Maunoury et al. demonstrated that AGO1 and AGO2 are 
redundant in miRNA-mediated silencing [265], and thus the redundant AGO1 and AGO2 
function in miRNA-mediated silencing. Therefore, based on our latest publication [253], 
this present study indicates AGO3 can function in miRNA-mediated silencing and specific 
functions as a compensatory miRNA-silencing pathway in the absence of the Akt3-
AGO2S387-LAW signalling axis or other AGO2Y393 signalling axes due to its two naturally 
existing residue within L2 domain.  
 
 
Figure 5.4 Multiple sequence alignment of the human AGO family 
AGO proteins contain a highly conserved Tyrosine residue: AGO1 Y391, AGO2 Y393 and AGO4 385. AGO3 
contains a phosphor-deficient phenylalanine residue (F394). 
 
5.4 Which residue functions dominantly, S387 or Y393? 
When considering the S387 phosphorylation-dependent mechanism on regulating 
AGO2-LIMD1 interaction, it raises a question of which residue (S387 or Y393) has the 
dominant role in inducing the association with LIMD1, and thus the miRNA-mediated 
silencing; whether the phosphorylation of S387 and dephosphorylation of Y393 occur 
simultaneously or sequentially. It was shown that Y393F (phospho-deficient) enhanced 
AGO2-LIMD1 association even when S387 was not able to be phosphorylated (S387A) 
(Figure 4.20 and Table 4.2). By considering the role of Y393 in miRNA maturation and 
loading ability on AGO2, this present study hypothesises a model for miRISC assembly 
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whereby AGO2 is initially dephosphorylated at Y393 residue by the specific 
phosphatases (such as protein tyrosine phosphatase 1B (PTP1B)) to bind to Dicer and 
process the miRNA maturation and thus promotes miRNA loading (Figure 5.5A). 
Meanwhile, the dephosphorylated AGO2 recruits LIMD1. S387 is then (or 
simultaneously with the dephosphorylation of Y393) phosphorylated by the Akt3-
signalling to secure the AGO2-LIMD1-TNRC6A association within miRISC complexes 
(Figure 5.5A).  
Smibert et al. demonstrated that AGO2 stability is positively regulated by the cellular 
availability of mature miRNAs and the ubiquitin-proteasome system, and the loading of 
siRNAs can rescue the stability of AGO2 in the absence of miRNA biogenesis [130]. 
Therefore, the phosphorylated Y393 reduces the maturation of miRNAs and in turn 
decreases AGO2 stability. To compensate/self-rescue this instability, siRNAs may be 
forced to load on AGO2 more efficiently and subsequently achieves the siRNA-mediated 
silencing (Figure 5.5B). This present study opens up the possibility for the functional 
differences in the combined phosphorylation status of S387/Y393 in AGOs with respects 
to the miRISC assembly. To elaborate the ‘switch-ON/OFF’ theory on S387 mentioned in 
the previous section, Y393 along with S387 collaborate as a molecular switch to 
determine whether AGO2 undergoes miRNA- or siRNA-mediated gene silencing. The 
phosphorylation of Y393 switches AGO2 to function in siRNA-mediated silencing and 
abrogates the association with LIMD1. Therefore this hypothesis would fit with the 
published data demonstrating that LIMD1 is exclusively involved in miRNA-mediated 
silencing but not siRNA-mediated silencing [1]. 
Nevertheless, the phosphorylation of Y393 abolishes the interaction of AGO2 with Dicer 
[128]. Considering Dicer binds to PIWI domain of AGO2, it raises a question whether 
Dicer binds L2 domain, or LIMD1 might be a scaffold regulating their interaction.  
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6 Introduction 
Given that LIMD1 is frequent down-regulated, targeting LIMD1 faces lots of challenges. 
By using the synthetic lethality approach, serine/threonine kinase 39 (STK39) was 
revealed a synthetic lethality function with LIMD1 loss in the Results Chapter 7. 
Therefore, this chapter will firstly introduce the kinase family that STK39 belongs to, 
followed by the overview of STK39 including its history of discovery, the structures and 
domains, binding partners, signalling cascades, the mammalian physiological roles and 
the role in cancer.  
6.1 The overview of STK39 
 
6.1.1 STK39 belongs to Ste20-related kinases  
The function of serine/threonine kinases is to hydrolyse ATP and transfer the inorganic 
phosphate to the side chain of the serine and threonine residues. This leads to the 
phosphorylation of the target protein, resulting in the regulation of cellular processes. 
The Sterile 20 (Ste20)-related kinases are a relatively large family of proteins highly 
conserved in fungi, plants, Drosophila, C.elegans and mammals, whose function is to 
regulate mitogen-activated protein kinase (MAPK) cascades [266, 267]. According to 
whether the catalytic domain is located at the N- or C-terminal, Ste20-related kinase 
family can be sub-grouped into the germinal centre kinases (GCKs) presenting a N-
terminal catalytic domain and the p21-activated kinases (PAKs) presenting a C-terminal 
catalytic domain [267]. GCKs can be further broken down into eight sub-groups (GCKI-
VIII). Indeed, GCK family has been demonstrated as MAP4Ks in MAPK signalling cascades 
function and thus regulates signalling transduction [267] (Table 6.1). STK39 belongs to 
GCK-VI sub-family and regulates several cellular processes, which will be elaborated in 
the next section.  
 
 




Table 6.1 List of GCK family members which regulate MAPK signalling pathway 
Summarised from Dan et al., and Gagnon et al., 2012[267, 268] 
Name Sub-family of GCKs Function Reference 
MAP4K5 GCK-I Wnt-mediated JNK activation [267] 
Mst2 GCK-II Positive role in Raf-1/ERK pathway [269] 
Mst4 GCK-III Modulation of ERK pathway [270] 
NIK, NRK GCK-IV Activation of JNK pathway [271] 
STK39 GCK-VI Activation of p38 [272] 
TAO1/2/3 GCK-VIII Activation of p38; Inhibition of JNK pathway [273] 
 
6.1.2 PASK, SPAK and STK39 are referred to the same protein 
The current literature is using two widely-accepted names to refer to the same protein 
(STK39). This inconsistently used name would confuse the researchers. Therefore, it is 
necessary to clarify how and where the name is derived from. A novel protein with the 
molecular weight of 66kDa was identified from rat brain tissue. This novel protein 
contained the similar catalytic domain with the Ste20 protein kinases and the 
abundance of proline and alanine residues. As a result, this novel protein was named 
proline-alanine-rich Ste20-related kinase (PASK) [274]. Two years later, based on the 
characterisation of a novel kinase which was previously identified in rat pancreatic beta 
cells containing the similar sequence with Ste20 serine/threonine kinases, this protein 
was named Ste20/SPS1-related proline alanine-rich kinase (SPAK) [272, 275]. The 
comparison of amino acid then showed that PASK and SPAK were the same protein. In 
addition, the National Centre for Biotechnology Information also assigned the name 
STK39 to human SPAK. Therefore, to be consistent and avoid confusion, STK39, as the 
same name for its encoded gene, is referred in this thesis.  
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6.1.3 The structure and domains of STK39  
STK39 contains the main domains in the order from the N- to C-terminus: PAPA box, 
catalytic domain, PF1 domain and PF2 domain (Figure 6.1). PAPA box is a region of 
proline and alanine repeats. A colonic STK39 variant was identified and analysed to show 
the lack of PAPA box upstream of the catalytic domain [276]. However, evidence has 
shown that the absence of PAPA box does not impair the binding and phosphorylation 
of its target [277]. Although this result indicated that PAPA box is not essential for the 
kinase activity, it does not rule out the possibility that it has the unknown functions for 
the kinase.  
 
 
Figure 6.1 Schematic of the structure of STK39 
STK39 contains proline/alanine-rich (PAPA) box, catalytic domain, PF1 (not shown) and PF2 (also called 
CCT). C-loop, catalytic loop. T-loop, activation loop. P+1, after activation loop for substrate binding. NLS, 
nuclear localisation signal. DEMD, a putative caspase cleave site. The pocket structure recognises the 
binding other proteins containing the RFxV motif.  
 
The activation segment consists of the activation loop and P+1 loop. The 
phosphorylation of the activation loop activates the kinase activity. P+1 loop is after the 
activation loop, whose function is to bind the substrate for phosphorylation. The swap 
of activation segment is critical for STK39 function; mutating the threonine residue 
within the P+1 loop into an alanine residue (T237A) inhibits STK39 from phosphorylating 
and activating its target [277]. The PF1 domain is just after the catalytic domain, which 
contains a conserved serine-motif (S-motif) [268, 278]. S-motif is targeted by with-no-
lysine kinase 1 (WNK1) on S373 for the activation of STK39 [279]. Within the PF1 domain, 
there are three identified regions: nuclear localisation signal (NLS), a tryptophan-
glutamic acid-tryptophan motif (WEW motif), and DEMD [268]. NLS’s function has not 
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been determined. WEW motif is capable of binding with Calcium-binding protein 39 
(Cab39) to regulate the activation of Na-K-Cl cotransporters (NKCCs) [280]. DEMD is a 
putative caspase cleavage site. The study showed that TRAIL-induced cleavage occurred 
two amino acids downstream of this site, leading to inactivation of SPAK and 
subsequently increased cell sensitivity to apoptosis [281].  
The PF2 domain, also known as conserved C-terminal (CCT) domain, is the last 90 amino 
acids of STK39 [268, 282]. The phenylalanine (F481), leucine (L497), alanine (A499) and 
leucine (L502) residues form a ‘pocket’ structure for the binding of the benzyl side chain 
of the phenylalanine residue (Figure 6.1). F481A mutation resulted in the decreased 
NKCC1 activation by WNK4-STK39 axis pathway [268]. An important binding motif, RFxV 
(where x stands for any amino acid), was identified in STK39 binding partners for the 
interaction with this pocket structure [283]. The mutation of the phenylalanine residue 
within RFxV motif impairs the kinase-substrate interaction. In addition, it has been 
demonstrated that the protein with both PF2-like domain and RFxV binding motif can 
achieve self-regulation, contributing to auto-inhibition [284]. Taken together, PF2 of 
STK39 is of importance in regulating protein interaction.  
6.1.4 The biological functions of STK39 
STK39 expression is widely expressed in different tissues. The well-established pathway 
for STK39 is to regulate the cotransporters. Therefore, the function of STK39 will be 
reviewed in the following section with regards to the cotransporter and the role in the 
cancers.  
6.1.4.1 WNK-STK39-NKCC/KCC axis pathway regulates blood pressure 
The RFxV motif is responsible for the binding to STK39. Therefore it can be used to 
predict potential proteins interacting with STK39. Studies have been done and 
successfully identified multiple proteins containing this RFxV motif and expanded this 
binding motif sequence to [V/S/G]RFx[V/I/T/S] [283, 285]. Sodium chloride 
cotransporter 12 (SLC12) family is one of the cation-chloride cotransporters that 
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regulates the cellular secretion of salt and protects cells from damage by osmotic stress 
[286]. The family contains three sub-groups based on their regulated ions: N-K-Cl 
cotransporters (NKCCs), K-Cl cotransporters (KCCs) and N-Cl cotransporters (NCCs). The 
first co-transporter found to interact with STK39 was NKCC1, which controls the cell 
volume and keep the osmotic balance between the external and internal cellular 
environments by taking up Na+, K+ and Cl-[287]. The interaction takes place through PF2 
domain on STK39 and two RFxV motifs located within the N-terminal cytosolic domain 
of NKCC1 [288]. The mutation of these motifs caused the inhibition of the binding to 
STK39 and the inactivation of NKCC1 [288]. A cluster of conserved threonine within the 
cytosolic domain of NKCC1 was reported to be phosphorylated by STK39 [288]. This 
cluster is highly conserved within NKCC2 and NCC, which is phosphorylated by STK39 as 
well. Therefore, evidence has been shown that STK39 can interact with NKCC2 and NCC 
through the single RFxV motif [287, 289]. As NKCC2 and NCC only express in the kidney, 
they, therefore, regulate renal salt re-absorption and subsequently hypertension [290]. 
After phosphorylation by STK39, a conformational change takes place on cotransporters 
to induce their activities [291].  
WNKs belong to serine-threonine kinases and are named after the lack of lysine residue 
in the catalytic domain [292]. The mutation of WNKs has been demonstrated to be 
correlated to hypertension [293]. The overexpression of WNK decreases K+ excretion 
and in turn increases salt re-absorption in the kidney, leading to salt-sensitive 
hypertension. All four WNK isoforms (WNK1-4) contain the putative RFxV motif at the 
N-terminal for the interaction with STK39. It has been demonstrated that co-expression 
of human NKCC1 with wild-type STK39 in Xenopus laevis oocytes did not cause 
cotransporter activation, but co-expression of NKCC, wild-type STK39 and wild-type 
WNK4 resulted in the activation of NKCC1 activity [294]. This indicated the activation of 
NKCC required both WNK4 and STK39. Variety of independent studies have 
demonstrated that WNKs bind STK39 and regulate STK39-mediated NKCCs activity [283, 
294-296]. The activation of WNKs depends on either hyperosmotic stress or hypotonic 
low-Cl- conditions but is not stimulated by signal-transduction pathway activators and 
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non-osmotic cellular stresses [297, 298]. The serine located within T-loop for regulating 
the protein kinase activity is phosphorylated by hyperosmotic stress or hypotonic low-
Cl- conditions. The phospho-deficient mutation (alanine) on S382 abolished WNK activity, 
whereas the glutamic acid substitute enhanced the activity [299].  
The thick ascending limb (TAL) and distal convoluted tubule (DCT) in the kidney re-
absorb the filtered salt to preserve salt homeostasis and regulate blood pressure. The 
reabsorption is based on the expression of specific ion transport proteins. In general, in 
the epithelial cells of the TAL, the Na+ and Cl- reabsorption are achieved by the 
combination of the NKCC2 and the renal outer medullary potassium channel (ROMK) on 
the apical membrane with Na+-K+ ATPase and chloride on the basolateral membrane 
[300]. In the epithelial cells of the DCT, NCCs are expressed along the entire DCT segment. 
The general mechanism for Na+ absorption is achieved by the NCC expression on the 
apical to influx Na+ and Cl-. The basolateral expression Na+-K+ ATPase effluxes Na+ for 
reabsorption. STK39 and NKCC2 are expressed and co-localised in the TAL [301]. 
Carmosino et al. demonstrated that the increased phosphorylation of STK39 and NKCC2 
presented in the Milan hypertensive rat strain, in which the Na+ reabsorption increased 
due to the mutation for Na+-K+ ATPase. Taken together with the study demonstrating a 
significant increase of STK39 and NCC found in WNK4 knockin in hypertension mice[302], 
the improper salt homeostasis (for example, the increased salt reabsorption) was 
contributed to hypertension. In addition, WNK-STK39-NKCC1 has also been 
demonstrated to express in vascular smooth muscle and regulate contractility of blood 
vessels and blood pressure [303, 304]. Angiotensin II (ANGII), which causes vascular 
constriction and subsequently increase blood pressure, was reported to induce the 
activation of WNK-STK39 cascade [305]. The STK39 null mice demonstrate hypotension, 
presenting an increased expression of total NKCC1 but a decreased amount of the 
phosphorylated NKCC1 [306].This observation indicated STK39 is the predominant 
regulatory kinase of NKCC1 activity. Taken together, these findings demonstrated that 
STK39 functions predominantly in regulating blood pressure. The overexpression of 
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STK39 causes hypertension by the over-phosphorylation of the downstream sodium 
chloride cotransporters to increase salt reabsorption.  
Genome-wide association studies (GWAS) provides a promising way to identify the 
association of genes with the single nucleotide polymorphisms (SNPs) with the 
particular disease. GWAS has identified that the strong association between STK39 and 
hypertension [307]. In two large cohorts of Swedish patients, the rs35929607 A/G 
polymorphism was revealed to correlate with hypertension, and the female carrying the 
G-allele had a higher prevalence of hypertension [308]. However, one of Chinese cohort 
demonstrated that male presented the significant association of STK39 with 
hypertension [309]. Nevertheless, another Chinese cohort along with another individual 
cohort of African Americans argued that none of the STK39 SNPs was associated with 
hypertension [310, 311]. Despite these contradictions, from the biological function 
aspect, STK39 is a vital protein that links WNKs and sodium-chloride cotransporters to 
regulate sodium absorption and hypertension.  
6.1.4.2 The role of STK39 in human cancers 
Little is known about the role of STK39 in the cancers. However, based on the fact that 
cancers present aberrant cell proliferation and migration, it is indicated that there are 
connections with cation-chloride cotransporters due to their regulation of cell volume. 
Indeed, Shen et al. have demonstrated that KCC3 mRNA was abundant in human cervical 
cancer and was associated with the process of cervical malignancy [312]. They also 
observed the enhanced cell growth in KCC3-transfected cells [313]. An increasing 
number of studies have been shown that that cation-chloride cotransporters play an 
important role in tumour biology proliferation and migration [314]. The brain tumour 
originating from glial cells intend to modify the cell volume by releasing K+ and Cl- to 
migrate and invade into the neighbouring brain parenchyma rather metastasis [315, 
316]. NKCC1 expression was highly expressed in glioblastoma, the depletion of which 
resulted in the decreased cell migration and invasion [317]. Haas et al. revealed the 
physical interaction between WNK3 and NKCC1 stimulates the invasion by regulating 
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cell volume. The malignant glioblastoma showed the increased WNK3 but decreased 
WNK2 and STK39 [318]. It is of note that this study did not preclude that STK39 as an 
adaptor protein to facilitate the physical interaction between WNK3 and NKCC1.  
Receptor expressed in lymphoid tissues (RELT), which is a member of tumour necrosis 
factor-α (TNF-α) superfamily, was reported to interact with STK39 through RFxV motif. 
The interaction then activates p38 mitogen-activated protein kinase (MAPK) [272]. 
Recently, studies have been revealed the role of STK39 in tumourigenesis [319, 320]. 
Chiu et al. demonstrated that STK39 promoted cervical cancer aggressiveness and 
tumour formation via p38 MAPK, suggesting STK39 may be a potential target for 
pharmacological intervention [319]. In addition to this study, another independent 
study on the non-small cell lung cancer (NSCLC) defined STK39 as a novel oncogene [320]. 
This study showed the high expression of STK39 significantly positively correlated to the 
advanced tumour stage, large tumour size, metastasis and poor prognosis [320]. The 
depletion of STK39 led to the decreased cell proliferation by inducing apoptosis through 
the inactivation of p38 MAPK and decreased migration and invasion [320]. Besides, this 
study also showed a significant correlation to p38 MAPK.  
Little is known about the association between STK39 with breast cancer, but STK39 is 
expressed at high level in most of breast cancer cell lines investigated in one study [321]. 
For breast cancer, Fos-related antigen 1 (Fra-1) is a member of the Fos family that forms 
the heterodimer with the Jun family members. This heterodimerisation forms the 
activating protein (AP-1) which is a transcription factor regulating cell proliferation and 
tumorigenesis [322]. Belguise et al. demonstrated that the aberrantly hyper-
phosphorylated Fra-1 found in the invasive breast cancer cell lines was due to the 
protein kinase C (PKC) θ activity regulated by STK39 [323]. The normal human prostate 
and the prostate cancer cell lines express a significantly increased STK39 as a response 
to androgen treatment in a dose- and time-dependent manner [321]. This suggested 
that androgen presents a positive regulation of STK39. On the other hand, the prostate 
cancer cells would disable the STK39-related stress responses resulting in the cancer 
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metastasis and the primary prostate tumour relapse [324]. It has shown that the 
reduced STK39 contributed to the breast cancer presenting the resistance to 
doxorubicin and cyclophosphamide [325]. These studies suggested the importance of 
STK39 in the development of cancers, treatment resistance and tumour relapse. More 
importantly, STK39 shows differential biological effects in various malignant tumours, 
suggesting STK39 (or related signalling pathway) might have differential roles.  
6.2 The overview of MAPK 
STK39 was defined as an oncogene contributing to the activation of p38 MAPK and 
regulated apoptosis, and several studies have demonstrated that the sodium chloride 
cotransporters are associated with MAPK [326, 327]. Additionally, with regards to be 
relevant to Chapter 7 in this thesis, the role of MAPK in cancer and apoptosis will be 
reviewed in this section.  
6.2.1 Conventional regulation of MAPK pathways 
MAPKs are ubiquitous and evolutionarily conserved kinases that phosphorylate their 
own and substrates to control fundamental cellular processes such as growth, 
proliferation, differentiation, migration and apoptosis. The activation of MAPK cascade 
is initiated by the multiple stimuli [328, 329]. There are three-tiered core signalling 
modules to subsequently activate MAPK signalling cascade. A MAP kinase kinase kinase 
(MAP3K) phosphorylates MAP2K on the serine and threonine in the activation loop [330, 
331]. Sequentially, MAP2K catalyses MAPK on the tyrosine and threonine within the 
conserved TxY motif located in the T-loop [330, 331].  
MAPKs consist of three family members, the extracellular signal-regulated kinase (ERK1 
and ERK2), the p38 MAPK (p38α, p38β, p38δ and p38γ), and the c-Jun NH2-terminal 
kinase (JNK1, JNK2 and JNK3) (Figure 6.2). Raf-MEK1/2-ERK1/2, MLK-MKK4/7-JNK and 
ASK1/2-MEK3/6-p38 are classical axes in MAPK signalling pathway. Assembly of MAPK 
cascade components by scaffold proteins is important for efficient phosphorylation and 
pathway activation. Kinase suppressor of Ras (KSR) has no kinase activity due to the lack of 
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catalytic lysine residue, but it direct interacts with Raf-1, MEK1/2 and ERK1/2 to form a complex 
and subsequently facilitates the activation of ERK1/2 (Figure 6.2) [332]. In the JNK signalling 
pathway, it is JNK interacting proteins (JIPs) that functions as a scaffold protein 
associating with mixed lineage kinases (MLKs), MEK4/7, JNK [333]. JIPs also function as 
a scaffold in the p38 signalling pathway [334, 335]. p38 family contains four members, 
whose sequences only show 60% identity within the same family [333]. This property 
suggests that each family members has highly diverse functions. After activation by 
ASK1/2, MEK3/6 is allowed to selectively phosphorylate p38 isoforms. p38α, p38δ and 
p38γ isoforms can be phosphorylated by both MEK3 and MEK6, while p38β is 
phosphorylated by MEK6 [336]. As the activation of MAPK signalling pathway depends 
on the phosphorylation at TxY motif within the T-loop, the activity of MAPK can be 
negatively regulated by the activation of MAPK phosphatases (MKPs) or dual-specificity 
phosphatase (DSP) [331, 337].  
  





Figure 6.2 Simplified MAPK signalling pathways related to the role in tumour and in apoptosis 
Three modules of MAPK signalling cascade. ERKs are activated by growth factors, initiating the signalling 
axis. KSR (Blue) functions as a scaffold protein to facilitate the phosphorylation. JNK/p38 are preferable 
to be activated by stress. JIPs (Green) functions as a scaffold protein to facilitate the phosphorylation. The 
activation of ERK/JNK/p38 depends on the dual-phosphorylation at tyrosine and threonine within the 
conserved TxY motif. MKPs and DSP functions phosphatase to negatively control the MAPK signalling 
cascade. The role of each module in tumour and apoptosis is indicated. Summarized from Raman et al., 
2007, Soares-Silon et al., 2016 and Wada et al., 2004 [333, 338, 339]. 
 
6.2.2 The role of MAPK in human cancers 
MAPK pathways convert the extracellular stimuli into a wide range of cellular responses 
such as immunity [340], apoptosis [339] and cell cycle progression [341]. The 
deregulation of these cellular responses has been demonstrated as hallmarks of cancer 
[342], suggesting the importance of MAPK pathways in tumourigenesis and the 
development of cancer [343]. Cancer cells can utilise these pathways to facilitate their 
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proliferation, survival and invasion. The deregulation of MAPK pathways has been 
correlated with human cancer. The ERK signalling pathway is up-regulated and 
constitutively activated in most human cancers (30%) [344], due to the overexpression 
of growth factors, B-Raf mutations [343, 345, 346]. It has been shown that B-raf 
presented V600E mutation in the T-loop leading to the constitutive activation of 
catalytic activity and contributed to the malignant melanoma, colorectal and thyroid 
cancers [346]. The V600E mutation dramatically enhanced B-raf activity and subsequent 
MEK-ERK activity. Therefore, ERK pathway is considered as an oncogenic pathway that 
promotes tumourigenesis [347].  
The JNK pathway presents dual functions as either oncogenic or tumour suppressive. 
For example, JNK1 functions as oncogenic in hepatocellular carcinoma (HCC) with the 
increased activity to proliferate tumour cells caused by the downregulation of p21, a cell 
cycle inhibitor [348]. The gene expression analysis confirmed the oncogenic function of 
JNK in prostate cancer [349]. By contrast, the loss-of-function mutation of JNK3 has been 
demonstrated to promote the brain tumour [350]. Similar to JNK, the p38 signalling 
pathway also presents dual functions in apoptosis, and the precise mechanism remains 
unclear [351]. Lyoda et al. revealed that the decreased p38 was associated with HCC, 
and it showed that p38 had pro-apoptotic function [352]. This study indicated p38 had 
a tumour suppressive function. However, a number of cancers have been demonstrated 
to be correlated with the increased phosphorylated p38. [353, 354], indicating its 
oncogenic function. Nevertheless, the mutations of these pathways result in the 
inflammatory disorders, which are important for cancer cell survival [355]. In summary, 
the role of MAPK pathways, especially for JNK/p38 pathways, in human cancers shows 
the complexity and the precise mechanism is unclear (simplified summarised in Figure 
6.2). The oncogenic role and the apoptosis controlled by MAPK pathways are dependent 
on tumour cells.  
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6.3 Aims and objectives 
Considering the frequent down-regulation of LIMD1 in cancers [229], this study aims to 
identify the synthetic lethal gene encoded the human kinase with LIMD1 loss to provide 
a novel target for specifically treating LIMD1 negative cancers. Therefore, the key aim 
of this study is as follows: 
• Aim 1: Using the concept of synthetic lethality, a screening on Human Kinome 
siRNA library will be conducted to identify the synthetic lethal target with LIMD1 
loss. The investigation of the validated target will be carried on to understand 
the potential unknown function of LIMD1 and may subsequently represent a 
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7 Identification and investigation of synthetic lethal genes to LIMD1 
LIMD1, as a tumour suppressor gene, is frequently down-regulated in more than 80% 
human lung tumours [229]. The loss of LIMD1 enables the cancer cells to grow rapidly 
and aggressively [229]. Genetic mutations causing the gain-of-function are often 
druggable, whereas loss-of-function mutations or deletions of tumour suppressors such 
as LIMD1 often proves much more difficult to target. A synthetic lethality, therefore, 
was employed to identify the potential protein kinases (or related pathways), whose 
loss could cause the specific cell death in LIMD1 negative cells. 
7.1 Identification of synthetic lethal targets in LIMD1 negative cells 
The concept of synthetic lethality is defined as a simultaneous loss of function of two 
genes causing cell death, while the loss of function of either gene alone does not [356, 
357] (Figure 7.1A). Therefore, a number of techniques to alter LIMD1 expression in 
cancer cell lines were employed in this study to generate screening platforms on which 
the strategy of synthetic lethality was applied to identify protein kinase targets. The 
isogenic pairs of cell lines with regards to LIMD1 expression were seeded in the format 
of 96-well plate and treated with Human Kinome siRNA library (Figure 7.1B). A synthetic 
lethal target (kinase) will cause cell death in LIMD1-/- cells rather than LIMD1+/+ cells 
(Figure 7.1B). 
  





Figure 7.1 The concept of synthetic lethality 
A) Simultaneous loss of function of two genes causes cell death, while mutation of either gene alone does 
not. (Adapted from Sebastian et al., 2011 [357]). B) An isogenic pair of cell lines expressing LIMD1+/+ or 
LIMD1 -/- was used as the screening platform treated with the individual siRNA targeting the specific 
human kinase. The ablation of target causing synthetic lethality is highlighted in red. This represents the 
cytotoxicity to cells with the loss of LIMD1, whereas it spares LIMD1+/+ cells.  
 
The initiation of cancer is a process by which a series of genetic mutations drive normal 
cells to acquire the hallmarks of cancer over time and gradually results in uncontrolled 
growth, inappropriate invasion, and, ultimately, metastasis. Lung cancer is the leading 
cause of cancer mortality as a result of late diagnosis and recurrence. Although the well-
studied first-line chemotherapy drugs, for example, cisplatin, which interferes with DNA 
repair mechanisms, has been approved to be clinically successful, cancer cells could 
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develop resistance to such broad-spectrum drugs. The resistance arises from the 
alteration of a number of genes and the redundant pathways due to secondary 
mutations caused by cisplatin [358]. Furthermore, the genetic alteration of cancer cells 
differs not only between cancer types but also between individuals. Therefore, it is 
necessary to develop drugs for patients who acquire resistance to the first line drugs or 
broad-spectrum drugs.  
For the screening of the synthetic lethality, the siKinome library which targets the 
Human Kinome, which is the complete set of protein kinases encoded in the human 
genome [359]. Protein kinases and phosphatases are responsible for conducting the 
majority of signal transduction in the cells, regulating the function of proteins by the 
phosphorylation [359]. Phosphorylation events, therefore, regulate a host of cellular 
processes such as metabolism, transcription, apoptosis, cellular proliferation, survival 
and migration. Mutation and dysregulation of human protein kinases correlate to many 
human diseases, including cancers [360]. In addition, it was revealed in 2004 according 
to the Cancer Gene Census that the most common protein domain encoded by 
oncogenes was the protein kinase domain [361]. Two individual studies defined 120 
protein kinase mutations in a cohort of 210 specimens, and 157 mutations within 230 
kinases in a 441 specimen cohort, respectively [362, 363]. These studies indicated that 
protein kinases play the crucial roles in the development of cancers. Therefore, there is 
significant scope and president to develop new therapies by targeting these 
dysfunctions and mutated protein kinases.  
7.1.1 Generation of the screening platforms 
To identify synthetic lethal genes with LIMD1, different molecular techniques were used 
to generate isogenic pairs of cell lines to knockdown, knockout or re-express LIMD1. 
Lung cancer cell line A549 and cervical cancer cell line HeLa were selected to be the 
screening platforms in this study due to the original aim (lung cancer treatment), the 
rapid growth and widely used in anti-cancer studies. In addition, breast cancer cell line 
MDA-MB-435 was also selected as a screening platform as the result of the lack of LIMD1 
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expression. Stable knockdown of LIMD1 in A549 was generated by Dr John Foster, using 
lentiviral plasmid system depending on the short hairpin RNA (shRNA) [1, 364]. The 
shRNA system results in some of the target RNA remaining at low levels, creating an 
incomplete knockdown of LIMD1 in A549 shLIMD1 (Figure 7.2A). Therefore, the residual 
LIMD1 expression may affect the cellular processes. As a result, for a total knockout 
platform for the study of the synthetic lethality with LIMD1 loss, CRISPR-Cas9 gene 
editing was employed to generate HeLa with the complete knockout of LIMD1 (Figure 
7.2B and Figure 11.1). Furthermore, to study the possible effects on the synthetic 
lethality with the gain-of-function of LIMD1, the isogenic pair of MDA-MB-435, which 
was previously reported to not express LIMD1 due to the hyper-methylation of the 
promoter region [217, 229], lentivirally expressing lentivirus only and LIMD1 were 
generated (Figure 7.2C).  
 
 
Figure 7.2 Three isogenic pairs of cell lines as the screening platforms were generated with regards to 
LIMD1 expression by different molecular techniques 
Western blot analysis of LIMD1 expression in A549 (made by Dr John Foster), MDA-MB-435 and HeLa 
(made by Dr Daniel Foxler) isogenic pairs with regards to LIMD1 expression. shSCR, non-targeting 
scramble shRNA; FH-VO, FlagHis-tagged lentivirus only.  
 
7.1.2 Transfection optimisation 
To ensure the transfection reagents were not cytotoxic to the cells, mock transfection 
was performed to use different transfection reagents in the absence of siRNA (Mock). 
Besides the cytotoxicity, the transfection efficiency is another important parameter for 
consideration. PLK1 locates to centrosomes and regulates mitosis, which is an early 
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trigger for G2/M transition [365, 366]. siRNA targeting PLK1, depletion of which induces 
apoptotic pathway and inhibits cell growth [367], was employed to assess the 
transfection efficiency according to the inhibitory of cell growth. In addition, the 
cytotoxicity and transfection efficiency are reagent type- and cell type-dependent [368]. 
Therefore, the mock transfection and optimisation were conducted on the three 
isogenic pairs of cell lines (A549, MDA-MB-435 and HeLa).  
Two transfection reagents, INTERFERin and Lipofectamine RNAiMAX (hereafter refer to 
Lipofectamine), were used. More than 80% relative cell viability was considered as an 
acceptable cytotoxicity, and less than 20% treated with siPLK1 was considered as a good 
transfection efficiency. The results showed no reagents cytotoxicity on three isogenic 
pairs according to the relative cell viability of mock (only transfection reagents used) 
compared with that in Media (Figure 7.3A-F). Although the depletion of PLK1 inhibited 
more than 80% cell growth, which indicated both transfection reagents worked and had 
the similar transfection efficiency on A549 and HeLa, INTERFERin showed higher toxicity 
when HeLa was treated with the non-targeting siRNA control (<80%) (Figure 7.3C). As a 
result, both reagents were suitable for the A549 isogenic pair, and Lipofectamine was 
suitable for HeLa isogenic pair. For MDA-MB-435, to reduce the cytotoxicity caused by 
Lipofectamine (Figure 7.3F), media was changed after 4h post-transfection and achieved 
a reduction of cytotoxicity (Figure 7.3G). Taken together, according to the mock 
transfection and optimisation of two transfection agents, Lipofectamine showed lower 
cytotoxicity and higher transfection efficiency in three different cell lines. Therefore, it 
was used for the library screening. 
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7.1.3 Human Kinome siRNA Library screening on three different cell-based platforms 
Human Kinome siRNA library (G-003505, Dharmacon) contains 720 kinases and 
pseudokinases for sufficient silencing of the target gene expression, which was 
previously used for identification of early regulators of cell proliferation [369]. Three 
pairs of isogenic platforms A549, MDA-MB-435 and HeLa were applied to screen Human 
Kinome siRNA Library using the optimal transfection reagents (Lipofectamine). Z-score 
was calculated for each well treated with the individual siRNA in each cell line according 
to the cell viability (details described in Chapter 2.3). It describes the difference in cell 
viability between cells treated with the individual siRNA and the median of the whole 
population. The individual dot in Figure 7.4 implied how great effect on the cell growth 
with the depletion of each gene. The positive value indicated the increasing growth of 
the cells, while the negative value indicated an inhibitory or cytotoxicity to the cells 
(Figure 7.4 and Table 11.1). However, most of the dots located in the range from -1 to 
1 (Figure 7.4). This was considered as no effects on the cells when treated with the 
specific siRNA. Therefore, with the aim of this project that finds the specific siRNA would 
cause cell death in LIMD1-/- but not in LIMD1+/+ cell line, the siRNAs that present the z-
score with the greater negative value in LIMD1-/- and the greater positive value in 
LIMD1+/+ are required to be investigated.  
 
  





Figure 7.4 Z-score of the human kinome siRNA library screening on three isogenic pairs of cell lines 
A) A549 isogenic pair (shSCR and shLIMD1), B) MDA-MB-435 isogenic pair (FH-VO and FH-LIMD1) and C) 
HeLa CRISPR-Cas9 isogenic pair (Cas9 Control and LIMD1-/-) were screened against the Human Kinome 
siRNA Library containing 720 kinases at 50nM concentration in 96-well plate format. Z-score of individual 
siRNA targeting the specific kinase on each cell line was calculated. Z-score was considered as a 
measurement of cell growth (positive value) or cell death (negative value). The positive value indicated 
the increasing growth of the cells, while the negative value indicated an inhibitory or cytotoxicity on the 
cells  
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To identify the synthetic lethal protein kinase with LIMD1 that only kill LIMD1 negative 
cell line, ΔZ-score, which is the difference in Z-score between LIMD1 negative cell line 
and LIMD1 positive cell line, was generated (Figure 7.5 and Table 11.1). Therefore, the 
greater of ΔZ-score in the negative direction, the greater of the synthetic lethality with 
LIMD1 was. According to ΔZ-score in the negative direction, the top 10 ‘hits’ were 
ranked on three isogenic pairs (Figure 7.6). STK39, AAK1, and DCK respectively showed 
the greatest synthetic lethality with LIMD1 in A549, MDA-MB-435, and HeLa isogenic 
pairs (Figure 7.6). However, there was no overlapping ‘hit(s)’, and as a result, further 
investigation and data analysis were required.  
 
 
Figure 7.5 ΔZ-score was generated to identify the potential ‘hits’ from the screening on three isogenic 
pairs of cell lines 
ΔZ-score is the difference in the Z-score of the LIMD1 negative cell line and LIMD1 positive cell line, 




Figure 7.6 Top 10 ‘hits’ are ranked by ΔZ-score on each isogenic pair of cell lines 
The top 10 ‘hits’ identified according to ΔZ-score on A) A549 isogenic pair; B) MDA-MB-435 isogenic pair; 
C) HeLa isogenic pair. 
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7.2 Target validation from Human Kinome siRNA Library screen 
As no common synthetic lethal ‘hits’ to LIMD1 were identified in all three isogenic pairs 
of cell lines (Figure 7.6), it was decided to investigate whether there were any common 
synthetic lethal pathways. DAVID pathway analysis was therefore employed to identify 
enriched functionally-related gene groups [370, 371]. The complete results of DAVID 
analysis are shown in 
 
Table 11.2-11.4. In addition to the DAVID pathway analysis, cell-based target validation 
was also conducted for the top ‘hits’ from the screening. 
7.2.1 Investigation of the common synthetic lethal pathways by the DAVID pathway 
analysis 
The results of DAVID analysis were presented based on two databases (KEGG and 
BioCarta). Upon KEGG database, there were some overlapping pathways from top 100 
‘hits’ across three cell platforms. The following pathways occurred in any two or all cell 
types according to the statistical significance (PValue): MAPK signalling pathway (A549 
and HeLa, Figure 7.7A and Figure 7.7E), neurotrophin signalling pathway (A549 and HeLa, 
Figure 7.7A and Figure 7.7E) and ErbB signalling pathway (MDA-MB-435 and HeLa, 
Figure 7.7C and Figure 7.7E). By considering the number of genes involved in the 
pathways, the common pathways were MAPK signalling pathway (A549 and HeLa, 
Figure 7.7A, Figure 7.7B and Figure 7.7F), Rap1 signalling pathway (A549 and MDA-MB-
435, Figure 7.7A, Figure 7.7B and Figure 7.7D) and neurotrophin signalling pathway 
(A549 and HeLa, Figure 7.7B and Figure 7.7F). Therefore, MAPK signalling pathway, 
Rap1 signalling pathway and neurotrophin signalling pathway were two common 
enriched pathways containing the most significance and highest number of genes 
among top 100 ‘hits’ from the library screening.  
According to BioCarta database, MAPK signalling pathway occurred in all three cell 
platforms with not only the greatest significance but also the most enriched pathway 
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(Figure 7.8). Taken together, the combined result of KEGG and BioCarta showed MAPK 
signalling pathway is the most enriched pathway (Figure 7.7 and Figure 7.8), indicating 
the most synthetically lethal kinases across the three screening platforms were involved 
in the MAPK signalling pathway (Figure 7.9).  
 
 
Figure 7.7 KEGG data-based DAVID analysis of top 100 ‘hits’ from three isogenic pairs of cell lines.  
Top 5 enriched pathways from top 100 ‘hits’ of screening were ranked by LogPValue on A) A549 isogenic 
pair, C) MDA-MB-435 isogenic pair and E) Hela isogenic pair. Top 5 enriched pathways from top 100 ‘hits’ 
of screening was ranked by the number of genes involved in B) A549 isogenic pair, D) MDA-MB-435 
isogenic pair and F) HeLa isogenic pair. 
 
  





Figure 7.8 BioCarta data-based DAVID analysis of top 100 ‘hits’ from three isogenic pairs of cell lines.  
Top 5 enriched pathways from top 100 ‘hits’ of screening were ranked by LogPValue on A) A549 isogenic 
pair, C) MDA-MB-435 isogenic pair and E) Hela isogenic pair. Top 5 enriched pathways from top 100 ‘hits’ 
of screening was ranked by the number of genes involved in B) A549 isogenic pair, D) MDA-MB-435 
isogenic pair and F) HeLa isogenic pair. 
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7.2.2 Knockdown of STK39 is synthetic lethal to LIMD1 negative cells 
The identification of multiple kinases within the MAPK signalling pathway as 
synthetically lethal with LIMD1 was therefore investigated. MAPK signalling contains 
p38 signalling pathway which is activated by STK39 [272]. STK39 was a top ‘hit’ on A549 
from the screen (Figure 7.6A). STK39 therefore within this pathway was targeted in 
validation experiments in the HeLa CRISPR isogenic cell line pair, as this conferred the 
cleanest mechanistic platform for interrogating LIMD1 ablation. SMARTPool (SP) of each 
kinase was used in Kinome siRNA Library screening. Therefore, four individual siRNAs 
contained in the SMARTPool were also used in target validation to minimise the off-
target effects. To define the synthetic lethality with LIMD1 in the target validation, two 
basic rules were followed: 1) more than 25% difference in the relative cell viability 
between isogenic cell lines with statistical significance was considered to be synthetic 
lethal and 2) SMARTPool must cause the synthetic lethality with LIMD1. The validation 
on HeLa isogenic pair showed that all four individual siRNA (#1-4) targeting STK39 could 
cause the synthetic lethality with LIMD1 loss, and the SMARTPool and siRNA #1 showed 
the least cell viability on LIMD1-/- cell line (Figure 7.10). Therefore, the SMARTPool and 
siRNA #1 were used in the whole project.  
 
 
Figure 7.10 STK39 validation on HeLa isogenic pair of cell lines 
Cells were transfected with the indicated siRNAs: Non-targeting (siSCR); SMARTPool, (SP) and individual 
siRNA, (#1, #2, #3, and #4). Cell viability was measured by CellTiter-Glo Luminescent Cell Viability Assay. 
Data shown are mean ±SEM, n=3. *, p<0.05. **, p<0.01. ***, p<0.001 
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The further validation of STK39 was performed on A549 isogenic pair. The results 
showed a significant difference in cell viability with LIMD1 loss in A549 isogenic pair not 
only for the SMARTPool but siRNA #1 as well (Figure 7.11A). The result also showed 
STK39 mRNA was repressed by 80% when treated with STK39 siRNAs in A549 isogenic 
pair (Figure 7.11B). This indicated a good knockdown efficiency of STK39 in A549 
isogenic pair. Taken together, STK39 was validated to be synthetically lethal for LIMD1 
in A549.  
 
 
Figure 7.11 Further validation of STK39 siRNAs on A549 and MDA-MB-435 isogenic pairs  
A) A549 isogenic pair of cell lines were transfected with the indicated siRNAs. Cell viability was measured 
by CellTiter-Glo Luminescent Cell Viability Assay and relative to the value of SCR. B) qRT-PCR analysis of 
STK39 siRNA knockdown efficiency. C) MDA-MB-435 isogenic pair of cell lines were transfected with the 
indicated siRNAs. Cell viability was measured by CellTiter-Glo Luminescent Cell Viability Assay and relative 
to the value of SCR. D) qRT-PCR analysis of STK39 siRNA knockdown efficiency. SCR, non-targeting siRNA. 
SP, SMARTPool. siRNA #1, the individual siRNA of STK39 contained in the SMARTPool. Data shown are 
mean ±SD, n=3. *, p<0.05. **, p<0.01. 
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The validation on MDA-MB-435 showed the knockdown of STK39 did not kill both cell 
lines; the relative cell viability did not significantly change when treated with the 
SMARTPool and siRNA #1 (Figure 7.11C). In addition, the qRT-PCR result showed the 
knockdown efficiency of SKT39 siRNAs in MDA-MB-435 isogenic pair was poor (Figure 
7.11D). For example, the poorest transfection efficiency was 50% repression of SKT39 
mRNA in FH-LIMD1 line (Figure 7.11D). These results indicated there might be no 
synthetic lethality with LIMD1 in MDA-MB-435 treated with STK39 siRNAs, which may 
be due to the poor transfection efficiency. 
To elaborate the synthetic lethality of STK39, HeLa CRISPR-Cas9 isogenic pair was 
treated with STK39 siRNAs. The results confirmed that knockdown of STK39 by the 
SMARTPool, and siRNA #1 caused a synthetic lethality with LIMD1 loss (Figure 7.12A). 
The knockdown efficiency of STK39 mRNA was around 75% (Figure 7.12B and Figure 
7.12C). STK39 siRNAs resulted in a rounding-up effect on the adherent cells (Figure 
7.12D). This morphologic change by STK39 siRNAs was observed more in the LIMD1 
negative cells, which directly represented the significant synthetic lethality with LIMD1 
loss.  
The clonogenic assay is to assess the effectiveness on the survival and proliferation of 
cells under the specific treatment. Therefore, it was employed to investigate the effects 
on the survival and proliferation caused by the knockdown of STK39. For Cas9 Control, 
knockdown of STK39 by the SMARTPool and siRNA #1 inhibited the cell colony formation 
by 45% and 40% respectively, whereas they inhibited the colony formation by70-80% 
when there was no LIMD1 expression (Figure 7.12E and F). This indicated the ablation 
of STK39 dramatically (p<0.001) reduced the proliferation rate in LIMD1-/- cell line, which 
supports its synthetic lethality to LIMD1.  
  




Figure 7.12 Further validation of STK39 on HeLa CRISPR-Cas9 isogenic pair  
A) Cells transfected with the indicated siRNAs were measured by CellTiter-Glo Luminescent Cell Viability 
Assay. B) qRT-PCR analysis of STK39 siRNAs knockdown efficiency. C) Western blot analysis of STK39 
siRNAs knockdown efficiency. D) Cells morphological changes treated with the indicated siRNAs were 
observed by the bright field microscope (400x). E) Clonogenic assay of HeLa isogenic pair treated with the 
indicated siRNAs. F) The percentage of the change in colony numbers in the indicated siRNAs-treated 
cells. SCR, non-targeting siRNA. SP, SMARTPool. STK39 #1, the individual siRNA contained in the 
SMARTPool. Data shown are mean ±SD, n=3. ***, p<0.001. 
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7.2.2.1 Knockdown of STK39 caused the reduction of p38 activity and induced 
apoptosis in LIMD1 negative cells 
DAVID pathway analysis showed MAPK signalling was enriched for the synthetic lethality 
with LIMD1 loss (Chapter 7.2.1). p38 signalling pathway was previously reported to be 
activated by STK39 [272]. In addition, according to the KEGG pathway (Figure 7.7), p38 
along with its three downstream effectors were in the top 100 ‘hits’. Therefore, to 
investigating whether p38 MAPK signalling pathway was altered with the depletion of 
STK39, the expression of p38 and phospho-p38 (p-p38) were examined in HeLa isogenic 
pair. These experiments/analysis showed that LIMD1 knockout caused an increased 
STK39 expression and in turn increased p-p38 expression, but not the total p38 
expression (Figure 7.13A). These data were in agreement with the previous report that 
p38 is activated by STK39 [272]. Intriguingly, knockdown of STK39 showed a different 
pattern in p-p38 expression between HeLa CRISPR-Cas9 isogenic pair. In LIMD1 
expressing line (Cas9 Control), p-p38 remained unchanged with the depletion of STK39, 
whereas p-p38 expression decreased in LIMD1-/- line (Figure 7.13B). This indicated the 
validated synthetic lethality of STK39 with LIMD1 might be due to the 
dephosphorylation of p38 and therefore possible inactivation of p38 and its 
downstream signalling.  
 
 
Figure 7.13 p38 and p-p38 expression in HeLa CRISPR-Cas9 isogenic pair altered  
A) Western blot analysis of the indicated proteins in HeLa CRISPR-Cas9 isogenic pair. B) Western blot 
analysis of the indicated proteins in HeLa CRISPR-Cas9 isogenic pair treated with the indicated siRNAs. 
SCR, non-targeting siRNA. SP, SMARTPool. 
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p38 signalling is involved in modulating and regulating apoptosis [339, 373]. Depending 
on the cell type and stimuli, p38 can function as a pro-apoptotic mediator or an anti-
apoptotic mediator; for example, p38 induces apoptosis in HCT-116 (colon cancer), 
whereas p38 presents anti-apoptosic function in LNCap (prostate cancer). Therefore, 
Annexin V/(PI) staining was used to investigate whether knockdown of STK39 leads to 
the apoptosis in HeLa isogenic pair. Compared to Cas9 Control line, there was a 
significant apoptotic induction in LIMD1-/- line (Figure 7.14). This indicated the synthetic 
lethal caused by knockdown of STK39 in HeLa CRISPR-Cas9 isogenic pair resulted from 
the apoptosis. 
In summary, loss of LIMD1 in HeLa cell line altered the expression of STK39 and in turn 
caused the dephosphorylation of p38. The synthetic lethality of STK39 to LIMD1 loss was 
caused by apoptosis according to these observations.  
 
 
Figure 7.14 Apoptotic induction of HeLa CRISPR-Cas9 treated with STK39 siRNAs  
A) Annexin V/PI analysis of the apoptotic induction of HeLa Cas9 control cell line treated with STK39 siRNA 
(SMARTPool and siRNA). B) Annexin V/PI analysis of the apoptotic induction of HeLa LIMD1-/- cell line 
treated with STK39 siRNA (SMARTPool and siRNA #1). SCR, non-targeting siRNA. SP, the SMARTPool of 
STK39 siRNAs. STK39 #1, the individual siRNA of STK39 contained in the SMARTPool. Data shown are 
mean ±SEM, n=3. ***, p<0.001. 
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7.2.3 Validation of the top ‘hits’ from the screening by the cell-based assay  
Apart from the DAVID pathway analysis, cell-based target validation was also employed 
using HeLa isogenic pair with the complete LIMD1 knockout. AAK1 and HIPK2 from the 
screening of MDA-MB-435, the top 5 ‘hits’ from the screening of A549, and the top 10 
‘hits’ from the screening of HeLa CRISPR-Cas9 were validated. AAK1, which was the top 
‘hit’ in MDA-MB-435 (Figure 7.6B), showed a significant difference in cell viability (Figure 
7.15A), but it did not result in the sufficient synthetical lethality (referred to the basic 
rules described in Chapter 7.2.2). Therefore, AAK1 was not validated as a synthetic lethal 
with LIMD1 loss.  
 
 
Figure 7.15 Target validation on HeLa isogenic pair of cell lines 
Cells were transfected with the indicated siRNAs. SCR, Non-targeting. SP, the SMARTPool of siRNAs. #1, 
#2, #3, and #4 represent the individual siRNA. Cell viability was measured by CellTiter-Glo Luminescent 
Cell Viability Assay. A) AAK1. B) HIPK2. Data shown are mean ±SEM, n=3. **, p<0.01. 
 
For the ‘hits’ screened from A549 (Figure 7.6A), although MAGI3, TWF2/PTK9L, 
TSSK1B/STK22D and ERBB4 showed the statistically significant difference in cell viability, 
they did not cause lethal to LIMD1 negative cells (Figure 7.16). The validation results of 
the top 10 ‘hits’ from HeLa isogenic pair showed that only ACVR2B presented a 
significant synthetic lethality with LIMD1 loss (Figure 7.17 and Figure 7.18). Taken 
together, ACVR2B was validated as a synthetic lethal target with LIMD1 loss due to that 
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more than 25% difference in cell viability with significance and synthetic lethality in 
SMARTPool were observed (Figure 7.17)  
 
 
Figure 7.16 Target validation on HeLa isogenic pair of cell lines 
Cells were transfected with the indicated siRNAs. SCR, Non-targeting. SP, the SMARTPool of siRNAs. #1, 
#2, #3, and #4 represent the individual siRNA. Cell viability was measured by CellTiter-Glo Luminescent 
Cell Viability Assay. A) MAGI3. B) TWF2/PTK9L. C) TSSK1B/STK22D. D) ERBB4. Data shown are mean ±SEM, 











Figure 7.17 Target validation on HeLa isogenic pair of cell lines 
Cells were transfected with the indicated siRNAs. SCR, Non-targeting. SP, the SMARTPoolof siRNAs. #1, 
#2, #3, and #4 represent the individual siRNA. Cell viability was measured by CellTiter-Glo Luminescent 
Cell Viability Assay. A) ACVR2B. B) AURKB. C) BMPR1A. D) DCK. E) DUSP21. F) EFNB3. Data shown are 
mean ±SEM, n=3. *, p<0.05. **, p<0.01. ***, p<0.001. 
 
 





Figure 7.18 Target validation on HeLa isogenic pair of cell lines 
Cells were transfected with the indicated siRNAs. SCR, Non-targeting. SP, the SMARTPoolof siRNAs. #1, 
#2, #3, and #4 represent the individual siRNA. Cell viability was measured by CellTiter-Glo Luminescent 
Cell Viability Assay. A) NEK1. B) NRBP2. C) WEE1. D) PRKWNK1. Data shown are mean ±SEM, n=3. *, 
p<0.05. **, p<0.01. ***, p<0.001. 
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7.2.4 Knockdown of ACVR2B is synthetic lethal to LIMD1 negative cells 
To further confirm the synthetic lethality with LIMD1, HeLa CRISPR-Cas9 isogenic pair 
were treated with ACVR2B SMARTPool and the individual siRNA #1. The results showed 
non-targeting siRNA did not cause any cell death observed by the bright field microscope 
(Figure 7.19). Knockdown of ACVR2B using the SMARTPool siRNA did not cause 
dramatical cell death (~25%) in HeLa Cas9-Control line, whereas it led to significant cell 
death (60%) in HeLa LIMD1-/- line (Figure 7.19A). However, ACVR2B siRNA #1 caused a 
more lethal effect on both cell lines. (Figure 7.19A).  
To investigate the survival and proliferation under the treatment of ACVR2B siRNAs, the 
clonogenic assay was performed. For the non-targeting siRNA, LIMD1-/- showed an 
increased proliferation rate as more colonies were formed than Cas9 Control (Figure 
7.19C), which agrees with the function of LIMD1 as a tumour suppressive gene [217]. 
When treated with ACVR2B SMARTPool siRNAs, HeLa Cas9 Control cell line survived and 
proliferated, whereas LIMD1-/- cell line was very sensitive causing cell death (Figure 
7.19C and Figure 7.19D). Treatment with ACVR2B siRNA #1 resulted in a significant 
reduction in colony formation in both cell lines (Figure 7.19C and Figure 7.19D). By 
corroborating the cell viability assay, the results indicated that the SMARTPool of 
ACVR2B was synthetic lethal to LIMD1 in HeLa isogenic pair. However, the individual 
siRNA #1 was too lethal to conclude the synthetic lethality. These results suggested the 
further investigations were required on individual siRNAs with regards to transfection 
efficiency and off-target effects.  
To sum up, using DAVID pathway analysis, MAPK signalling was an overlapping synthetic 
lethal pathway among three individual screenings. STK39 was validated on the cell-
based validation. In addition, STK39 is an oncogene, and the inhibition of it causes cell 
death [320]. Furthermore, as STK39 has been reported to activate p38, which is a 
canonical signalling protein kinase in MAPK signalling pathway [272]. Taken together, 
STK39 was the main focused of the synthetic lethality aspect of this study. On the other 
hand, ACVR2B is involved in the transforming growth factor-beta (TGF-β) signalling 
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pathway [374]. Although this pathway did not come up as an enriched signalling 
pathway in DAVID analysis, it has also shown that ACVR2B presented some degree of 
specific synthetic lethality with LIMD1 loss. As a result, the further investigations of 
ACVR2B are required. 
  




Figure 7.19 Further validation of ACVR2B siRNAs on HeLa CRISPR-Cas9 isogenic pair of cell lines  
A) Cells transfected with the indicated siRNAs were measured the cell viability by CellTiter-Glo 
Luminescent Cell Viability Assay and relative to the value of SCR. B) Cells morphology treated with the 
indicated siRNAs was observed by the bright field microscope (400x). C) Clonogenic assay for HeLa 
isogenic pair treated with the indicated siRNAs. D) The percentage of the change in colony numbers in 
the indicated siRNAs-treated cells. SCR, non-targeting siRNA. SP, the SMARTPoolof siRNAs. siRNA #1, the 
individual siRNA contained in the SMARTPool. Data shown are mean ±SEM, n=3. *, p<0.05. **, p<0.01. 
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7.3 Investigation of the inverse relationship between LIMD1 and STK39 
 
7.3.1 LIMD1 regulates STK39 via miRNA-mediated silencing  
During the target validation, the increased expression of STK39 was observed with 
LIMD1 knockout. It showed a dramatically increased expression not only in protein level 
but also in mRNA level (increased by ~2.7-fold) (Figure 7.20). Considering the biological 
functions of LIMD1 that regulates the gene expression via miRNA-mediated gene 
silencing pathway [1] (Figure 7.21A), it was reasonable to examine whether the 
increased expression of STK39 resulted from this pathway. The results showed 
knockdown of LIMD1 in HeLa WT contributed to an increased STK39 expression (Figure 
7.21A), which corroborated the observation in HeLa isogenic pair. Besides, STK39 
expression increased when two key miRISC components, AGO2 and TNRC6A, were 
depleted (Figure 7.21B). These results suggested that the impairment of miRISC 
increased STK39 expression.  
 
 
Figure 7.20 STK39 expression increases with LIMD1 knockout  
A) Western blot analysis of the indicated proteins in HeLa isogenic pair. B) qRT-PCR analysis of STK39 
mRNA in HeLa CRISPR-Cas9 isogenic pair. Data shown are mean ±SEM, n=3. ***, p<0.001. 
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To further investigate the regulation of STK39, the 3’UTR (1476bp) of STK39 was cloned 
into a reporter system construct (psiCHECK-2) by Dr Kunal Shah (Figure 2.3 and Figure 
7.21C). The reporter assay results showed the luciferase activity significantly increased 
in LIMD1-/- line (Figure 7.21D), indicating the change of luciferase activity was controlled 
by the 3’UTR of STK39. This implied that STK39 mRNA is regulated by miRNA-mediated 
gene silencing in a LIMD1-dependent manner.  
 
 
Figure 7.21 STK39 expression is regulated by 3’UTR via miRNA-mediated silencing 
A) Proposed model of LIMD1-regulated miRNA-mediated silencing. LIMD1 interacts AGO2 and TNRC6A 
simultaneously to repress mRNA translation. B) Western blot analysis of the indicated proteins in HeLa 
(wild type) with the depletion of LIMD1, AGO2 and TNRC6A, which are key components of miRISC. siSCR, 
non-targeting control. C) Schematic of the cloning of 3’UTR of STK39 into the reporter construct 
(psiCHECK-2). D) The reporter construct was transfected into HeLa CRISPR-Cas9 isogenic pair. Relative 
luciferase activity increased with LIMD1 knockout. Data shown are mean ±SEM, n=3. ***, p<0.001. 
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In the 1476bp 3’UTR of STK39, there are three miR-26 binding sites (Figure 7.22A). It 
was reported that miR-26 regulates STK39 expression by targeting these three seed 
sequences in its 3’UTR [375]. Therefore, the mature miR-26 expression level was 
examined in HeLa isogenic pair to investigate the reasons for the inverse relationship 
between LIMD1 and STK39. Total mRNA was extracted from HeLa isogenic pair of cell 
line and reverse-transcribed into cDNA, followed by qRT-PCR for quantification miR-26 
and STK39 mRNA (Chapter 2.2.9 and Chapter 2.2.10). The result showed the abundance 
of miR-26 was significantly down-regulated in LIMD1-/- line (Figure 7.22B). In addition, 
STK39 mRNA was significantly up-regulated in LIMD1-/- line (Figure 7.22C). As a result, 
these results would suggest that the increased STK39 mRNA expression was due (in part) 
to the down-regulated mature miR-26 level via miRNA-mediated gene silencing pathway 
and subsequent mRNA degradation.  
 
 
Figure 7.22 miR-26 reduction might cause the increase expression of STK39 in HeLa CRISPR-Cas9 
isogenic pair  
A) The sequence of 3’UTR of STK39, containing three miR-26 seed sequences. B) qRT-PCR analysis of miR-
26 expression in HeLa CRISPR-Cas9 isogenic pair. C) qRT-PCR analysis of STK39 mRNA expression in HeLa 
CRISPR-Cas9 isogenic pair Data shown are mean ±SD, n=3. *, p<0.05. ***, p<0.001. 
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7.3.2 LIMD1-STK39 inverse relationship commonly occurs in various of cancers 
The inverse relationship between LIMD1 and STK39 was observed in HeLa isogenic pair 
(Figure 7.20). Considering STK39 as an oncogene [320] and LIMD1 as a tumour 
suppressor gene [217], an inverse relationship between LIMD1 and STK39 might 
fundamentally exists. To test this hypothesis, western blot analysis was performed in a 
panel of lung cancer cell lines to check the expression of LIMD1 and STK39. The result 
revealed ~45% lung cancer cell lines presenting an inverse relationship (Figure 7.23A). 
The cancer cell lines, therefore, were divided into two groups: high LIMD1 expression 
with low STK39 expression and low LIMD1 expression with high STK39 expression. For 
example, in high LIMD1 with low STK39, there were A549, H838, H1299, HCC193, H2951 
and H28 (Figure 7.23A). There were Hop62, H358, H358M, H520, H2170 and H69 
expressing low LIMD1 and high STK39 (Figure 7.23A). Notably, SAEC and HBEC are non-
transformed cell controls for adenocarcinoma and squamous cancer cell respectively. 
The expression of STK39 was up-regulated in both lung adenocarcinoma and squamous 
cancer cells (Figure 7.23A). The bioinformatics was then performed to analyse the RNA 
expression (FPKM, fragments per kilobase million) across different types of cancer cell 
lines. The result showed a significant inverse correlation between LIMD1 and STK39 
(Figure 7.23B). This demonstrated a fundamental inverse relationship between LIMD1 
and STK39 existed in cancer cell lines.  
  





Figure 7.23 An inverse relationship between LIMD1 and STK39 exists across different cancer cell lines  
A) Western blot analysis of LIMD1 and STK39 expression in lung cancer cell lines. B) The bioinformatics 
showed a significant inverse relationship (p<0.001) between LIMD1 and STK39. Data of FPKM were 
obtained from Human Protein Atlas. The Spearman's correlation was performed. FPKM, fragments per 
kilobases million.  
 
The cell viability assay indicated knockdown of STK39 caused synthetic lethality in LIMD1 
negative cancer cell lines (Chapter 7.2.2). To test whether such synthetic lethality with 
LIMD1 loss exists in the lung cancer cell lines, a number of lung cancer cell lines were 
selected to represent the two groups of cells with regards to the LIMD1-STK39 inverse 
relationship. The lines selected had low STK39 with high LIMD1 (SAEC, A549, H838 and 
H28) and high STK39 with low LIMD1 (H522, H358M, H520 and MSTO-211H) (Figure 
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7.24A). Knockdown of STK39 in these lung cancer cell lines caused the differential cell 
viability regarding the differential expression ratio of LIMD1 and STK39. SAEC expressing 
low STK39 showed no significant cell death when STK39 was depleted (Figure 7.24B). 
H358M, H520 and MSTO-211H expressing low LIMD1 with high STK39 showed 
significant cell death upon the STK39 depletion (Figure 7.24B). For high expression of 
LIMD1 and relative low STK39, H28 and H838 did not have much cell death in STK39 
siRNA-treated lines compared to that in SCR siRNA-treated lines (Figure 7.24B). These 
results showed a potential phenotype that the high ratio of LIMD1 and STK39 expression 
did not respond to the depletion of STK39, whereas cells expressing the low ratio of 
STK39 and LIMD1 expression were sensitive, resulting in significant cytotoxicity.  
 
 
Figure 7.24 Targeting STK39 in lung cancer cells with differential expression of LIMD1 and STK39  
A) A number of lung cancer lines were selected for STK39 siRNA treatment with regards to LIMD1-STK39 
expression, analysed by Western blot. B) Cells transfected with STK39 siRNA was measured the cell 
viability by CellTiter-Glo Luminescent Cell Viability Assay and relative to the value of SCR. SAEC is small 
airway epithelial cell. Data shown are mean ±SEM, n=3. n.s, not significant. *, p<0.05. ***, p<0.001. 
 
To be clinical relevant, a cohort of patients with lung cancers was examined for the 
expression of LIMD1 and STK39. The result showed a significant correlation of STK39 
with tumour size and stage (p=0.022) and metastasis (p=0.024) (Figure 7.25A). Patients 
with high STK39 suffered from a larger tumour (T2+T3) than those with low STK39. The 
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cancer cells are localised not metastasis with high STK39. The prognosis analysis showed 
that lower expression of STK39 correlated to the poor prognosis (p=0.097, approaching 
significance). Taken together, high expression of STK39 caused the localised but larger 
tumour with high prognosis, whereas low STK39 contributed more invasive which 
showed more fatal to the patients. 
 
 
Figure 7.25 IHC analysis of STK39 in a cohort of 276 patients with lung cancers 
A) Correlation of STK39 protein expression with patients’ features. B) Kaplan-Meier survival analysis 
showed that patients with low STK39 expression level had a worse prognosis than that of patients with 
higher STK39 expression (p=0.097). 
 
7.4 Summary 
Upon the screening on Human Kinome siRNA Library and cell-based validation, STK39 
was validated as a synthetic lethal gene with LIMD1 loss (Figure 7.12). Taken together 
with the previous study demonstrating that STK39 activates p38 [272], this present 
result corroborated the database-validation that MAPK signalling pathway is an enrich 
pathway for synthetic lethality with LIMD1 loss (Figure 7.7 and Figure 7.8). The 
depletion of STK39 in LIMD1-/- negative cell lines inactivated p38 and caused cell death 
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by apoptosis (Figure 7.13 and Figure 7.14). In addition, LIMD1 loss resulted in an 
increased STK39 expression via miRNA-mediated silencing (Figure 7.21 and Figure 7.22). 
To sum up, with regards to synthetic lethality, LIMD1 and STK39 function normally in the 
normal healthy cells (Figure 7.26A). Cells use two pathways for survival. The loss of 
LIMD1 led to a decreased in mature miR-26 level and in turn, increased STK39 expression 
mediated via miRNA-mediated silencing (Figure 7.26B). This further increased p38 
activity and cells keep proliferating. By targeting STK39, p38 function was inactivated 
resulting in apoptosis which caused cells death (Figure 7.26C). Furthermore, the 
regulation of STK39 by LIMD1 resulted in an inverse relationship between LIMD1 and 
STK39 which was showed to exist in numbers of cancer cell lines (Figure 7.23). Upon 
such inverse relationship, lung cancer cell lines expressing high STK39 with low LIMD1 
were sensitive to STK39-targeted treatment, whereas those expressing low STK39 with 
high LIMD1 did not (Figure 7.24).  
 
 
Figure 7.26 Summary for the synthetic lethality of STK39 with LIMD1 
A) LIMD1 and STK39 function normally in healthy cells and cell survive. B) In LIMD1-/- cells, mature miR-
26 was up-regulated. This led to the increased STK39 expression and subsequently increased p38 activity. 
Cells use STK39-p38 axis for survival. C) When targeting STK39, it inhibited STK39-p38 axis, which induced 
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8 Discussion 
This study was to investigate the novel synthetic lethal kinase to LIMD1 loss for cancer 
treatment. Therefore, this chapter will discuss the overall mechanistic implications of 
the findings presented so far and postulate the proposed/hypothesised model of the 
pathway that LIMD1 involved in the above study.  
8.1 STK39-p38 signalling pathway is synthetic lethal with LIMD1 loss via apoptosis  
By screening the Human Kinome siRNA library, this study discovered STK39 is a synthetic 
lethal gene with LIMD1 loss. Johnston et al. demonstrated that STK39 interacts with 
RELT to activates p38 [272], and Zhao et al. showed that STK39 is an oncogene highly 
expressed in cancers and inhibits cell apoptosis via STK39-activated p38 signalling [320]. 
However, this present study suggested STK39-activated p38 and the apoptosis caused 
by the depletion of STK39 could only occur in LIMD1-/- cells rather than LIMD1+/+ cells 
(Figure 7.14). It is of note that this present study has not examined whether it altered 
the downstream effectors of p38 related to the apoptosis pathway (for example Bcl2 
and Bax). Indeed, Zhao et al. provided the evidence that the depletion of STK39 results 
in an increased Bax (pro-apoptotic function) and a decreased Bcl2 (anti-apoptotic 
function), indicating the activation of the apoptosis pathway [320]. Therefore, this 
present study is with the agreement with Zhao’s. In addition, it has shown that TRAF6 
interacts with LIMD1 to mediate receptor activator of NF-κB (RANK) signalling [218]. The 
depletion of LIMD1 resulted in the decreased p38 activation, indicating TRAF6-LIMD1 
complex activated p38 signalling. Taken together with the DAVID analysis that p38 
pathway was an enriched synthetic lethal pathway with LIMD1 loss, it suggested that 
p38 signalling may be a compensatory pathway for the cells survive when LIMD1 lose its 
function. Therefore, this present study proposed a model for the synthetic lethal 
pathway of STK39 with LIMD1 loss related to p38 signalling (Figure 8.1). Binding of the 
ligand, RANK is initiated and activates p38 via the TRAF6-LIMD1 complex in LIMD1+/+ cell 
[218] (Figure 8.1A). When LIMD1 is depleted or down-regulated, it enhances STK39 
expression (Figure 8.1B). The enhanced STK39 interacts with RELT to positively control 
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p38 activity, resulting in the activation of STK39-p38 signalling, which subsequently 
causes the activation of anti-apoptotic protein Bcl-2 and apoptotic protein Bax (Figure 
8.1B). This drives the cells to become more dependent on the STK39-p38 axis to protect 
the cells from apoptosis and therefore survive. Once STK39 is depleted in LIMD1-/- cells, 




Figure 8.1 Schematic model of LIMD1-STK39 synthetic lethal pathway  
A) In LIMD1+/+ cells, RANK-mediated TRAF6-LIMD1 complex activates p38 MAPK signalling pathway. B) In 
LIMD1-/-cells, the STK39 expression is up-regulated, and the cells become addicted to the STK39-p38 axis 
for survival. The enhanced p38 activates Bcl2 to increase p38-mediated anti-apoptotic function and 
inhibits Bax to decrease p38-mediated apoptotic function. The cells are protected from the apoptosis and 
thus keep proliferating. The dashed line represents the decreased effect. The thick line represents the 
increased effect. 
 
8.2 TGF-β signalling pathway may also be synthetic lethal to LIMD1  
Besides STK39, this study also found ACVR2B as a potential synthetic lethal gene with 
LIMD1 loss. ACVR2B belongs to TGF-β superfamily. Binding of the ligand causes bridging 
of the pre-formed dimers of TGF-β type I receptors and dimers of type II receptors to 
Chapter 8                                                                    Discussion 
217 
form hetero-tetrameric receptor complexes. The type II receptor kinase is constitutively 
active and phosphorylates the type I receptor, which in turn recruits SMADs and 
phosphorylate SMADs to allow them to form homomeric complexes [376]. Two pieces 
of evidence have shown that the activin family binds to the TGF-β type I receptor, Nodal, 
to activate p38 signalling in a SMAD-dependent manner, and the apoptosis induced by 
TGF-β signalling is mediated by p38 [377, 378]. Therefore, these studies suggested that 
ACVR2B may function on the activation of p38 (Figure 8.2A). Alternatively, p38 
activation can also be activated by a SMAD-independent manner via the interaction of 
LIMD1 with TRAF6 [218, 379] (Figure 8.2B). Taken together, the results of the present 
study along with these previous findings suggest that a potential synthetic lethal 
pathway in TGF-β signalling was generated (Figure 8.2). We hypothesised that loss of 
LIMD1 and the depletion of ACVR2B induces cell death, while LIMD1+/+ cells survive by 
using the compensatory TRAF6-LIMD1-p38 axis signalling [218].  
 
 
Figure 8.2 Potential synthetic lethal pathway with regards to LIMD1 and ACVR2B within TGF-β signalling 
Binding with type I receptor initiates TGF-β signalling pathway which subsequently activates SMAD 
complexes to regulate gene transcription. A) ACVR2B interacts with Nodal to activate p38 via SMAD 
complexes. B) LIMD1 has an interaction between TRAF6, which binds the hetero-tetrameric receptor 
complexes to activate p38 signalling in a SMAD-independent manner. The loss of LIMD1 and ACVR2B 
simultaneously is fatal to the cells. 
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8.3 LIMD1 regulates STK39 expression 
LIMD1 binds AGO2 and TNRC6A simultaneously to regulate miRNA-mediated silencing 
to control mRNA expression [253]. This present study revealed that LIMD1 controls 
STK39 expression by miRNA-mediated silencing pathway (Chapter 7.3.1); by the 
transient impairment of key components of miRISC, it leads to the increased STK39 
expression (Figure 7.21). Our latest publication suggested the long term of LIMD1 loss 
does not affect the miRNA-mediated silencing pathway because of the compensatory 
silencing pathway via AGO-LAW association (Chapter 3 and Chapter 4) [253]. However, 
previously published data has shown that the maturation of miR-26 reduces in response 
to the phosphorylation at Y393 on AGO2 in hypoxia [114]. This present study did not 
examine the amount of mature miR-26 in hypoxia but found a decreased amount of the 
mature miR-26 in normoxia (Figure 7.22). This could be explained by one of the 
biological functions of LIMD1 that the loss of LIMD1 stabilises HIF-1α, resulting in the 
pseudo-hypoxia [216]. Interestingly, HIF-1α was reported to negatively regulate PTP1B 
activity for dephosphorylation of Y393 on AGO2 [128, 380]. The maturation of miR-26 is 
then down-regulated and subsequently decrease the post-transcriptional repression of 
STK39. Therefore, a potential mechanism on how STK39 is regulated by LIMD1 is 
hypothesised. Firstly, the regulation of STK39 is mediated by LIMD1-HIF-1α-PTP1B-miR-
26 axis (Figure 8.3). The loss of LIMD1 loss stabilises HIF-1α expression, which in turn 
inhibits the dephosphorylation of Y393 on AGO2 by PTP1B activity and keep AGO2 
hyper-phosphorylated at Y393 residue. Therefore, the hyper-phosphorylation of AGO2 
reduce the maturation of miR-26 and consequently, increase STK39 via miRNA-
mediated silencing.  
HIF-1α regulates the transcription of multiple genes by binding hypoxia response 
element (HRE) in the promoter region. STK39 transcription was reported to be regulated 
by NF-κB [239]. Evidence has shown that the depletion of HIF-1α increased NF-κB 
activity [381], which is contradictive to the observation in this present study, suggesting 
STK39 increase in LIMD1-/- may not be caused by NF-κB activity. As a result, this present 
study did not examine STK39 expression with regards to NF-κB activity. Except for the 
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NF-κB binding site within the promoter region of STK39, bioinformatics analysis showed 
it contains HRE in the promoter region. Taken together, this present study postulates 
the second potent pathway for regulation of STK39 by HIF-dependent transcription 
(Figure 8.3).  
 
 
Figure 8.3 Investigation of the regulation of STK39  
The loss of LIMD1 stabilises HIF-1α. Y393 on AGO2 cannot be dephosphorylated by HIF-1α-repressed 
PTP1B activity [380], resulting in the inhibition of maturation of miR-26 [128]. This results in the increase 
of STK39. Alternatively, the stabilised HIF-1α may enhance the transcription of STK39 gene.  
 
8.4 LIMD1-STK39 inverse relationship exists across variety of cancer cells and is a 
potential predictive marker for STK39-targeted therapy 
This study revealed a common inverse relationship between LIMD1 and STK39 exists 
across different types of cancers. According to the cohort (276 patients with lung 
cancers) in this study, the high expression of STK39 significantly correlates with tumour 
stage and size (Figure 7.25A). It also showed that lower expression of STK39 correlates 
to poor prognosis (Figure 7.25B). These results are partially in agreement with the 
previous study from another independent cohort (135 patients with lung cancers) that 
STK39 correlated with tumour size, tumour stage and lymph node metastasis [320]. 
However, it showed a contradictive result to this present study that patients with high 
expression have a worse prognosis than that of patients with lower STK39 [320]. One 
possible explanation for the contradictive prognosis results between the two individual 
cohorts would be the ethnic genetic variation of STK39. It has been observed that STK39 
correlates to hypertension in Caucasian populations, but not in Chinese populations 
regarding differential SNPs [307, 310, 382]. It is of note that lung cancers contain two 
SNPs (rs10176669 and rs4438452) located within intron 1 [383], implying that STK39 
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expression regarding the clinical significance may be different. Therefore, a cohort 
containing Chinese patients are under-investigation for the expression of LIMD1, STK39 
as well as p38 (phospho-p38) to examine whether there is the difference in correlation 
between different ethnic populations. Furthermore, this study finds cancers cells 
expressing high STK39 with low LIMD1 are more sensitive to the depletion of STK39 
(Figure 7.24). It defines a subgroup of LIMD1-/- cancers that can benefit from STK39-
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9 Conclusion 
The first study has put forward the current knowledge of the interactions between 
LIMD1 and miRISC components AGO2 into the next level, understanding how LIMD1 
regulates the miRNA-mediated silencing pathway in humans. The two key aims of this 
study were achieved as follows: 
• Aim 1: Characterisation of the direct binding domains on LIMD1 and AGO2 
The recombinant LIMD1 and AGO2 proteins (with mutants) have been 
constructed and expressed. The direct binding assay (GST pulldown and MBP 
pulldown) were optimised for the investigation of the direct binding between 
LIMD1 and AGO2. The precise interaction domains on LIMD1 (a.a 140-166) and 
AGO2 (L2 domain) were determined. In addition, the interaction of AGO2 and 
LIMD1 enhanced by a phospho-mimic glutamic acid substitution (S387E). This 
suggests that the phosphorylation of S387 enhances the interaction with LIMD1. 
(Chapter 3)  
• Aim 2: Investigation of the association between AGOs and LAW  
By over-expressing phospho-deficient (alanine) and phospho-mimic (glutamic 
acid) point mutants on the S387, the co-localisation data corroborated the direct 
binding assay that the phosphorylation of S387 on AGO2 enhanced the binding 
to LIMD1, while the binding to LIMD1 abrogated when S387A was unable to be 
phosphorylated. In addition, this interaction was shown to be Akt3-dependent. 
The conserved serine exists in AGO1 and AGO4. Therefore this study elaborates 
the Akt-dependent association to all human AGOs and LAW. AGO3 contains the 
naturally existing glutamic acid was not shown to rely on the Akt3 signalling, 
suggesting AGO3-LAW is a compensatory complex for miRNA-mediated silencing. 
Furthermore, the phosphorylation of Y393 on AGO2 can also regulate the 
association with LIMD1, indicating S387/Y393 cooperate together for the 
regulation of its binding to LIMD1 and determine whether to undergo miRNA- or 
siRNA-mediated silencing. (Chapter 4) 
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The second study has revealed the synthetic lethal gene (pathway) with LIMD1 loss, and 
investigated the relationship between such gene and LIMD1. This provided a deeper 
understanding of the function of the tumour suppressor protein LIMD1 with regards to 
tumourigenesis. In addition, this study provided a novel concept for target therapy. The 
key aim of this study was achieved as follows: 
• Aim 1: Investigation of the novel synthetic lethal kinase to LIMD1 loss 
STK39 and ACVR2B were identified as synthetic lethal genes with LIMD1 loss. 
STK39 expression is regulated by LIMD1 via miRNA-mediated silencing, and the 
synthetic lethality was achieved by apoptosis via dephosphorylation of p38. The 
synthetic lethality of ACVR2B with LIMD1 may be within TGF-β signalling to 
activate p38. The inverse relationship between LIMD1 and STK39 commonly 
exists, and by using such inverse relationship, patients stratification with low 
LIMD1 and high STK39 can be predicted for benefits from STK39-target therapy. 
(Chapter 7) 
The following chapter will briefly discuss the future directions to extend the present 
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10 Future plans  
This final chapter puts forward the perspective based on the present findings in this 
study to highlight areas of the potential interests and improvements for the future work 
within the group.  
10.1 Characterisation of the eIF4E-LIMD1-AGO2 interaction 
As a scaffold protein, LIMD1 interacts with not only AGO2-TNRC6A but also eIF4E, 
forming an inhibitory loop for miRNA-mediated silencing [1]. James et al. demonstrated 
that the induction of LIMD1 resulted in an increase in the co-immunoprecipitation of 
AGO2 with eIF4E [1]. Bioinformatics shows a putative 4E binding motif (a.a 144-155) 
within LIMD1 AB-motif (a.a 140-166). The preliminary data showed LIMD1 AB-motif (a.a 
140-166) could also interact with eIF4E (Figure 10.1). Further investigations are required 
to confirm this interaction and if so, to identify the precise domain within AB-motif for 
eIF4E interaction as well as AGO2 interaction. LIMD1 may be a molecular ‘clamp’ for 
eIF4E-LIMD1-AGO2 as same as that for AGO2-LIMD1-TNRC6A, which will help to answer 
the previous observation that LIMD1 facilities the eIF4E-AGO2 association [1]. 
Furthermore, according to PhosphoSitePlus® [384], two putative phosphorylation sites 
(S145 and S150) within AB-motif are indicated. Whether these sites are responsible for 
the interaction with AGO2 (probably eIF4E) are required for further investigation. 
  





Figure 10.1 The preliminary data shows LIMD1 binds eIF4E via a.a 140-166 
A) GST-VO and GST-eIF4E were purified on the resin and incubated with MBP-VO and MBP-LIMD1 140-
166 respectively, analysed by Western blot. Coomassie staining was performed to visualise the 
concentration of the GST-tagged protein for pull-down. B) Western blot analysis of the purified GST-eIF4E.  
 
10.2 Investigation of the combined phosphorylation at S387/Y393 with regards to the 
AGO2-LIMD1 interaction 
The phosphorylation status of S387 and Y393 regulate the association of AGO2 and 
LIMD1. The interaction of AGO2 with LIMD1 with regards to Y393 residue needs to be 
confirmed by the direct binding assay (GST pull-down) and/or PLA. In addition, it 
requires the examination whether the dephosphorylated Y393 involved in miRNA-
mediated silencing. This present study has defined a ‘Switch ON/OFF’ function for the 
interaction of AGO2 with LIMD1 for simplicity (Figure 4.20 and Table 4.2). Therefore, 
the different combinatorial phosphorylation of both S387 and Y393 are required for 
understanding which residue is dominant in regulating LIMD1 binding and thus miRNA-
mediated silencing. It is also of interest and importance to examine whether the 
phosphorylation of Y393 affects the siRNA silencing, which will indicate the role of S387 
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and Y393 of AGO2 along with LIMD1 in switching the functions in miRNA/siRNA 
pathways.  
Furthermore, there is no evidence so far to preclude the interaction between LIMD1 and 
Dicer. Dicer-AGO2 and AGO2-LIMD1 interaction are impaired by the phosphorylation of 
Y393. Therefore, it is reasonable and of interest to investigate whether there is an 
interaction between Dicer and LIMD1 and if so, it will help for introduce a novel LIMD1 
function in miRNA biogenesis. 
10.3 Investigation of LAW-AGO association 
Although this present study revealed that the AB-motif is responsible for the interaction 
between AGO2, LAW family members contain the sequence variations within the pre-
LIM region where the AB-motif locates. Therefore, it requires revealing the precise 
interaction domain within both AJUBA and WTIP. In addition, the specific antibody 
against the phospho-serine on each AGO protein is required to further confirm the 
mechanism whether the association between AJUBA/WTIP with AGOs is 
phosphorylation-dependent.  
10.4 Potential dual-regulation of STK39 by LIMD1 
STK39 contains HRE in its promoter region, indicating the regulation of STK39 might also 
be regulated by HIF-driven transcription. Here, the preliminary data showed STK39 
expressions in HeLa isogenic pair increased at 4h hypoxic induction, and then they 
decreased at 24h hypoxic induction (Figure 10.2A). The STK39 expression was 
demonstrated to be regulated by miRNA-mediated silencing, and miR-26 was reported 
to target the 3’UTR of STK39 and responds to hypoxia, respectively [375, 385]. In 
agreement with these studies, the preliminary study confirms miR-26 abundance 
increased in the hypoxic condition (1% O2) (Figure 10.2B). These observations implied 
the alteration of STK39 expression observed in hypoxia might be regulated by HIF-driven 
transcription which dominantly functions at 4h hypoxic induction and with the increase 
of hypoxia, miRNA-mediated silencing starts to take over the responsibility to negatively 
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control STK39 expression. The balance and dynamic process of regulating STK39 is also 




Figure 10.2 Potential dual-regulation of STK39 by LIMD1 
A) Western blot analysis of the indicated proteins in HeLa isogenic pair under the normoxic and hypoxic 
conditions (n=1). B) qRT-PCR analysis of the relative expression of miR-26 in HeLa isogenic pair under the 
normoxic and hypoxic conditions. Data shown are mean ±SEM, n=1. N, Normoxia (20% O2). H, hypoxia 
(1% O2). 
 
According to the bioinformatics, there are two SMAD binding elements (SBEs) within the 
promoter region of STK39, indicating the transcription of STK39 might be driven by 
SMADs. Nevertheless, TGF-β induces HIF-1α accumulation and its DNA binding activity 
[386]. Therefore, the synthetic lethality of ACVR2B with LIMD1 observed in this study 
could also result from the down-regulated STK39 caused by the depletion of ACVR2B. 
To link two separate pathway together, it is of interest to investigate whether the 
depletion of ACVR2B diminishes the STK39 expression. If so, mutating the SBE sites 
would suggest whether SBE is involved in regulating the transcription of STK39. 
In summary, this present study opens the possibility whether there is a specific group of 
genes like STK39 whose expression are synergistically dual-regulated by LIMD1 via 
miRNA-mediated silencing pathway and gene transcription pathway (probably other 
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unknown LIMD1 biological functions). This would matches the biological function of 
LIMD1 as a tumour suppressor, which lose function in the early stage of lung cancer 
[229]. The down-regulated LIMD1 may contribute to the over-expression of oncogenes 
such as STK39 observed in this study. This will provide a better understanding of 
tumourigenesis with regards to the biological consequences caused by LIMD1 loss and 
develop effective approaches for the cancer treatment.  
10.5 STK39-LIMD1 inverse relationship predicts the benefits of STK39-target therapy 
on cancers 
The depletion of STK39 was demonstrated to be lethal in low LIMD1 and high STK39 cells. 
The future work will focus on applying the ratio of LIMD1 and STK39 upon other cancer 
cells to investigate the threshold of this ratio that the cells would respond to the 
depletion of STK39. In addition, the genetic alteration of cancer cells differs not only 
from cancer types but also from individuals. The cohort with regards to LIMD1, STK39 
p38 expressions is under investigation. It is of importance to examine whether there is 
an inverse relationship between STK39 and LIMD1. Therefore, this ratio would be a 
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Figure 11.1 Sequencing results for CRISPR-Cas9 edited HeLa to knockout LIMD1 
A) Chromatograms of Cas9 control (LIMD1+/+) and LIMD1-/- HeLa cells surrounding the gRNA target 
sequence. Erroneous non homologous end joining surrounding the PAM motif results in the frameshift 
mutations and premature stop codon formation leading to LIMD1 knockout. B) Amino acid alignment of 









Figure 11.2 Chemical structure of amino acids 
A) The chemical structure of serine. B) The chemical structure of phospho-serine. C) The chemical 
structure of alanine. D) The chemical structure of glutamic acid. 
 
  





Figure 11.3 Chemical structure of amino acids 
A) The chemical structure of tyrosine. B) The chemical structure of phospho-tyrosine. C) The chemical 













































































Table 11.1 Table of Z-score and ΔZ of the full list of genes targeting the specific kinase from Human Kinome siRNA Library. 
 A549 MDA-MB-435 HeLa CRISPR-Cas9 







shSCR shLIMD1 FH-VO FH-LIMD1 Cas9 Control Knock-out 
AAK1 -1.414 -0.923 0.491 -6.495 -1.287 -5.208 -0.118 -0.148 -0.030 
AATK -0.554 -1.244 -0.690 -0.148 0.278 -0.426 -0.041 0.860 0.901 
ABL1 -0.150 0.370 0.520 -0.465 0.193 -0.658 0.852 0.809 -0.043 
ABL2 -0.177 0.364 0.541 0.604 0.799 -0.196 -0.262 0.044 0.306 
ACVR1 -0.858 -0.117 0.741 0.353 -0.401 0.755 0.002 -0.015 -0.016 
ACVR1B 0.230 0.573 0.343 -0.328 -0.069 -0.259 0.861 0.525 -0.337 
ACVR1C 0.255 0.415 0.161 -0.553 -0.658 0.105 0.411 0.168 -0.243 
ACVR2 0.772 1.033 0.262 1.359 0.494 0.865 0.891 0.351 -0.541 
ACVR2B -0.855 -0.376 0.479 -1.242 -1.225 -0.017 0.153 -3.368 -3.521 
ACVRL1 0.891 1.172 0.281 0.671 -0.264 0.935 -0.510 0.147 0.657 
ADCK1 -0.541 -0.292 0.249 0.328 0.120 0.208 -0.131 -0.090 0.042 
ADCK2 -1.135 -0.149 0.985 -0.047 0.083 -0.131 0.506 -1.211 -1.716 
ADCK4 -0.838 0.492 1.330 0.590 0.275 0.315 0.053 0.282 0.229 
ADCK5 -0.277 -0.260 0.017 -1.103 -0.367 -0.736 0.788 -1.655 -2.442 
ADK -0.018 -0.544 -0.526 -0.103 0.461 -0.565 -0.129 0.091 0.220 
ADP-GK 0.655 0.508 -0.147 -0.091 -0.381 0.289 -0.470 -0.149 0.322 
ADRBK1 -1.121 -0.988 0.133 -0.664 -0.723 0.060 0.322 -1.110 -1.432 
ADRBK2 1.054 1.071 0.017 0.538 0.676 -0.139 -0.566 1.073 1.639 
AIP1 -0.934 0.021 0.954 -0.670 -0.127 -0.544 0.475 0.326 -0.149 











































































AK2 -0.280 0.332 0.612 0.429 -0.565 0.993 0.468 -1.575 -2.043 
AK3 0.082 0.283 0.201 0.421 0.718 -0.297 0.270 0.768 0.499 
AK3L1 0.717 0.621 -0.096 0.033 0.395 -0.361 1.280 0.957 -0.323 
AK5 1.843 1.081 -0.762 -0.059 0.526 -0.585 0.872 0.179 -0.692 
AK7 0.847 0.131 -0.716 0.568 0.063 0.505 0.159 -0.034 -0.193 
AKT1 0.052 0.237 0.185 0.155 0.650 -0.495 0.471 0.264 -0.207 
AKT2 0.243 -0.064 -0.308 0.352 -0.671 1.022 -0.164 -0.073 0.091 
AKT3 -1.795 -1.048 0.746 1.446 0.594 0.852 -1.673 -0.343 1.330 
ALK -0.517 -0.434 0.083 1.523 1.256 0.267 0.102 0.680 0.578 
ALS2CR2 -0.518 -0.404 0.113 -0.675 -1.681 1.006 -0.290 -0.240 0.050 
ALS2CR7 0.629 0.574 -0.055 0.362 0.551 -0.189 0.074 0.391 0.317 
AMHR2 -0.946 -0.817 0.129 -0.607 -0.066 -0.541 -0.481 -0.623 -0.142 
ANKK1 -0.616 -0.197 0.419 -0.108 -0.352 0.243 0.440 0.561 0.121 
ANKRD3 -0.195 0.388 0.583 -0.362 0.427 -0.789 -0.163 -0.171 -0.009 
ARAF1 1.236 1.232 -0.004 0.017 0.219 -0.202 0.212 0.871 0.659 
ARK5 0.218 0.213 -0.005 1.098 0.861 0.236 0.286 0.053 -0.233 
ASK 1.166 1.332 0.166 -0.695 -0.314 -0.381 0.166 0.164 -0.002 
ATM -0.283 -0.228 0.055 -1.115 -1.735 0.620 -1.057 -0.879 0.178 
ATR -1.499 -1.394 0.106 0.585 0.415 0.170 -1.192 0.809 2.001 
AURKA -3.123 -2.260 0.863 -5.593 -5.418 -0.175 -3.677 -3.969 -0.292 
AURKB -1.131 -0.347 0.783 -0.155 -0.049 -0.106 1.269 -2.270 -3.539 
AURKC -2.716 -1.923 0.793 -0.892 -1.333 0.441 -0.365 -0.444 -0.079 
AXL 0.230 0.710 0.480 0.055 0.333 -0.278 0.273 0.650 0.377 
BAIAP1 -0.465 -1.070 -0.605 -0.164 -0.586 0.422 0.721 1.382 0.661 











































































BCR -1.887 -0.719 1.168 -0.351 -0.309 -0.042 -0.077 -1.563 -1.487 
BLK 1.616 1.380 -0.236 0.920 1.583 -0.663 0.582 0.388 -0.194 
BMP2K 0.159 -0.235 -0.395 0.385 0.456 -0.071 0.364 0.263 -0.101 
BMPR1A 0.954 0.380 -0.574 -0.490 0.111 -0.601 0.344 -2.714 -3.058 
BMPR1B -1.569 -0.661 0.908 -0.505 -0.045 -0.460 0.426 -0.154 -0.580 
BMPR2 0.997 0.519 -0.478 0.726 0.040 0.686 1.056 0.559 -0.497 
BMX 0.211 -0.022 -0.233 0.578 0.067 0.511 0.095 1.475 1.380 
BRAF -1.706 -1.260 0.445 -3.193 -3.121 -0.072 -0.734 -2.030 -1.296 
BRD2 1.062 1.147 0.085 1.493 1.199 0.294 1.193 0.804 -0.389 
BRD3 1.164 1.278 0.114 0.534 1.834 -1.300 0.126 0.271 0.146 
BRD4 -1.395 -1.764 -0.369 -1.188 -0.332 -0.856 0.006 -0.526 -0.532 
BRDT 0.374 0.070 -0.304 0.693 0.188 0.505 0.496 -0.409 -0.905 
BTK -0.573 0.116 0.689 -0.304 -0.290 -0.014 0.167 0.321 0.153 
BUB1 0.636 0.382 -0.254 0.172 -0.135 0.307 -0.261 -0.119 0.142 
BUB1B 0.500 -0.011 -0.511 1.336 1.574 -0.237 0.108 -0.180 -0.288 
C10ORF89 -0.807 -0.959 -0.151 -1.408 -1.394 -0.013 0.669 -0.665 -1.334 
C14ORF20 0.177 0.248 0.071 -0.815 -0.520 -0.295 0.960 2.170 1.210 
C7ORF2 1.811 1.576 -0.235 1.041 1.870 -0.828 0.486 0.002 -0.484 
C9ORF12 -1.625 -1.490 0.135 -0.637 -0.112 -0.525 -0.036 0.378 0.414 
C9ORF96 -0.939 -1.282 -0.342 0.997 0.674 0.323 -0.415 1.113 1.528 
CALM1 -0.422 0.084 0.506 -0.411 -0.008 -0.403 1.418 0.806 -0.612 
CALM2 -3.074 -2.467 0.607 1.179 0.948 0.231 -1.103 -0.771 0.331 
CALM3 -0.409 -0.958 -0.549 0.003 -0.277 0.279 -0.657 -1.283 -0.626 
CAMK1 -1.829 -1.541 0.287 0.743 -0.279 1.022 -0.099 -0.297 -0.199 











































































CAMK1G 0.981 0.804 -0.177 -0.481 -0.042 -0.439 0.701 -0.680 -1.381 
CAMK2A -0.020 -0.391 -0.371 0.788 0.676 0.112 -1.096 0.274 1.370 
CAMK2B -0.225 -0.181 0.045 0.590 -0.446 1.036 0.693 0.245 -0.449 
CAMK2D 0.555 0.233 -0.323 0.658 0.660 -0.002 0.488 -0.652 -1.140 
CAMK2G 0.263 0.156 -0.107 0.245 0.492 -0.247 0.860 -0.638 -1.498 
CAMK4 -0.372 -0.405 -0.033 -0.070 -1.385 1.314 0.467 2.089 1.622 
CAMKIINALPHA -1.669 -1.499 0.170 -0.718 -0.432 -0.285 -0.890 -1.489 -0.599 
CAMKK1 0.540 0.585 0.045 -0.216 -0.223 0.007 0.942 0.694 -0.247 
CAMKK1 -0.250 0.355 0.606 0.301 0.387 -0.086 -0.709 1.787 2.495 
CAMKK2 0.878 0.436 -0.442 0.185 0.174 0.011 0.630 0.450 -0.180 
CARKL 0.006 -0.213 -0.219 -1.468 -1.257 -0.211 -0.903 -0.517 0.386 
CASK -2.315 -1.643 0.672 0.385 -0.475 0.860 0.175 0.147 -0.028 
CCRK -2.879 -2.818 0.061 -0.837 -1.705 0.868 -0.729 -1.289 -0.560 
CDADC1 -0.103 -0.827 -0.724 0.209 1.502 -1.293 -0.042 -0.285 -0.243 
CDC2 -2.550 -0.854 1.696 -1.293 -1.778 0.486 -0.378 0.123 0.501 
CDC2L1 -0.458 -0.332 0.126 -0.162 0.769 -0.932 0.770 0.397 -0.372 
CDC2L2 -2.332 -1.908 0.424 0.275 1.165 -0.890 -0.961 -1.718 -0.758 
CDC2L5 0.430 0.597 0.167 -1.068 -0.544 -0.524 -0.813 -1.281 -0.469 
CDC42BPA -0.897 -0.916 -0.019 -0.124 -1.246 1.122 -1.171 -1.462 -0.291 
CDC42BPB 0.205 0.564 0.359 -0.382 0.665 -1.046 -0.043 0.232 0.274 
CDC7 -0.449 0.188 0.637 0.665 -0.054 0.718 -0.872 -1.885 -1.013 
CDK10 0.154 -1.166 -1.320 -0.727 -1.079 0.352 -0.131 -0.224 -0.093 
CDK11 -1.694 -1.632 0.062 0.531 0.460 0.071 0.494 -0.040 -0.534 
CDK2 -0.206 0.234 0.440 0.891 0.159 0.732 0.366 -1.061 -1.427 











































































CDK4 -0.759 -0.252 0.507 -1.858 -1.816 -0.042 -0.023 -0.546 -0.523 
CDK5 0.160 0.765 0.605 0.273 0.156 0.117 0.491 -0.484 -0.975 
CDK5R1 0.388 0.901 0.514 0.201 -0.093 0.293 -0.352 -0.728 -0.377 
CDK5R2 0.268 0.306 0.037 1.621 1.051 0.570 -1.572 -1.673 -0.101 
CDK6 -0.834 -0.869 -0.035 -1.226 -1.707 0.481 -0.083 0.109 0.192 
CDK7 0.488 0.569 0.081 1.523 1.176 0.347 0.151 0.312 0.161 
CDK8 0.902 0.596 -0.306 0.097 0.697 -0.600 1.185 -0.007 -1.192 
CDK9 0.067 0.255 0.188 0.551 0.744 -0.193 -0.128 -0.278 -0.150 
CDKL1 -1.317 -1.324 -0.007 -0.443 -0.072 -0.372 -0.394 0.590 0.984 
CDKL2 -1.224 -1.849 -0.625 -1.566 -0.938 -0.629 1.413 -1.250 -2.663 
CDKL3 0.271 0.385 0.114 1.902 1.507 0.395 -0.019 0.204 0.223 
CDKL4 0.369 -0.897 -1.266 0.286 0.231 0.055 -0.479 0.434 0.912 
CDKL5 1.674 1.733 0.059 1.581 1.866 -0.286 0.883 0.732 -0.151 
CDKN1A 1.340 1.587 0.248 -0.420 -0.178 -0.242 -0.083 -0.228 -0.144 
CDKN1B 0.499 0.738 0.239 0.338 -0.116 0.454 0.398 0.958 0.560 
CDKN1C -0.006 -0.077 -0.071 1.356 0.582 0.774 -3.023 -1.562 1.461 
CDKN2B 1.176 1.436 0.260 0.650 0.597 0.052 0.468 0.918 0.449 
CDKN2C -0.607 -0.012 0.594 -0.146 -0.367 0.221 0.013 -0.369 -0.382 
CDKN2D -1.975 -1.432 0.543 -0.751 -1.396 0.645 -1.689 -0.684 1.006 
CERK 0.629 -0.336 -0.965 -0.131 -0.235 0.104 0.491 -0.067 -0.558 
CHEK1 -2.969 -2.709 0.260 -1.277 -2.751 1.474 -1.423 -1.208 0.215 
CHEK2 0.015 0.416 0.401 0.287 -0.039 0.326 -1.386 -1.171 0.215 
CHKA -1.889 -1.477 0.412 -1.471 -0.553 -0.918 -0.756 -0.412 0.345 
CHKB 0.540 0.711 0.171 0.236 0.136 0.100 0.813 2.208 1.394 











































































CIB2 -5.186 -3.865 1.322 -1.185 -0.441 -0.743 -1.913 -1.726 0.187 
CIT -1.397 -1.570 -0.173 0.233 -0.460 0.693 -0.248 -1.434 -1.186 
CKB 1.643 1.251 -0.393 0.778 0.976 -0.198 0.835 0.178 -0.657 
CKM 0.141 0.177 0.036 0.836 0.908 -0.072 1.640 -0.544 -2.184 
CKMT1B -0.469 -0.452 0.017 -0.476 -0.154 -0.322 -0.616 -2.239 -1.622 
CKMT2 -0.116 -0.046 0.070 1.007 -0.489 1.496 -0.949 -0.353 0.596 
CKS1B 0.076 -0.430 -0.505 -0.999 -0.932 -0.067 0.275 0.526 0.251 
CKS2 0.825 0.952 0.128 0.206 1.280 -1.074 0.886 0.940 0.055 
CLK1 0.102 0.047 -0.055 0.409 0.078 0.331 1.483 0.753 -0.730 
CLK2 1.604 0.811 -0.794 -0.457 -0.332 -0.125 -1.596 -0.461 1.135 
CLK3 0.263 -0.221 -0.484 -0.722 -0.763 0.041 -0.026 1.367 1.393 
CLK4 -1.049 -0.607 0.442 -0.422 0.010 -0.432 -0.118 -0.589 -0.471 
COASY -1.800 -1.102 0.699 -2.131 -1.682 -0.449 -3.818 -3.345 0.473 
COL4A3BP 0.920 0.933 0.013 -1.515 -0.012 -1.502 1.756 1.662 -0.094 
COMMD3 0.214 0.093 -0.121 0.766 0.615 0.150 0.413 1.498 1.085 
CPNE3 0.187 -0.434 -0.621 -0.360 -0.277 -0.083 0.788 0.714 -0.074 
CRIM1 -0.242 0.696 0.937 0.157 0.918 -0.761 0.099 -0.002 -0.101 
CRK7 0.577 0.380 -0.197 -0.196 -0.933 0.737 -0.453 0.089 0.542 
CRKL 0.816 0.525 -0.291 -1.098 -1.695 0.597 0.409 -0.573 -0.982 
CSF1R -1.353 -2.205 -0.852 -1.216 -0.820 -0.396 -1.375 -1.314 0.061 
CSK -1.160 -1.078 0.082 0.385 0.401 -0.016 0.080 0.689 0.609 
CSNK1A1 0.139 1.117 0.978 0.162 -1.013 1.175 -0.665 1.179 1.844 
CSNK1A1L 0.302 0.011 -0.291 1.103 0.440 0.663 0.254 1.225 0.971 
CSNK1D -0.106 -0.225 -0.118 -0.017 0.028 -0.046 0.212 0.528 0.316 











































































CSNK1G1 -1.503 -1.866 -0.362 -0.475 -0.753 0.278 -2.215 -1.690 0.525 
CSNK1G2 0.147 0.100 -0.046 0.286 0.559 -0.273 1.462 1.229 -0.232 
CSNK1G3 0.998 0.617 -0.381 0.246 -0.563 0.809 0.683 0.582 -0.102 
CSNK2A1 1.592 1.509 -0.083 1.467 2.021 -0.554 1.798 -0.169 -1.967 
CSNK2A2 -1.008 -0.244 0.764 -0.378 -0.006 -0.372 0.177 -0.179 -0.357 
CSNK2B 0.085 -0.368 -0.454 -0.866 -1.086 0.220 -1.706 -2.862 -1.156 
DAPK1 -0.698 -1.041 -0.343 -0.463 -0.111 -0.352 0.684 0.007 -0.677 
DAPK2 0.240 0.573 0.333 -0.114 0.169 -0.282 -0.589 0.655 1.244 
DAPK3 -0.207 -1.208 -1.001 -0.231 -0.424 0.193 0.701 0.087 -0.614 
DCAMKL1 0.530 0.015 -0.515 -0.195 -0.133 -0.062 2.319 -0.135 -2.454 
DCK 0.476 1.294 0.818 -0.809 -0.706 -0.103 0.385 -4.674 -5.059 
DDR1 -1.343 -1.159 0.184 -0.204 0.395 -0.599 1.415 2.370 0.954 
DDR2 -0.074 -0.116 -0.042 0.137 0.144 -0.006 0.882 0.659 -0.223 
DGKA -2.342 -1.386 0.955 -0.625 -0.255 -0.369 -0.766 -0.545 0.221 
DGKB -2.446 -1.585 0.861 -0.943 -1.088 0.145 1.041 0.303 -0.738 
DGKD 0.505 0.646 0.141 0.540 0.393 0.148 0.286 1.302 1.016 
DGKG 0.305 0.106 -0.199 0.315 0.222 0.093 -1.794 -1.682 0.112 
DGKH -0.876 -0.751 0.124 -0.452 -1.001 0.549 1.169 1.318 0.149 
DGKI 0.894 1.135 0.241 1.139 1.527 -0.389 -0.412 -0.657 -0.244 
DGKK 0.270 0.237 -0.033 0.787 0.440 0.347 -0.246 0.089 0.335 
DGKQ 0.138 -0.389 -0.527 0.225 1.220 -0.995 -0.079 0.187 0.265 
DGUOK -0.324 -0.302 0.022 1.042 1.064 -0.022 0.970 0.319 -0.652 
DKFZP434C131 0.879 0.894 0.015 -0.502 -0.231 -0.272 -0.304 0.559 0.863 











































































DLG1 0.326 -0.818 -1.144 0.195 0.486 -0.291 0.153 1.234 1.081 
DLG2 2.160 0.952 -1.208 1.516 2.101 -0.585 1.191 -0.154 -1.344 
DLG3 2.045 1.739 -0.306 0.017 0.005 0.012 -0.744 1.230 1.974 
DLG4 -1.035 -1.124 -0.089 0.441 0.828 -0.387 0.264 0.288 0.024 
DMPK -2.982 -1.145 1.838 -1.350 -0.563 -0.786 -2.892 -0.456 2.436 
DTYMK 1.654 1.490 -0.165 0.678 0.616 0.062 0.360 0.510 0.150 
DUSP21 0.438 -0.002 -0.440 0.092 0.047 0.044 3.258 0.017 -3.242 
DUSTYPK 0.479 0.158 -0.321 -2.928 0.413 -3.341 0.462 0.464 0.003 
DYRK1A 0.152 0.240 0.088 -0.452 -0.175 -0.277 0.875 1.957 1.082 
DYRK1B -0.044 0.463 0.507 0.631 0.104 0.528 0.106 0.193 0.087 
DYRK2 -0.731 -0.044 0.686 -0.612 -0.123 -0.489 -0.883 -0.737 0.147 
DYRK3 0.750 0.415 -0.335 0.037 -0.066 0.104 -0.641 -0.112 0.530 
DYRK4 0.459 0.311 -0.148 0.856 0.939 -0.083 1.247 1.073 -0.174 
EEF2K -3.041 -1.941 1.099 -2.615 -3.962 1.347 -1.888 -1.808 0.080 
EFNA3 -0.023 -0.023 0.000 1.169 0.646 0.523 -0.339 -0.206 0.133 
EFNA4 -1.361 -1.488 -0.127 -0.320 -0.988 0.668 -1.690 -1.234 0.455 
EFNA5 -0.320 -0.027 0.293 0.558 0.654 -0.096 1.240 0.676 -0.564 
EFNB3 -2.130 -0.726 1.404 -0.224 -0.163 -0.062 3.667 -1.148 -4.815 
EGFR -0.583 -0.054 0.529 -0.416 -0.732 0.316 0.485 -0.238 -0.723 
EIF2AK3 0.281 0.400 0.119 0.198 0.519 -0.321 0.293 -0.446 -0.739 
EIF2AK4 0.194 -0.167 -0.361 0.051 0.195 -0.144 0.264 1.350 1.086 
EPHA1 -1.386 -1.721 -0.335 -0.147 -0.141 -0.007 0.335 -0.877 -1.212 
EPHA10 -0.700 -0.622 0.078 0.039 -0.018 0.058 0.497 0.187 -0.311 
EPHA2 0.858 1.037 0.179 0.868 0.860 0.008 -0.327 0.286 0.612 











































































EPHA4 -0.772 -0.217 0.555 -0.946 -0.747 -0.199 -1.334 -0.008 1.325 
EPHA5 0.421 0.211 -0.210 0.850 1.251 -0.401 0.129 0.189 0.059 
EPHA6 -2.873 -2.609 0.265 -1.686 -2.030 0.344 -1.146 -1.209 -0.064 
EPHA7 -0.419 -0.327 0.093 0.789 -0.118 0.906 0.721 0.262 -0.458 
EPHA8 0.392 0.648 0.256 0.037 0.544 -0.507 -1.000 0.910 1.910 
EPHB1 0.403 0.169 -0.234 -0.741 -0.213 -0.527 0.309 0.680 0.371 
EPHB2 1.429 0.502 -0.926 -0.194 -0.139 -0.055 0.998 0.422 -0.576 
EPHB3 -0.062 -0.353 -0.292 -0.630 -0.637 0.007 -1.504 -1.419 0.085 
EPHB4 1.187 1.032 -0.155 1.068 0.397 0.671 0.839 1.790 0.951 
EPHB6 -1.807 -1.381 0.426 -0.958 -1.092 0.134 -1.215 -0.229 0.985 
ERBB2 1.034 0.893 -0.142 1.077 1.291 -0.214 0.461 0.549 0.088 
ERBB3 -0.377 -0.691 -0.314 -0.240 0.881 -1.121 1.434 1.030 -0.404 
ERBB4 -0.263 -1.778 -1.515 -0.457 -1.551 1.094 0.038 -1.671 -1.710 
ERK8 0.682 0.714 0.033 -0.008 -0.094 0.085 -1.594 -2.092 -0.498 
ERN1 -2.008 -1.401 0.607 -0.895 -0.230 -0.666 -0.472 -2.265 -1.793 
ERN2 -1.009 -1.033 -0.024 0.777 0.435 0.343 -0.223 0.049 0.272 
ETNK1 0.600 0.208 -0.393 0.772 0.261 0.511 -0.204 -0.364 -0.160 
EXOSC10 -0.856 -2.104 -1.248 -0.532 -0.171 -0.362 -0.642 -0.286 0.356 
FASTK 0.553 0.337 -0.215 -0.283 0.063 -0.346 -0.840 -0.549 0.291 
FER 0.150 -0.137 -0.287 -0.375 -1.235 0.860 0.492 0.273 -0.220 
FES -0.443 -0.378 0.065 0.619 0.366 0.253 -1.704 -2.579 -0.876 
FGFR1 0.645 -0.194 -0.838 0.248 -0.973 1.221 0.575 0.654 0.079 
FGFR2 -0.391 -1.051 -0.660 -0.810 0.853 -1.663 0.287 -0.071 -0.359 
FGFR3 -0.055 0.786 0.841 1.043 0.731 0.313 0.596 0.697 0.101 











































































FGFRL1 1.151 0.915 -0.236 -1.269 -0.616 -0.654 0.136 0.406 0.270 
FGR -2.078 -1.403 0.675 0.122 -0.601 0.723 -2.014 -2.780 -0.767 
FLJ10761 -1.475 -0.931 0.544 -1.007 -0.975 -0.032 -0.364 0.067 0.431 
FLJ13052 -0.106 0.018 0.124 0.658 1.207 -0.549 -2.592 0.362 2.953 
FLJ23074 -2.231 -0.999 1.233 -0.349 -0.572 0.223 -0.852 -0.474 0.378 
FLJ23356 -0.509 -1.296 -0.787 -1.019 0.008 -1.027 0.452 0.432 -0.020 
FLJ23356 0.018 -0.164 -0.182 -0.252 0.105 -0.357 0.255 0.245 -0.010 
FLJ25006 0.014 0.385 0.371 -0.023 -0.301 0.278 0.563 0.084 -0.479 
FLJ32685 -0.531 0.134 0.666 0.035 -0.764 0.799 -1.722 -0.479 1.242 
FLJ34389 0.854 0.515 -0.339 -0.073 -0.019 -0.055 -0.066 -0.717 -0.651 
FLT1 1.431 1.145 -0.286 -1.818 -1.909 0.091 1.339 0.490 -0.849 
FLT3 -0.581 -1.082 -0.501 0.207 -0.467 0.674 -0.742 -0.561 0.181 
FLT4 -2.826 -3.060 -0.234 -1.375 -1.888 0.513 0.533 0.077 -0.456 
FN3K -0.864 -0.030 0.834 0.521 0.999 -0.478 0.633 0.516 -0.117 
FN3KRP -2.011 -3.495 -1.484 -0.861 -2.253 1.392 -1.939 -1.271 0.668 
FRAP1 -1.060 -1.041 0.019 0.412 0.720 -0.308 -0.281 -0.471 -0.190 
FRDA 1.888 0.867 -1.021 0.019 -0.474 0.493 0.280 0.854 0.573 
FRK 0.764 1.112 0.348 0.743 0.013 0.730 1.502 1.714 0.212 
FUK -0.955 -0.590 0.364 -0.112 0.236 -0.347 0.002 0.200 0.198 
FYN 1.542 0.781 -0.762 -0.685 -0.388 -0.297 1.007 -0.573 -1.580 
GAK -0.231 -0.770 -0.539 -0.017 0.264 -0.281 0.092 -0.006 -0.098 
GALK1 -0.721 -0.795 -0.075 -1.655 -2.082 0.427 -0.715 0.934 1.649 
GALK2 -0.559 -1.284 -0.725 -0.531 -0.777 0.246 -0.274 0.368 0.642 
GCK -0.890 -0.270 0.619 -2.098 -2.607 0.509 0.355 0.675 0.320 











































































GK2 0.717 0.770 0.053 -0.267 0.332 -0.599 -0.637 0.692 1.329 
GNE 0.399 0.701 0.302 -0.065 0.523 -0.588 1.077 -0.080 -1.157 
GOLGA5 0.740 0.807 0.067 0.644 0.650 -0.006 1.191 0.686 -0.505 
GRK1 0.071 0.539 0.468 0.675 0.142 0.533 0.858 -0.771 -1.629 
GRK4 -1.242 -1.309 -0.067 -1.024 -0.521 -0.503 0.315 -2.001 -2.317 
GRK5 0.116 -0.905 -1.021 0.477 0.488 -0.012 0.428 0.465 0.036 
GRK6 -1.776 -0.742 1.034 -2.275 -1.001 -1.274 0.580 -0.351 -0.931 
GRK7 -1.580 -1.057 0.522 -0.830 -1.519 0.689 0.151 -0.152 -0.303 
GSG2 0.224 0.312 0.088 -0.999 -1.477 0.478 -0.264 -1.109 -0.845 
GSK3A -1.309 -1.574 -0.265 -0.324 -0.735 0.412 0.028 0.107 0.079 
GSK3B 0.405 0.443 0.038 -0.090 -0.047 -0.043 0.355 2.023 1.668 
GTF2H1 0.297 0.158 -0.139 0.473 0.111 0.362 -0.153 0.766 0.919 
GUCY2C 0.480 0.324 -0.156 0.326 -0.330 0.656 0.828 1.950 1.122 
GUCY2D -2.878 -3.200 -0.321 -2.431 -2.834 0.403 -3.957 -2.693 1.264 
GUCY2F 1.306 0.843 -0.463 0.586 0.452 0.134 0.382 1.307 0.925 
GUK1 -1.148 -0.736 0.412 1.212 0.815 0.397 -0.604 0.008 0.612 
HAK 0.226 -0.003 -0.229 0.677 0.198 0.479 0.019 1.167 1.148 
HCK 0.128 -0.047 -0.174 -1.008 -0.744 -0.264 0.920 0.749 -0.171 
HIPK1 1.454 0.271 -1.183 0.167 0.126 0.040 0.957 1.095 0.138 
HIPK2 0.509 0.153 -0.356 -2.603 0.739 -3.342 -0.779 0.619 1.397 
HIPK3 -0.158 -0.021 0.137 -0.734 -0.127 -0.607 -0.187 -0.483 -0.296 
HIPK4 1.596 1.519 -0.078 -0.600 -0.755 0.155 0.303 -1.099 -1.402 
HK1 -0.229 -0.418 -0.189 -0.302 -1.264 0.963 0.705 0.081 -0.625 
HK2 -1.284 -0.055 1.229 0.156 0.720 -0.564 -2.232 -1.761 0.471 











































































HRI -0.005 0.255 0.260 0.653 0.474 0.179 0.472 -0.028 -0.500 
HSMDPKIN -0.278 0.359 0.637 -0.961 -0.663 -0.298 -0.293 -0.254 0.039 
HSPB8 -0.439 -0.343 0.096 0.322 0.703 -0.381 0.023 -0.117 -0.140 
HUNK -3.232 -1.982 1.250 -0.652 -1.296 0.644 -0.746 0.561 1.307 
HUS1 1.071 1.407 0.336 0.095 0.264 -0.169 2.180 -0.210 -2.390 
ICK 0.472 0.222 -0.250 -0.042 -0.302 0.260 0.833 0.721 -0.112 
IGF1R -1.978 -1.492 0.486 -0.125 -0.070 -0.054 0.207 -0.061 -0.268 
IGF2R 1.777 1.060 -0.717 0.639 1.239 -0.599 2.185 2.661 0.477 
IHPK1 -0.455 -0.019 0.437 0.464 1.228 -0.764 -0.681 0.202 0.883 
IHPK2 0.195 0.048 -0.148 0.423 -0.057 0.480 -0.071 -1.844 -1.773 
IHPK3 -3.274 -2.776 0.497 -1.094 -0.844 -0.251 -0.096 -0.413 -0.317 
IKBKAP 0.205 0.184 -0.021 0.092 -0.189 0.281 -0.083 0.627 0.710 
IKBKB -0.089 -0.488 -0.400 -0.359 -0.922 0.563 -3.135 -0.799 2.336 
IKBKE -1.069 -1.204 -0.135 0.116 0.048 0.068 0.356 -0.978 -1.334 
IKBKG 0.857 0.389 -0.468 -0.748 -0.760 0.013 0.660 1.054 0.393 
ILK -0.402 -1.112 -0.711 0.145 -0.098 0.243 0.842 -1.384 -2.226 
ILK-2 0.206 0.915 0.708 0.085 0.029 0.057 -0.343 0.342 0.684 
INSR -0.545 -0.698 -0.153 -2.047 -1.443 -0.604 -0.688 -1.344 -0.655 
INSRR 0.204 -0.711 -0.915 -0.598 -0.436 -0.162 1.165 -0.337 -1.502 
IPMK 1.173 0.872 -0.301 -0.464 -0.477 0.013 0.755 1.249 0.494 
IRAK1 -0.089 -0.609 -0.519 0.328 0.453 -0.125 0.006 -0.311 -0.317 
IRAK2 0.413 0.510 0.097 -0.730 -0.508 -0.222 1.254 -0.441 -1.695 
IRAK3 -2.771 -2.928 -0.157 -0.847 -1.178 0.331 -2.060 -2.084 -0.024 
IRAK4 0.237 -0.215 -0.452 0.785 1.434 -0.649 1.364 1.203 -0.161 











































































ITPK1 -0.300 0.100 0.400 -0.495 -0.640 0.146 -0.939 -0.613 0.326 
ITPKA 0.621 1.217 0.595 0.937 0.927 0.010 0.133 0.184 0.051 
ITPKB 0.651 1.105 0.454 1.206 0.930 0.277 -0.363 1.124 1.487 
ITPKC 0.020 -0.772 -0.792 0.475 0.338 0.137 -0.015 -0.304 -0.289 
JAK1 0.021 0.022 0.001 0.449 0.466 -0.017 0.627 -0.216 -0.843 
JAK2 1.529 1.384 -0.145 -3.238 -5.112 1.874 1.366 0.744 -0.622 
JAK3 -0.688 -0.650 0.037 0.053 -0.794 0.846 0.433 0.457 0.024 
JIK -0.965 -0.546 0.419 -0.291 -1.243 0.952 -1.949 0.145 2.094 
KALRN 0.724 0.607 -0.118 -0.562 -0.898 0.337 0.872 0.663 -0.209 
KCNH2 -0.548 -0.470 0.078 0.174 1.497 -1.323 -1.713 -0.556 1.158 
KCNH8 -0.285 -0.963 -0.678 0.594 0.353 0.241 -0.163 -0.456 -0.293 
KDR -0.853 -1.054 -0.201 0.012 0.012 -0.001 -3.169 -2.387 0.782 
KHK -1.083 -1.196 -0.112 -1.058 -0.047 -1.010 0.791 -1.054 -1.845 
KIAA0999 1.268 0.317 -0.951 0.018 -0.109 0.127 0.154 0.353 0.199 
KIAA1361 0.247 0.341 0.094 1.361 1.483 -0.122 0.618 0.358 -0.260 
KIAA1639 0.579 0.580 0.000 -0.059 -0.514 0.455 0.563 0.124 -0.439 
KIAA1765 0.973 0.595 -0.378 0.617 0.409 0.209 1.070 1.918 0.848 
KIAA1804 1.170 1.182 0.011 0.805 0.813 -0.008 -0.006 0.600 0.607 
KIAA1811 1.088 1.399 0.311 1.206 0.933 0.273 -0.048 0.002 0.050 
KIAA1811 -0.039 0.413 0.453 1.342 1.123 0.220 1.236 1.645 0.408 
KIAA2002 -0.262 -0.711 -0.450 -0.787 -1.435 0.648 0.100 -1.134 -1.234 
KIT -0.797 -0.640 0.157 -0.629 -0.830 0.201 -1.080 -1.074 0.005 
KSR -1.233 -1.871 -0.638 -0.719 -0.102 -0.618 -1.587 -1.998 -0.411 
KSR2 0.099 0.157 0.058 -1.084 -0.692 -0.392 -1.042 -0.764 0.278 











































































LAK 0.507 -0.291 -0.798 -1.099 0.289 -1.388 -0.461 0.490 0.951 
LATS1 -1.185 -0.769 0.416 0.194 -0.841 1.035 0.173 -0.241 -0.413 
LATS2 0.689 0.407 -0.281 1.628 1.421 0.207 0.177 0.523 0.346 
LCK -1.044 -0.495 0.549 -0.134 -0.321 0.187 -0.222 0.281 0.503 
LIMK1 -0.773 -0.207 0.566 -0.939 0.112 -1.051 -0.035 0.271 0.306 
LIMK2 0.456 0.641 0.185 0.654 0.490 0.165 0.903 0.073 -0.830 
LMTK2 1.514 0.487 -1.027 -0.477 0.180 -0.657 -3.218 0.993 4.211 
LMTK3 -3.889 -1.885 2.004 -2.001 -2.837 0.835 -6.495 -5.170 1.325 
LOC340156 0.039 -0.293 -0.332 1.304 1.585 -0.281 -0.565 0.184 0.749 
LOC390226 0.695 0.895 0.200 0.166 -0.400 0.565 0.567 2.061 1.494 
LOC91461 0.642 0.340 -0.303 1.304 0.918 0.386 0.341 0.256 -0.085 
LRRK1 0.637 0.295 -0.342 0.617 0.809 -0.193 0.480 -0.534 -1.014 
LRRK2 -0.713 0.030 0.743 0.068 -0.745 0.813 0.019 -0.038 -0.057 
LTK 0.986 0.804 -0.182 0.913 1.321 -0.408 0.348 0.705 0.358 
LYK5 -0.146 0.027 0.173 -0.184 -0.420 0.236 -0.288 2.155 2.443 
LYN -0.146 0.131 0.277 -0.040 0.330 -0.369 -0.517 -0.002 0.515 
MAGI-3 2.064 -0.485 -2.549 -0.169 0.442 -0.611 0.575 -0.615 -1.190 
MAK -0.497 0.135 0.632 -0.070 -0.744 0.674 -1.241 -0.450 0.790 
MAP2K1 0.872 1.306 0.434 0.831 0.580 0.251 0.246 1.318 1.072 
MAP2K2 1.016 0.561 -0.455 -0.222 0.001 -0.222 0.403 -1.382 -1.786 
MAP2K3 -1.507 -1.000 0.508 -0.517 -0.478 -0.039 -0.320 -0.204 0.116 
MAP2K4 -1.841 -1.063 0.778 1.133 1.292 -0.159 -0.611 -1.107 -0.497 
MAP2K5 0.164 -0.402 -0.566 1.314 1.534 -0.219 0.357 0.398 0.041 
MAP2K6 0.296 0.439 0.142 1.952 2.613 -0.661 -0.852 0.447 1.299 











































































MAP3K1 -0.885 -0.018 0.867 -0.748 -0.956 0.209 -0.428 -0.994 -0.566 
MAP3K10 0.511 0.857 0.346 0.177 1.472 -1.295 1.879 -0.060 -1.939 
MAP3K11 -1.147 -1.214 -0.066 -0.138 -0.477 0.339 0.306 -0.938 -1.244 
MAP3K12 -0.838 -0.866 -0.028 0.356 -0.757 1.113 0.348 0.514 0.166 
MAP3K13 0.253 -0.370 -0.624 -0.806 -1.257 0.451 -0.566 0.937 1.503 
MAP3K14 0.297 0.117 -0.180 -0.101 0.034 -0.135 -0.435 -1.050 -0.616 
MAP3K15 0.567 1.235 0.668 0.766 0.578 0.188 -0.176 -0.204 -0.027 
MAP3K2 1.316 1.420 0.104 1.818 1.566 0.252 0.095 0.602 0.506 
MAP3K3 0.029 0.256 0.226 -0.119 0.049 -0.167 0.098 -0.289 -0.387 
MAP3K4 0.892 -0.048 -0.940 0.852 0.885 -0.033 0.517 1.242 0.725 
MAP3K5 0.352 -0.293 -0.645 -0.125 -0.659 0.534 0.701 0.390 -0.312 
MAP3K6 0.048 -0.723 -0.771 0.218 -0.295 0.513 0.147 0.750 0.603 
MAP3K7 -0.006 -0.265 -0.259 0.029 -0.214 0.243 0.229 -0.386 -0.616 
MAP3K7IP1 0.583 0.914 0.331 0.456 -0.333 0.789 -0.969 0.508 1.477 
MAP3K8 -0.080 0.154 0.234 -0.665 -0.550 -0.115 0.256 -0.342 -0.599 
MAP3K9 -0.562 -1.028 -0.466 -0.146 0.461 -0.607 -0.730 -0.508 0.223 
MAP4K1 -2.628 -1.999 0.629 -0.194 -1.036 0.843 -1.592 -1.047 0.545 
MAP4K2 0.047 0.063 0.016 0.609 0.314 0.295 0.338 -0.012 -0.350 
MAP4K3 -0.323 -0.560 -0.237 -0.451 -0.620 0.169 -0.519 -0.202 0.316 
MAP4K4 1.081 0.251 -0.830 1.165 1.406 -0.241 0.958 0.318 -0.640 
MAP4K5 -0.682 -0.518 0.164 0.458 0.260 0.198 -1.955 -3.400 -1.445 
MAPK1 -2.951 -2.279 0.672 -2.257 -1.962 -0.295 -0.082 0.152 0.234 
MAPK10 0.613 0.354 -0.259 -0.041 0.649 -0.689 0.581 -1.663 -2.244 
MAPK11 -0.654 0.687 1.341 0.145 0.338 -0.193 0.457 0.543 0.086 











































































MAPK13 0.254 -0.525 -0.778 0.827 0.537 0.290 0.991 0.644 -0.347 
MAPK14 -0.534 -0.497 0.037 0.502 0.555 -0.053 -1.137 0.954 2.091 
MAPK3 -0.334 -0.323 0.011 -0.866 -1.237 0.371 -0.513 -0.320 0.193 
MAPK4 -1.045 -0.760 0.285 -2.198 -2.342 0.143 -1.376 -1.044 0.332 
MAPK6 -1.807 -1.276 0.531 -0.261 -0.694 0.433 0.474 0.249 -0.225 
MAPK7 0.505 1.047 0.542 -0.059 0.067 -0.126 0.353 0.053 -0.300 
MAPK8 1.091 0.500 -0.592 0.703 0.232 0.471 0.796 0.674 -0.123 
MAPK9 0.146 0.463 0.317 0.453 0.806 -0.353 0.686 0.488 -0.198 
MAPKAPK2 0.718 -0.414 -1.132 -0.369 -0.557 0.188 0.632 -0.569 -1.201 
MAPKAPK3 -1.706 -1.381 0.325 -0.794 -1.520 0.725 0.582 -1.242 -1.824 
MAPKAPK5 1.081 0.265 -0.816 1.114 0.782 0.332 -1.667 -0.142 1.524 
MARK1 -0.264 -0.427 -0.164 0.113 0.326 -0.213 -0.848 -0.694 0.154 
MARK2 -1.254 -1.001 0.253 0.529 0.173 0.356 0.723 0.385 -0.338 
MARK3 -3.728 -3.670 0.058 0.009 -0.565 0.574 -2.050 -1.909 0.141 
MARK4 -0.094 -0.324 -0.230 -0.124 0.051 -0.175 0.618 -0.702 -1.320 
MAST2 -0.392 -0.152 0.240 -1.029 -1.187 0.158 -2.793 -0.697 2.096 
MAST3 -0.458 -0.022 0.436 0.525 0.886 -0.361 0.428 0.444 0.016 
MAST4 1.069 0.801 -0.268 0.918 -0.886 1.804 0.343 0.466 0.124 
MASTL -0.833 -0.203 0.630 -0.440 -0.682 0.242 0.032 0.007 -0.025 
MATK 0.174 -0.628 -0.802 0.987 0.561 0.426 -0.194 -0.129 0.064 
MELK 0.227 0.097 -0.130 2.276 1.862 0.413 0.138 0.167 0.029 
MERTK 0.722 0.001 -0.722 1.230 1.231 -0.001 -0.483 0.221 0.704 
MET 1.358 0.993 -0.365 -1.114 -0.836 -0.278 1.025 -0.283 -1.309 
MGC16169 -0.484 -0.213 0.271 -1.051 -1.059 0.008 0.539 0.354 -0.185 
MGC42105 0.409 0.012 -0.397 1.071 0.401 0.670 0.380 0.321 -0.059 











































































MGC4796 -0.621 -0.490 0.131 -1.447 -1.372 -0.075 -0.656 -1.017 -0.361 
MGC4796 0.152 0.299 0.146 -1.597 -1.923 0.326 1.393 1.347 -0.046 
MGC8407 -1.652 -0.836 0.816 -0.438 0.414 -0.852 0.308 0.371 0.063 
MIDORI 0.018 0.396 0.378 -0.758 -1.056 0.298 0.109 -0.131 -0.239 
MINK -0.828 -0.265 0.563 0.029 -0.692 0.721 -0.415 -0.528 -0.113 
MKNK1 0.254 0.402 0.148 0.380 0.748 -0.368 0.573 -0.326 -0.899 
MKNK2 0.095 -1.014 -1.109 0.164 0.265 -0.101 -0.643 -0.717 -0.075 
MLCK -0.318 -0.058 0.259 0.358 0.036 0.322 0.450 0.259 -0.191 
MOS -0.321 -0.455 -0.135 -1.089 -1.648 0.559 -0.366 -1.140 -0.774 
MPP1 -0.256 -0.750 -0.494 1.671 1.900 -0.230 0.321 0.036 -0.284 
MPP2 -0.467 -0.460 0.007 0.526 0.066 0.461 0.057 -0.572 -0.629 
MPP3 -0.001 -0.292 -0.290 -0.151 -0.212 0.061 -0.187 0.069 0.256 
MST1R -1.054 -1.050 0.003 -0.935 -1.516 0.581 -0.303 0.836 1.139 
MULK 0.184 0.642 0.458 -1.032 0.471 -1.503 0.635 0.649 0.013 
MUSK -1.696 -1.672 0.025 -4.127 -0.221 -3.906 0.312 0.364 0.052 
MVK -0.707 -0.216 0.491 0.634 0.469 0.165 0.220 0.163 -0.057 
MYLK -0.503 -0.638 -0.135 -0.228 -0.724 0.496 -0.326 0.926 1.252 
MYLK2 -5.959 -5.878 0.081 -2.118 -2.124 0.006 -2.003 -3.047 -1.043 
MYO3A -0.901 -0.744 0.157 -0.373 -0.742 0.369 -0.391 -0.001 0.390 
MYO3B 0.139 0.666 0.527 -0.338 -0.393 0.055 -1.203 0.683 1.886 
N4BP2 0.719 0.379 -0.339 1.450 1.316 0.134 -0.398 -0.102 0.296 
NAGK -3.353 -2.893 0.460 -1.535 -1.590 0.054 -1.413 -1.518 -0.105 
NEK1 -0.202 -0.070 0.132 0.681 0.587 0.095 1.203 -2.365 -3.567 
NEK11 -2.050 -1.639 0.410 0.008 0.055 -0.047 -1.732 -2.207 -0.475 











































































NEK3 -1.136 -1.490 -0.355 -3.640 -2.267 -1.373 1.192 0.400 -0.792 
NEK4 -0.290 -0.060 0.230 -0.805 -0.483 -0.322 -0.507 -0.156 0.351 
NEK5 1.040 1.200 0.160 -0.011 1.053 -1.065 0.394 0.958 0.564 
NEK6 0.502 0.341 -0.161 0.253 0.355 -0.102 0.731 0.155 -0.576 
NEK7 2.196 1.676 -0.520 -0.347 0.277 -0.625 -0.507 0.011 0.518 
NEK8 -3.409 -3.618 -0.210 -1.533 -2.236 0.703 -0.690 -0.755 -0.065 
NEK9 -0.253 -0.571 -0.317 -0.239 0.601 -0.840 0.115 -0.083 -0.197 
NLK -0.915 -0.034 0.880 1.459 0.923 0.535 -0.332 0.058 0.390 
NME1 1.365 0.718 -0.648 -0.128 0.660 -0.788 0.372 0.845 0.473 
NME2 -0.292 0.444 0.735 -0.050 -0.786 0.736 -0.657 1.519 2.176 
NME3 0.278 0.639 0.360 0.753 0.014 0.739 0.090 -0.657 -0.747 
NME4 -0.378 0.217 0.595 -0.852 -0.719 -0.133 0.586 1.236 0.650 
NME5 1.125 0.607 -0.518 0.999 1.219 -0.220 0.625 0.407 -0.219 
NME6 -1.123 -1.443 -0.320 -1.021 -1.225 0.204 0.161 0.796 0.635 
NME7 -0.200 -0.399 -0.199 1.730 1.072 0.658 1.358 1.393 0.035 
NPR2 1.302 0.676 -0.626 1.343 1.127 0.216 1.026 0.690 -0.336 
NRBP 0.376 0.246 -0.129 1.521 0.979 0.542 0.831 0.254 -0.577 
NRBP2 0.296 -0.367 -0.663 -1.978 -3.080 1.102 1.541 -2.063 -3.604 
NRK 1.141 0.346 -0.796 0.818 1.186 -0.368 1.390 -0.275 -1.665 
NTRK1 -0.772 -1.032 -0.260 -0.208 0.089 -0.297 0.342 1.660 1.318 
NTRK2 0.466 -0.219 -0.684 0.776 0.384 0.392 0.746 1.441 0.695 
NTRK3 1.775 1.172 -0.602 -1.011 -0.284 -0.727 0.122 0.004 -0.118 
NUCKS 0.676 -0.230 -0.905 -0.022 -0.147 0.125 0.778 0.331 -0.446 
NUP62 -0.190 -0.750 -0.559 -1.277 -0.979 -0.298 -1.594 -2.456 -0.862 











































































OSR1 1.630 0.998 -0.632 1.259 0.769 0.490 -0.295 0.437 0.732 
P101-PI3K -0.630 -0.414 0.216 0.919 0.571 0.348 -0.600 -0.648 -0.048 
PACE-1 0.471 0.156 -0.315 0.160 -0.153 0.313 -2.159 1.021 3.180 
PACSIN1 -0.447 -0.508 -0.060 0.192 -0.365 0.557 0.987 0.395 -0.591 
PAK1 -1.266 -1.337 -0.070 0.723 0.056 0.667 -1.922 -1.878 0.044 
PAK2 -0.324 -0.115 0.209 -0.276 -0.657 0.381 -0.238 0.081 0.319 
PAK3 -1.103 -1.581 -0.478 0.136 0.593 -0.456 -0.726 -2.185 -1.460 
PAK4 -0.888 0.124 1.013 -1.568 -0.829 -0.739 0.751 0.793 0.042 
PAK6 0.623 0.105 -0.518 -2.041 -0.800 -1.241 -0.328 0.313 0.641 
PAK7 -0.270 0.074 0.344 0.399 0.158 0.241 -0.656 -0.081 0.575 
PANK1 0.702 0.372 -0.330 0.231 -0.669 0.900 0.554 0.593 0.039 
PANK2 1.019 0.345 -0.675 -0.193 -0.254 0.062 -0.043 -0.590 -0.546 
PANK3 0.346 -0.016 -0.361 0.421 0.061 0.360 0.416 0.814 0.398 
PANK4 -1.366 -0.903 0.463 -1.687 -1.838 0.151 -1.091 -0.030 1.061 
PAPSS1 0.530 0.188 -0.341 -0.003 0.891 -0.893 0.052 0.219 0.167 
PAPSS2 0.701 0.055 -0.646 0.227 0.317 -0.091 -0.429 -0.065 0.364 
PASK 0.784 0.734 -0.050 -0.207 -0.310 0.103 -2.230 -1.330 0.901 
PCK1 -0.916 -0.848 0.068 -0.863 -1.821 0.958 -1.405 -2.738 -1.333 
PCK2 -0.471 0.161 0.632 -0.023 -0.061 0.038 0.696 1.202 0.505 
PCTK1 -1.731 -2.266 -0.535 0.307 -0.067 0.374 -0.180 -0.054 0.126 
PCTK2 0.074 0.662 0.588 0.237 0.459 -0.222 0.796 0.239 -0.557 
PCTK3 -0.189 -0.300 -0.111 -0.055 -0.805 0.750 -1.931 -2.058 -0.127 
PDGFRA -1.289 -0.849 0.439 -1.170 -1.051 -0.119 0.325 1.473 1.148 
PDGFRB -2.112 -1.351 0.761 -1.261 -1.682 0.421 -1.840 -0.978 0.862 











































































PDIK1L 0.455 0.696 0.242 0.976 0.522 0.454 0.596 0.625 0.029 
PDK1 -0.232 0.148 0.380 0.097 -0.313 0.410 -0.717 1.599 2.316 
PDK2 -1.722 -1.397 0.324 -0.033 0.486 -0.519 -0.681 -0.963 -0.281 
PDK3 0.078 0.131 0.052 -0.292 0.417 -0.709 0.504 0.587 0.083 
PDK4 -0.511 -0.981 -0.470 0.445 0.125 0.320 0.368 1.276 0.908 
PDPK1 0.001 -0.348 -0.350 -1.864 -2.007 0.143 0.251 0.732 0.481 
PDXK 1.026 0.482 -0.543 0.800 0.363 0.437 0.438 -1.274 -1.713 
PFKFB1 -0.930 -1.370 -0.440 -1.549 -1.152 -0.397 -1.355 -3.069 -1.714 
PFKFB2 0.498 -0.197 -0.694 -0.952 0.215 -1.166 0.522 -0.583 -1.105 
PFKFB3 0.018 0.291 0.273 1.482 1.409 0.073 -0.492 -0.149 0.344 
PFKFB4 0.445 -0.277 -0.722 -1.568 -1.802 0.234 0.214 0.588 0.373 
PFKL 1.981 1.701 -0.279 1.666 1.379 0.287 0.823 1.713 0.890 
PFKM 0.060 0.147 0.088 0.155 -0.041 0.196 0.514 0.861 0.347 
PFKP -0.601 -0.780 -0.179 -0.332 -0.043 -0.289 0.459 -0.249 -0.708 
PFTK1 -0.523 -0.990 -0.467 -0.130 0.251 -0.381 -0.370 -1.350 -0.980 
PGK1 -0.950 -0.363 0.587 0.715 0.312 0.403 0.835 1.254 0.419 
PGK2 0.651 0.844 0.193 0.800 1.377 -0.576 0.097 0.738 0.640 
PHKA1 0.316 0.090 -0.225 -0.642 -0.287 -0.354 0.198 0.340 0.142 
PHKA2 0.286 -0.463 -0.750 -0.143 -0.077 -0.065 -0.067 0.328 0.395 
PHKB 0.929 0.532 -0.397 -0.339 -0.476 0.137 0.814 0.531 -0.283 
PHKG1 0.671 -0.304 -0.975 0.105 -0.103 0.208 0.752 0.583 -0.168 
PHKG2 -0.352 -0.309 0.043 0.569 1.214 -0.645 0.240 0.054 -0.185 
PI4K2B -0.637 -0.207 0.430 0.616 0.795 -0.179 -0.135 -1.574 -1.440 
PI4KII 0.276 0.065 -0.211 -0.356 -0.716 0.360 0.201 0.252 0.051 











































































PIK3C2B -0.203 -0.113 0.090 -0.269 0.307 -0.576 0.944 0.567 -0.377 
PIK3C2G -0.008 -0.394 -0.386 -0.008 0.242 -0.250 -0.246 -0.302 -0.057 
PIK3C3 0.757 0.687 -0.070 0.194 0.740 -0.546 0.420 -0.562 -0.982 
PIK3CA -1.187 -0.334 0.854 0.633 0.381 0.251 -1.651 -0.002 1.649 
PIK3CB -0.391 -0.056 0.335 -0.607 -0.728 0.122 0.897 1.323 0.426 
PIK3CD 0.021 0.190 0.169 0.714 0.390 0.325 -0.537 0.692 1.229 
PIK3CG -1.069 -1.159 -0.091 -0.646 -0.948 0.303 -1.728 -0.711 1.017 
PIK3R1 0.488 0.697 0.210 1.002 0.772 0.230 0.508 0.530 0.022 
PIK3R2 0.064 0.702 0.638 -0.480 0.157 -0.636 0.052 -0.412 -0.464 
PIK3R3 1.048 1.276 0.228 -0.078 -0.991 0.913 1.004 0.289 -0.715 
PIK3R4 -0.426 -0.745 -0.319 -0.486 -1.045 0.559 -0.968 0.017 0.984 
PIK4CA -0.729 -0.381 0.348 -0.664 0.054 -0.718 -4.222 -5.393 -1.171 
PIK4CB 0.282 0.709 0.427 0.150 0.507 -0.357 0.268 0.353 0.084 
PIM1 -0.451 -0.133 0.318 -0.763 -0.068 -0.695 -0.328 -0.616 -0.288 
PIM2 -3.138 -1.734 1.404 -0.595 -0.983 0.388 -1.344 -0.754 0.590 
PIM3 -0.073 -0.152 -0.079 -1.391 -1.897 0.505 -0.656 1.139 1.795 
PINK1 -1.285 -1.002 0.283 -0.009 -0.449 0.440 -0.298 0.093 0.391 
PIP5K1A -0.275 0.414 0.689 -0.175 -0.124 -0.052 0.844 -0.447 -1.291 
PIP5K1B -0.050 -0.579 -0.528 -0.279 -0.711 0.432 0.632 0.452 -0.180 
PIP5K1C 1.144 0.446 -0.698 0.445 -0.701 1.146 -1.261 1.357 2.618 
PIP5K2A 0.759 0.376 -0.384 1.444 0.619 0.825 1.098 0.473 -0.625 
PIP5K2B -2.115 -2.239 -0.124 -1.239 -1.450 0.211 -0.067 -1.529 -1.462 
PIP5K2C 0.688 0.828 0.141 0.314 0.490 -0.176 0.569 0.914 0.345 
PIP5K3 -0.038 -0.338 -0.299 1.083 0.986 0.097 -0.115 -0.365 -0.250 











































































PKIA 1.370 0.374 -0.996 0.153 -0.090 0.242 -4.335 0.008 4.342 
PKIB 0.240 0.568 0.327 0.201 0.928 -0.727 0.367 -0.419 -0.786 
PKLR -0.159 0.665 0.824 0.473 0.152 0.321 -1.724 -0.263 1.461 
PKM2 -0.504 -0.066 0.439 0.279 -0.601 0.880 0.423 0.164 -0.258 
PKMYT1 0.123 0.498 0.375 -1.243 -1.100 -0.143 -2.344 -0.250 2.093 
PKN3 -1.282 -0.562 0.720 -0.503 -0.573 0.069 -0.051 -1.849 -1.799 
PLK1 -6.247 -6.253 -0.006 -10.546 -11.193 0.647 -7.677 -5.714 1.962 
PLK2 0.217 0.219 0.003 -0.776 0.668 -1.444 1.232 0.992 -0.241 
PLK3 -2.266 -0.966 1.300 -0.808 -0.789 -0.018 0.175 -0.245 -0.420 
PLK4 -0.459 -0.421 0.038 -1.476 -1.196 -0.280 -1.749 -2.005 -0.256 
PMVK -1.902 -3.009 -1.107 -0.978 -0.617 -0.361 -0.136 0.107 0.243 
PNCK -0.012 -0.268 -0.256 0.240 0.081 0.158 0.366 1.345 0.979 
PNKP -1.597 -1.065 0.532 -1.083 -1.409 0.326 -0.106 -0.041 0.065 
PRKAA1 -0.262 -0.080 0.182 0.897 0.493 0.405 1.056 0.572 -0.483 
PRKAA2 0.967 0.532 -0.435 0.143 0.153 -0.010 -1.112 0.639 1.750 
PRKAB1 -0.768 -1.475 -0.707 -0.334 -0.308 -0.027 0.140 0.040 -0.100 
PRKAB2 -2.071 -2.009 0.062 -1.885 -2.267 0.382 0.068 0.012 -0.056 
PRKACA 0.005 -0.105 -0.110 -1.284 -2.245 0.962 0.390 0.490 0.101 
PRKACB 1.596 0.981 -0.614 1.242 0.893 0.349 -0.002 -1.082 -1.080 
PRKACG 1.410 1.166 -0.244 -0.368 -0.612 0.244 0.601 1.205 0.604 
PRKAG1 0.955 0.905 -0.050 0.492 0.424 0.068 0.038 0.030 -0.007 
PRKAG2 1.336 0.534 -0.802 -0.066 0.083 -0.149 0.589 1.071 0.482 
PRKAG3 -0.726 -0.992 -0.265 -3.096 -3.108 0.012 -1.963 -1.113 0.850 
PRKAR1A -0.018 -0.030 -0.012 0.323 0.158 0.164 0.675 0.581 -0.094 











































































PRKAR2A 0.114 -0.484 -0.598 1.200 0.860 0.340 0.435 0.156 -0.280 
PRKAR2B -0.939 -0.826 0.113 -0.042 -0.169 0.126 -0.066 1.313 1.379 
PRKCA -0.828 -1.464 -0.636 -1.292 -0.730 -0.562 -0.307 -0.861 -0.554 
PRKCB1 -0.590 -0.893 -0.303 0.584 0.199 0.384 -0.134 1.142 1.277 
PRKCD -0.852 -0.338 0.514 -1.373 -1.029 -0.344 -3.449 -1.875 1.573 
PRKCE -2.915 -1.947 0.968 -0.967 -0.267 -0.700 -1.393 -0.758 0.635 
PRKCG 0.351 0.344 -0.006 0.737 0.710 0.027 1.527 0.864 -0.663 
PRKCH -2.183 -2.730 -0.547 -0.683 -0.786 0.103 -1.277 -0.521 0.756 
PRKCI -0.673 -0.519 0.154 0.128 -1.036 1.164 -0.926 -0.195 0.732 
PRKCL1 -0.316 -0.470 -0.153 -0.015 -0.157 0.142 -0.864 -1.565 -0.701 
PRKCL2 -0.736 -1.029 -0.293 -1.103 -0.269 -0.834 -0.859 -2.328 -1.469 
PRKCM -0.552 0.194 0.746 0.753 0.489 0.263 -0.129 -0.093 0.036 
PRKCN -0.445 -1.077 -0.633 -0.828 -0.587 -0.241 0.088 -0.659 -0.747 
PRKCQ -1.473 -0.441 1.032 -0.111 -0.406 0.295 -1.292 0.508 1.801 
PRKCSH 0.760 0.398 -0.362 -1.245 -1.476 0.231 1.207 1.399 0.192 
PRKCZ -1.221 -0.813 0.408 -1.797 -1.507 -0.291 -0.322 -0.249 0.073 
PRKD2 0.952 0.455 -0.497 1.141 1.444 -0.303 -0.519 -1.232 -0.714 
PRKDC -0.481 -1.450 -0.969 -0.502 -0.086 -0.415 -0.786 0.078 0.864 
PRKG1 0.106 0.195 0.090 0.197 0.440 -0.243 1.066 0.208 -0.858 
PRKG2 0.377 0.555 0.177 0.692 0.955 -0.262 0.058 -0.037 -0.095 
PRKR 1.050 0.967 -0.083 0.776 0.156 0.620 0.624 1.651 1.028 
PRKWNK1 0.958 0.002 -0.956 -0.214 -0.001 -0.213 3.128 -0.832 -3.961 
PRKWNK2 0.585 0.755 0.170 -0.580 -0.417 -0.162 -2.031 -0.529 1.502 
PRKWNK3 0.700 0.639 -0.061 -1.140 0.412 -1.552 -0.697 -0.502 0.194 











































































PRKY -1.135 -0.378 0.757 -2.746 -3.230 0.483 -0.072 -2.679 -2.607 
PRPF4B -0.092 -0.441 -0.349 -0.429 -0.647 0.218 -0.690 -0.092 0.598 
PRPS1 0.364 0.776 0.412 -1.266 -0.136 -1.131 -1.818 -0.021 1.797 
PRPS1L1 0.453 0.406 -0.047 1.158 0.943 0.216 0.026 -1.648 -1.674 
PRPS2 0.999 0.817 -0.182 0.064 -0.114 0.178 0.277 0.594 0.317 
PSKH1 0.726 0.441 -0.285 0.308 0.721 -0.413 0.475 -0.050 -0.524 
PSKH2 0.348 -0.397 -0.745 0.379 0.725 -0.346 0.520 -2.173 -2.693 
PTK2 -1.445 -0.271 1.174 -0.060 -0.014 -0.046 -0.266 -0.129 0.137 
PTK2B -0.755 -0.008 0.746 -1.265 -1.718 0.453 0.998 0.241 -0.757 
PTK6 0.809 0.591 -0.217 0.653 0.613 0.040 0.423 0.777 0.354 
PTK7 -2.115 -2.254 -0.140 -0.445 -1.083 0.638 -2.282 -0.836 1.445 
PTK9 1.338 0.865 -0.473 1.175 1.016 0.160 -0.281 0.077 0.358 
PTK9L 0.226 -1.669 -1.895 -0.231 -1.150 0.919 -0.731 0.720 1.451 
PXK 0.552 -0.505 -1.057 0.123 -0.600 0.723 -2.669 -2.199 0.470 
PYCS -2.612 -2.088 0.524 -0.883 -0.063 -0.820 -2.793 -0.558 2.235 
RAF1 -0.156 0.385 0.542 0.301 0.720 -0.419 1.559 1.269 -0.290 
RAGE 1.718 0.847 -0.871 0.905 0.050 0.856 0.093 0.442 0.349 
RBKS 1.384 0.767 -0.616 -0.110 0.414 -0.524 -0.203 0.417 0.620 
RELA -2.391 -2.310 0.081 -0.935 -0.925 -0.010 -0.366 -0.459 -0.093 
RET 0.178 0.039 -0.138 1.433 1.389 0.044 -1.715 -0.108 1.607 
RFK 1.471 0.292 -1.179 0.933 1.500 -0.567 0.926 1.069 0.143 
RFP -1.319 -0.438 0.881 -2.060 -3.358 1.298 -0.238 0.088 0.326 
RIOK1 -1.187 -0.946 0.241 -0.332 -0.957 0.626 0.742 0.424 -0.318 
RIOK2 0.398 0.538 0.140 -0.741 -0.677 -0.064 -1.471 -0.485 0.986 











































































RIPK1 0.214 -0.311 -0.526 -1.103 -0.008 -1.095 -0.135 0.296 0.431 
RIPK2 0.440 0.126 -0.314 -0.334 -0.434 0.099 -0.322 -0.867 -0.545 
RIPK3 0.871 0.674 -0.197 0.759 0.329 0.430 0.312 1.151 0.839 
RNASEL -0.452 -0.271 0.181 0.387 0.248 0.139 0.671 -0.757 -1.428 
ROCK1 0.741 0.488 -0.253 1.124 1.167 -0.044 0.786 -0.423 -1.209 
ROCK2 -0.275 -0.794 -0.519 -0.083 -0.098 0.015 -0.245 1.048 1.293 
ROR1 0.596 0.305 -0.291 0.870 0.185 0.685 -1.068 -0.079 0.988 
ROR2 0.865 0.968 0.103 -0.457 -0.109 -0.348 0.568 -0.075 -0.643 
ROS1 -0.046 -0.670 -0.624 -0.256 -0.211 -0.044 -0.061 -0.763 -0.701 
RP6-213H19.1 0.227 0.675 0.448 1.959 1.514 0.445 0.109 -0.148 -0.257 
RPS6KA1 -1.647 -1.351 0.296 -2.283 -1.934 -0.350 -0.048 -0.165 -0.117 
RPS6KA2 -2.553 -2.454 0.099 -2.067 -1.566 -0.502 -0.846 -2.335 -1.489 
RPS6KA3 1.204 0.580 -0.624 0.674 0.064 0.610 0.297 0.157 -0.140 
RPS6KA4 -0.434 0.113 0.547 -0.008 -1.174 1.166 1.121 0.427 -0.694 
RPS6KA5 -0.626 -0.528 0.098 -1.120 -1.632 0.512 -0.985 -2.435 -1.450 
RPS6KA6 1.662 1.527 -0.135 0.518 0.064 0.454 0.708 0.798 0.090 
RPS6KB1 -0.360 -0.697 -0.337 1.521 1.436 0.085 1.169 0.570 -0.599 
RPS6KB2 0.425 -0.267 -0.692 -0.262 -0.376 0.114 0.442 0.104 -0.338 
RPS6KC1 0.995 0.890 -0.105 2.160 2.021 0.139 0.714 0.695 -0.019 
RPS6KL1 -0.484 -0.304 0.181 -0.426 -0.915 0.489 0.490 0.001 -0.489 
RYK 0.814 0.658 -0.155 1.447 1.133 0.313 -0.100 -1.249 -1.149 
SAST 0.973 0.228 -0.745 0.397 -0.445 0.842 0.323 1.653 1.329 
SBK1 -0.298 -0.199 0.100 0.922 0.282 0.640 -0.721 0.210 0.931 
SCAP1 0.170 0.670 0.500 -1.879 1.165 -3.043 0.767 0.489 -0.278 











































































SGK 1.634 1.018 -0.616 -0.267 0.934 -1.200 0.568 -0.665 -1.234 
SGK2 -0.059 -0.067 -0.008 0.167 0.211 -0.044 0.463 0.395 -0.068 
SGKL 1.693 1.252 -0.441 0.352 0.056 0.296 0.436 0.944 0.508 
SIK2 -1.263 -1.060 0.203 -1.196 -1.407 0.210 -0.396 0.629 1.025 
SLK 0.386 -0.062 -0.447 -0.936 -0.152 -0.784 -1.589 0.404 1.994 
SMG1 0.039 -0.441 -0.480 0.393 -0.227 0.620 -0.171 -0.813 -0.643 
SNARK -0.898 -1.776 -0.878 -0.388 -0.382 -0.006 0.474 0.014 -0.460 
SNF1LK 0.894 0.524 -0.371 0.936 0.403 0.533 0.364 0.240 -0.124 
SNRK -1.187 -1.116 0.072 -0.402 0.095 -0.498 -1.386 -1.815 -0.429 
SPEG 0.502 0.100 -0.403 -0.388 0.074 -0.462 0.425 0.341 -0.084 
SPHK1 -1.472 -0.684 0.788 -2.129 -2.064 -0.064 -0.002 -0.225 -0.223 
SPHK2 0.656 0.443 -0.213 1.142 1.019 0.123 -0.759 -1.582 -0.823 
SRC 0.127 0.097 -0.030 -0.436 0.008 -0.444 0.114 0.376 0.262 
SRMS -6.241 -2.065 4.176 -0.923 -0.462 -0.461 -2.729 -2.974 -0.245 
SRP72 -0.305 -0.272 0.033 0.291 0.382 -0.092 -1.790 0.068 1.857 
SRPK1 0.641 0.445 -0.197 -1.118 -2.116 0.998 -0.660 0.165 0.825 
SRPK2 0.960 0.976 0.017 -0.214 -0.347 0.133 -0.035 -0.449 -0.414 
SSTK -0.281 -0.602 -0.321 -0.936 -1.140 0.204 0.632 -1.218 -1.850 
SSTK -1.395 -0.767 0.628 -1.758 -0.477 -1.282 0.284 -0.632 -0.916 
STK10 -0.606 -0.326 0.279 -0.836 -0.205 -0.631 -0.025 0.017 0.042 
STK11 -0.395 -0.501 -0.106 1.784 1.371 0.413 0.107 -0.271 -0.379 
STK16 0.473 0.506 0.033 0.746 0.132 0.614 0.546 -0.941 -1.487 
STK17A -0.510 -1.572 -1.062 -0.845 -0.989 0.144 -0.006 -1.621 -1.615 
STK17B -1.094 -0.905 0.189 0.176 0.282 -0.105 0.059 0.332 0.274 











































































STK22B 0.236 -0.539 -0.776 -0.042 0.456 -0.498 -1.321 -0.004 1.317 
STK22C 0.037 -0.817 -0.854 -0.815 -1.773 0.958 -1.287 -1.209 0.077 
STK22D 0.239 -1.455 -1.694 0.305 -0.324 0.629 0.271 0.142 -0.129 
STK22D 0.192 0.629 0.437 -0.296 0.287 -0.584 -0.126 0.653 0.779 
STK23 1.041 1.949 0.908 0.989 0.847 0.143 -1.703 0.117 1.820 
STK24 0.072 0.318 0.246 0.829 1.064 -0.235 1.352 0.259 -1.093 
STK25 -0.151 0.186 0.337 -1.654 -1.818 0.164 -0.293 -0.642 -0.349 
STK29 0.412 0.641 0.230 -1.216 -0.960 -0.256 0.709 0.023 -0.686 
STK3 -0.353 0.523 0.876 0.369 0.701 -0.332 0.939 0.335 -0.605 
STK31 -0.336 -0.279 0.057 0.937 0.101 0.836 -0.184 -0.013 0.171 
STK32A -0.797 -0.345 0.452 0.320 -0.010 0.330 -1.489 0.420 1.909 
STK32B 1.104 0.392 -0.712 -0.054 -0.271 0.217 -2.733 -1.118 1.615 
STK32C 0.337 1.064 0.727 -0.813 -0.949 0.137 1.423 2.156 0.733 
STK33 -0.594 -0.702 -0.108 -0.872 -0.455 -0.417 0.105 -0.771 -0.876 
STK35 -0.455 -0.355 0.100 0.716 0.990 -0.274 0.920 -0.334 -1.254 
STK36 -1.017 -0.242 0.775 -0.506 -0.056 -0.450 0.835 0.527 -0.308 
STK38 -2.312 -2.637 -0.326 -0.225 -0.792 0.567 0.002 -0.269 -0.271 
STK38L 0.347 0.484 0.138 0.088 -0.340 0.428 0.963 0.070 -0.893 
STK39 -0.541 -3.213 -2.672 1.883 0.895 0.988 -0.988 -2.390 -1.402 
STK4 0.794 1.013 0.219 -0.526 -0.442 -0.085 1.026 -0.304 -1.330 
STYK1 -0.549 1.036 1.585 -0.844 -0.312 -0.532 -0.435 -0.814 -0.379 
SYK -2.059 -1.138 0.922 -1.083 -2.542 1.459 -3.904 -1.664 2.240 
TAF1 -0.602 -0.902 -0.300 0.576 0.700 -0.123 1.032 -0.660 -1.692 
TAF1L 0.030 0.543 0.513 -0.718 -0.079 -0.639 0.160 -0.219 -0.378 











































































TBK1 -1.087 -1.239 -0.152 0.831 0.638 0.193 -0.893 -0.254 0.639 
TEC 0.447 -0.254 -0.700 0.723 0.802 -0.079 0.614 0.389 -0.225 
TEK 0.519 0.693 0.174 -0.211 -1.037 0.826 0.251 0.559 0.308 
TESK1 -0.629 -1.286 -0.658 -0.428 -1.147 0.718 -1.197 -2.684 -1.487 
TESK2 0.175 1.047 0.872 0.571 0.977 -0.406 0.975 0.882 -0.094 
TEX14 -0.043 -0.296 -0.253 0.484 -0.021 0.505 0.457 -2.133 -2.590 
TGFBR1 0.136 0.054 -0.082 0.522 -0.107 0.629 -1.130 -1.002 0.128 
TGFBR2 -0.126 -0.460 -0.335 -2.082 -1.085 -0.996 -0.927 -0.175 0.751 
TGFBR3 0.757 0.626 -0.130 1.978 0.324 1.654 0.054 0.235 0.182 
THNSL1 0.629 0.579 -0.050 1.087 0.412 0.675 0.864 0.010 -0.854 
TJP2 -0.014 -0.430 -0.416 0.577 0.976 -0.399 -1.583 -1.943 -0.361 
TK2 0.025 0.460 0.435 1.056 0.563 0.493 0.201 -0.927 -1.128 
TLK1 0.764 0.788 0.024 -1.297 -0.693 -0.604 -0.686 0.700 1.385 
TLK2 1.348 1.308 -0.039 1.579 2.046 -0.467 0.117 0.304 0.187 
TNIK -0.567 -0.602 -0.035 -1.151 -1.749 0.598 0.275 0.350 0.075 
TNK1 -0.386 -0.250 0.136 -0.299 0.139 -0.438 0.696 -0.679 -1.376 
TNK2 0.102 0.658 0.556 -0.991 -1.088 0.096 -0.700 -0.896 -0.196 
TNNI3K 1.173 -0.062 -1.234 0.355 0.685 -0.330 0.617 0.811 0.194 
TOPK 0.505 0.131 -0.374 0.079 0.701 -0.622 0.555 0.305 -0.250 
TP53RK 0.838 0.843 0.005 -0.012 -0.060 0.048 0.507 1.166 0.659 
TPK1 -3.209 -2.809 0.401 -1.106 -1.507 0.401 -2.076 -2.475 -0.399 
TRIB1 0.290 0.584 0.293 0.179 1.083 -0.904 0.411 -0.101 -0.513 
TRIB2 -2.208 -3.077 -0.870 0.033 0.057 -0.024 0.084 0.779 0.695 
TRIB3 -0.135 -0.129 0.006 -1.116 -1.324 0.208 0.115 -0.811 -0.927 











































































TRPM6 1.316 1.175 -0.140 0.466 0.920 -0.454 1.387 0.582 -0.805 
TRPM7 0.272 0.159 -0.113 -0.525 -0.547 0.022 -2.182 0.902 3.084 
TSKS 1.229 1.263 0.034 0.767 0.942 -0.175 -1.718 -0.315 1.403 
TTBK1 -1.485 -1.626 -0.142 -0.948 -0.603 -0.345 -0.062 -0.292 -0.231 
TTBK2 -0.685 -1.136 -0.451 0.086 0.996 -0.910 -0.429 0.019 0.448 
TTK -1.495 -0.902 0.594 -1.378 -2.094 0.716 -2.408 0.408 2.815 
TYK2 0.971 0.720 -0.251 0.600 0.006 0.594 -2.124 0.543 2.667 
TYRO3 0.312 0.913 0.601 -0.055 -0.419 0.365 -0.453 0.029 0.482 
UCK1 -0.128 -0.042 0.086 0.534 1.484 -0.950 0.953 -1.191 -2.144 
UHMK1 -0.768 -0.347 0.421 0.479 -0.621 1.100 -0.195 -0.133 0.063 
ULK1 0.520 0.785 0.265 0.897 0.933 -0.035 1.292 -0.695 -1.987 
ULK2 0.431 0.151 -0.280 0.310 0.994 -0.683 0.355 0.477 0.121 
ULK4 -0.739 -0.973 -0.234 0.460 -0.103 0.563 -0.189 -1.365 -1.175 
UMP-CMPK -0.511 0.047 0.558 0.904 0.926 -0.021 -0.595 1.717 2.312 
UMPK 0.095 0.637 0.543 -0.193 0.858 -1.052 0.875 0.691 -0.184 
URKL1 0.481 0.156 -0.326 0.368 0.157 0.211 0.414 0.303 -0.111 
VRK1 0.184 -0.114 -0.298 0.345 0.184 0.161 0.195 0.406 0.212 
VRK2 -0.182 -0.303 -0.121 0.526 0.111 0.415 -0.343 -0.015 0.328 
VRK3 -0.584 -0.731 -0.146 -0.189 0.216 -0.405 0.674 1.887 1.213 
WEE1 -0.761 -0.732 0.029 -5.688 -5.893 0.204 -0.864 -5.255 -4.391 
WNK4 0.013 0.411 0.399 0.706 0.904 -0.199 -0.032 -0.103 -0.071 
XYLB 0.641 1.121 0.480 2.232 1.782 0.450 0.625 -0.211 -0.836 
YES1 0.204 -0.157 -0.361 -0.278 0.029 -0.307 0.609 0.413 -0.197 
ZAK 0.012 -0.297 -0.309 1.147 1.261 -0.114 0.959 0.512 -0.447 
ZAP70 -1.616 -0.603 1.013 -0.792 -1.065 0.272 -5.877 -0.802 5.075 




Table 11.2 Table of DAVID data analysis of top 100 ‘hits’ from the screening on A549 isogenic pair 
The table indicates the number of genes analysed by DAVID belong to each signalling pathway. 
A549 
KEGG_PATHWAY 
Term Count PValue 
MAPK signalling pathway 15 1.44E-08 
Insulin signalling pathway 8 1.40E-04 
Neurotrophin signalling pathway 7 4.69E-04 
Rap1 signalling pathway 8 0.001746356 
Glucagon signalling pathway 5 0.009311845 
Calcium signalling pathway 6 0.016694189 
AMPK signalling pathway 5 0.018855997 
Endocytosis 7 0.020387447 
Proteoglycans in cancer 6 0.025616618 
Ras signalling pathway 6 0.040315077 
GnRH signalling pathway 4 0.040541457 
Oxytocin signalling pathway 5 0.043036799 
T cell receptor signalling pathway 4 0.055043129 
Purine metabolism 5 0.059620005 
Insulin resistance 4 0.061727743 
Sphingolipid signalling pathway 4 0.079229892 
mTOR signalling pathway 3 0.084924424 
VEGF signalling pathway 3 0.092553458 
Osteoclast differentiation 4 0.096967392 
BIOCARTA 
Term Count PValue 
MAPK Signalling Pathway 11 1.23E-07 
ChREBP regulation by carbohydrates and cAMP 4 0.003164398 
Signalling Pathway from G-Protein Families 4 0.012548636 
Attenuation of GPCR Signalling 3 0.014769915 
Nitric Oxide Signalling Pathway 3 0.040345274 
Stathmin and breast cancer resistance to anti-microtubule 
agents 
3 0.051009907 
Transcription factor CREB and its extracellular signals 3 0.058626058 
g-Secretase mediated ErbB4 Signalling Pathway  2 0.099090004 
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Table 11.3 Table of DAVID data analysis of top 100 ‘hits’ from the screening on MDA-MB-435 isogenic 
pair. 
The table indicates the number of genes analysed by DAVID belong to each signalling pathway. 
MDA-MB-435 
KEGG_PATHWAY 
Term Count PValue 
ErbB signalling pathway 6 5.49E-04 
Ras signalling pathway 8 0.001743635 
FoxO signalling pathway 6 0.003758183 
Type II diabetes mellitus 4 0.006088059 
Phosphatidylinositol signalling system 5 0.006995986 
Toll-like receptor signalling pathway 5 0.009190165 
Metabolic pathways 18 0.010026357 
Glycerolipid metabolism 4 0.010282067 
Neurotrophin signalling pathway 5 0.014028033 
Axon guidance 5 0.01695745 
Insulin signalling pathway 5 0.022290181 
Rap1 signalling pathway 6 0.023393265 
Aldosterone-regulated sodium reabsorption 3 0.036942815 
Inflammatory mediator regulation of TRP channels 4 0.04077648 
Choline metabolism in cancer 4 0.043960432 
T cell receptor signalling pathway 4 0.04615065 
Chagas disease (American trypanosomiasis) 4 0.047265885 
TNF signalling pathway 4 0.049536338 
Insulin resistance 4 0.051859733 
Toxoplasmosis 4 0.064253619 
Regulation of actin cytoskeleton 5 0.081896263 
Osteoclast differentiation 4 0.082214376 
Biosynthesis of antibiotics 5 0.083004747 
Colorectal cancer 3 0.084229879 
Central carbon metabolism in cancer 3 0.0889285 
Pancreatic cancer 3 0.091306894 
Renal cell carcinoma 3 0.091306894 
Fc epsilon RI signalling pathway 3 0.098553247 
BioCarta 
Term Count PValue 
MAPK Signalling Pathway 5 0.022784798 
Agrin in Postsynaptic Differentiation 3 0.080783813 
p38 MAPK Signalling Pathway  3 0.092459319 
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Table 11.4 Table of DAVID data analysis of top 100 ‘hits’ from the screening on HeLa CRISPR-Cas9 
isogenic pair 
The table indicates the number of genes analysed by DAVID belong to each signalling pathway. 
HeLa 
KEGG_PATHWAY 
Term Count PValue 
Neurotrophin signalling pathway 10 1.95E-06 
ErbB signalling pathway 8 1.85E-05 
MAPK signalling pathway 11 1.52E-04 
Long-term potentiation 6 4.17E-04 
Focal adhesion 9 7.84E-04 
Oxytocin signalling pathway 8 7.87E-04 
Regulation of actin cytoskeleton 9 9.17E-04 
FoxO signalling pathway 7 0.0018 
Phosphatidylinositol signalling system 6 0.002497 
Proteoglycans in cancer 8 0.003062 
Renal cell carcinoma 5 0.003507 
Inositol phosphate metabolism 5 0.004819 
Axon guidance 6 0.007538 
Aldosterone synthesis and secretion 5 0.007677 
Chemokine signalling pathway 7 0.008982 
Progesterone-mediated oocyte maturation 5 0.009837 
Wnt signalling pathway 6 0.010594 
Insulin signalling pathway 6 0.010594 
GnRH signalling pathway 5 0.011477 
cAMP signalling pathway 7 0.012004 
Pathways in cancer 10 0.012945 
Glucagon signalling pathway 5 0.015262 
Oocyte meiosis 5 0.020996 
Glioma 4 0.024827 
Vascular smooth muscle contraction 5 0.027902 
Adherens junction 4 0.031187 
Herpes simplex infection 6 0.031767 
Chronic myeloid leukemia 4 0.032323 
Gastric acid secretion 4 0.03348 
Fructose and mannose metabolism 3 0.038111 
Measles 5 0.039618 
Prion diseases 3 0.04032 
Salmonella infection 4 0.046221 
Prostate cancer 4 0.053371 
Bladder cancer 3 0.059618 
Circadian entrainment 4 0.06422 
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Ras signalling pathway 6 0.067378 
Inflammatory mediator regulation of TRP channels 4 0.069161 
Melanogenesis 4 0.072548 
Endometrial cancer 3 0.090154 
Tuberculosis 5 0.092128 
Cholinergic synapse 4 0.092461 
Calcium signalling pathway 5 0.095058 
BIOCARTA 
Term Count PValue 
MAPK Signalling Pathway 10 5.35E-05 
Integrin Signalling Pathway 5 0.007193 
Transcription factor CREB and its extracellular signals 4 0.018795 
Ca++/Calmodulin-dependent Protein Kinase Activation 3 0.030299 
Bioactive Peptide Induced Signalling Pathway 4 0.046138 
Regulation of PGC-1a 3 0.092561 
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